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1 Introduction 
Among the order Coleoptera a very beloved, popular, and diverse group of beetles can be 
found: the lady beetle family (Coccinellidae). Members of this huge family are present 
worldwide, exhibit vivid and colorful elytra and are very well-known to each and every child. 
In the vernacular they are among others called "ladybugs", "ladyclocks", "ladycows", 
"ladyflies" or even “Bishop Barnabee”.[1] A testimony to the continuous adoration for this 
beetle family is given in a lot of nursery rhymes and myths. Lady beetles are said to bring the 
sun, bring good luck and predict the harvest or one’s fortune of love:[1]  
“Bishop, Bishop Barnabee, tell me when my wedding be; 
If it be tomorrow day, take your wings and fly away! 
Fly to the east, fly to the west, fly to him that I love best.”[1]  
Despite the fact that most of the myths refer specifically to the seven spotted lady beetle 
(Coccinella septempunctata),[1] the family Coccinellidae comprises around 6000 species.[2] 
Lady beetles are in general 0.8 - 18 mm long and their body is shaped ovally. The dorsal 
surface is convex and the elytra show characteristic color patterns ௅ the spots ௅ which vary 
between species. The darker regions of the elytra consist of melanin and the lighter regions 
contain carotenoid derivatives, which are partly synthesized de novo and partly taken up from 
the food source.[3, 4] Many species are stenotopic and occupy only a very specific habitat. 
Coccinula sinuatomarginata, for example, can be found in dry meadows and steppes while 
Anisosticta novemdecimpunctata prefers marshes and moist meadows. However, very 
common species like C. septempunctata are eurytopic and can be found nearly everywhere.[5]  
Within the Coccinellidae phytophagous, mycophagous, and carnivorous species are known. 
The accepted food range of predaceous coccinellids is rather broad. They prey not only on 
phytophagous mites, aphids, hoppers, and cycadas (Homoptera) but have also been observed 
consuming younger instars of beetles (Coleoptera), bees, ants, wasps (Hymenoptera), and 
moths and butterflies (Lepidoptera) as well as small flies (Diptera) and thrips 
(Thysanoptera).[6] Despite the former opinion that no real food specificity exists in 
coccinellids, specialists and generalists can be found as well as a sort of “mixed feeding” 
behavior to select a balanced diet.[6, 7] Other food sources which are often used during the 
absence of alternative prey are eggs or young larvae of conspecific or heterospecific 
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coccinellids classifying lady beetles as cannibals and intraguild predators. To prevent non-
sibling cannibalism of newly laid eggs lady beetle females are able to identify larval tracks 
and to choose oviposition sites near aphid colonies but away from conspecific predators.[8] 
Furthermore, larvae are able to detect con- and heterospecific larval tracks to prevent frequent 
encounters. However, studies including the two generalist species C. septempunctata and 
Harmonia axyridis confirm that larval responses to these tracks differ between species. While 
C. septempunctata generally avoids larval tracks, H. axyridis only avoids conspecific 
tracks.[9] This asymmetric behavior of larvae suggests different levels of aggressiveness as 
intraguild predator between species.[9, 10]  
Additionally, various other predators and parasites may threaten the coccinellids.[11] Among 
others, predaceous bugs (Podisus maculiventris)[12] and crab spiders (Misumenops tricuspida-
tus)[13] are natural enemies of some lady beetle species. Parasitoids like the braconid wasp 
(Dinocampus coccinellae)[14] or entomopathogenic nematodes (Heterorhabditis bacterio-
phora and Steinernema carpocapsae)[15] as well as entomopathogenic fungi (Beauveria 
bassiana)[16, 17] are also known to attack/infect lady beetles.  
To defend themselves from the threats mentioned above, lady beetles developed various 
strategies. If a beetle is disturbed, it falls into thanatosis, death feigning, by keeping legs and 
antenna closely pressed to the body.[18, 19] Additionally, it releases droplets of hemolymph 
from the tibio-femoral joints of its legs. The hemolymph does not only contain repellent 
volatiles but also exhibits deterrent and sometimes toxic properties.[20-22] The toxic character 
of the hemolymph derives from contained alkaloids which are considered to be mostly 
synthesized autogenous by the beetles.[22]  
In 1971, the first defense alkaloids of C. septempunctata were identified to be coccinelline (1) 
and precoccinelline (2) (Fig. 1.1) and their repellent activity against ants, as well as their 
bitter taste, was proven. Further studies at this time already confirmed that 
C. undecimpunctata also carried these alkaloids in its hemolymph.[23] Only two years later 
adaline (3) was found to be the defense compound of Adalia bipunctata.[24] With ongoing 
research more and more Coccinellidae alkaloids were discovered, like hippocasine (4) ௅ the 
defense compound of Hippodamia caseyi[25] ௅ or harmonine ((R)-5). The latter was at first 
found to be present in Adonia variegata, H. quadripunctata, Semiadalia undecimnotata, Hip-
podamia convergens, and H. leis conformis.[26] Recently it was also reported to be the major 
defense compound of H. axyridis.[27, 28] In the pupal secretion of Subcoccinella vigintiqua-
tuorpunctata, dimeric polyazamacrolides, for example structure 6, were found as main com-
ponents, however, also isomeric forms or trimeric polyazamacrolides 7 could be detected.[29] 
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Figure 1.1: Some examples of alkaloids from popular lady beetle species.  
 
Out of these entire lady beetle species one species as well as its defense alkaloid gained 
enormous attention during the last years:[27, 30, 31] the Asian lady beetle H. axyridis and 
harmonine ((R)-5) ((17R,9Z)-octadec-9-ene-1,17-diamine).  
 
1.1 The Asian Lady Beetle Harmonia axyridis  
The Asian lady beetle H. axyridis displays a rather complicated taxonomic history which was 
reviewed, among other topics, in 2003 by R. L. Koch.[31] Briefly worded, this species had 
eight synonyms proposed as names, Harmonia was raised to generic status twice (1912, 
1943) and also various subspecies and aberrations have been characterized so far.[31] The 
latest taxonomic classification can be outlined as follows:[32] 
Order: Coleoptera 
Family: Coccinellidae 
Subfamily: Coccinellinae 
Tribe: Coccinellini 
Genus: Harmonia 
Species: axyridis   
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1.1.1 General Biology of H. axyridis  
The disagreement regarding the taxonomy of H. axyridis might have derived from the 
enormous amount of colorful variations and maculations that coexist in this species. The 
phenotypic color forms are divided into two groups: the light succinea type with reddish or 
brownish ground color and the melanic type, which shows dark elytra (Fig. 1.2 E).[33, 34] The 
appearance of different color forms was studied intensively, suggesting that it might derive 
from genetic polymorphism, different geographic ranges of the beetles or differences in the 
absorption of solar energy between different elytra colors.[33-35] 
Despite the unusual coloration of H. axyridis, its development and life cycle is similar to that 
of other coccinellids: it proceeds from the eggs through four larval instars, a prepupa and a 
pupa stage, to an adult stage (Fig. 1.2). The yellow eggs are laid in clusters and attached to 
the surface. Shortly before hatching their color changes to grey. The larvae remain on the 
eggs for approximately one day and consume unfertilized eggs or younger larvae. After three 
moulting processes the fourth instar is reached. The larvae stop eating and attach themselves 
with their anal discs, head down, to a surface. This prepupal stage can last up to several days 
before the moulting to the pupa is completed. Freshly hatched beetles are soft and exhibit a 
light, yellow color which changes only gradually to the common bright color with patterns.[36]  
 
 
Figure 1.2: Developmental stages of H. axyridis. A) freshly laid eggs, B) fourth instar larva, 
C) pupa on a leaf, D) H. axyridis adult feeding on aphids, E) H. axyridis adults with different 
coloration and maculation. (All photos were taken at the MPI-CE, Jena with help of A.-K. 
Dietel)  
 
The Asian lady beetle is natively distributed from southern Siberia to the South of China and 
from the Altai Mountains to the Pacific Coast. It can also be found on Formosa and Japan as 
well as on the Japanese Ryukyu Islands and the Bonin Islands.[31, 37]  
A 
B
C
D
E
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Like most predaceous lady beetles H. axyridis is able to consume a broad spectrum of prey 
including, among others, various aphid species (Aphididae), spider mites (Tetranychidae), 
larval stages of leaf beetles (Chrysomelidae), moths and butterflies (Lepidoptera), and also 
pollen and nectar.[31, 38, 39] Lucas et al. studied the feeding behavior of H. axyridis compared 
to another coccinellid species (C. septempunctata) and clearly demonstrated the enormous 
amounts of prey consumed by H. axyridis and its voracity.[39] 
 
1.1.2 Biological Control and Invasive Outbreak  
The voracious feeding behavior qualified the Asian lady beetle as an ideal biological control 
agent. First releases of H. axyridis were recorded in California, USA in 1916 and later on in 
1964 and 1965. They were followed by several introductions from 1978 to 1982 into various 
states of the USA like Georgia, Louisiana, Maine, Maryland, Mississippi, and Washington.[37] 
In Europe initial releases took place in the East ௅ for example in the Ukraine (1964) and 
Belarus (1968) ௅ followed by introductions into France (1982). H. axyridis was brought to the 
market as a biological control agent in 1995 and later on sold by various companies.[40]  
However, after a while populations began to establish in their non-native range and first 
“wild“ H. axyridis specimens were recorded in Lousiana and Mississippi in 1988.[37] With 
this event, the unstoppable radiation of the Asian lady beetles started and soon they became 
the most common lady beetles in various parts of the USA,[38] were observed in South 
America,[41] introduced into Egypt[42] and discovered in South Africa[43]. In 2004, H. axyridis 
beetles arrived in the UK from the European mainland and began to spread.[44] Since 1988 
Asian lady beetle populations have established in more than 38 countries. Their estimated 
rate of spreading is between 100 and 500 km per year.[45]  
The routes of the spreading of H. axyridis were examined by Lombaert et al.[46] and are 
illustrated in Figure 1.3 A (Europe: Fig. 1.3 B[45]). They used the analysis of population 
genetics and historical data of first observations as a basis and quantitatively compared 
invasion scenarios by applying approximate Bayesian computation methods. Their unex-
pected result is that only the populations in eastern and western North America originated 
from introductions from the native range. The South American and the African population are 
most likely to originate from North America. Genetic analysis of European H. axyridis 
populations revealed, however, that these beetles are a genetic mixture of beetles from 
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eastern North America and from the European biocontrol strain, which was introduced from 
the native range. These findings clearly indicate that first an “evolutionary shift triggering 
invasion occurred in eastern North America”[46] and that the worldwide invasion of H. axyri-
dis descends from this successful invasive population.[46]  
 
 
Figure 1.3: Worldwide distribution of H. axyridis. A) H. axyridis’ route of invasion. Likeliest 
ways of invasion are depicted by arrows and the years of the first observations are noted. 
(modified from Lombaert et al.[46]) B) Distribution of H. axyridis in Europe. First reported 
presence:  not reported,  2010-2009,  2008-2007,  2006-2005,  2004-2003, 
 2002-2001,  to 2000. (modified from Brown et al.[45])  
 
Wherever H. axyridis occurred and established not only positive effects like the biological 
control of pests were visible but also a lot of adverse effects could be observed. The Asian 
lady beetles can be associated with the decline of native coccinellid species. They are a pest 
to fruit and wine production as well as a household pest and an allergen.[44, 47] The direct 
negative effect on human health mostly derives from H. axyridis’ preference to gather at 
objects with sharp linear contrasts to find overwintering sites. These contrasts can mostly be 
found at buildings, which leads to massive congregations of beetles in homes, dirty curtains 
and furniture, and allergic reactions of the inhabitants.[48]  
Recently a methodology for risk assessment was developed to estimate the risks of a potential 
biological control agent to establish and to rate its effects on the non-target native species. 
H. axyridis was categorized to have a high-risk potential because it is not specific to any 
host.[49] Furthermore, the Asian lady beetle is nowadays seen as one of the most invasive 
species on earth showing unquestionably negative impact on native species.[44, 50]  
BA 
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With all these developments the question arises: Why is H. axyridis such a successful 
invader? The effective performance of the Asian lady beetle is certainly due to a variety of 
factors. First off all lady beetles are cannibals and predators. Studies have proven that 
H. axyridis, especially third and fourth instar larvae, acts as an aggressive intraguild predator, 
which dominates and thus decimates other lady beetle species.[10] Furthermore, H. axyridis 
larvae are less likely to be eaten by predatory crab spiders (Misumenops tricuspidatus) 
suggesting that the spiders are deterred by the larvae.[13] Last but not least H. axyridis is also 
more resistant to the entomopathogenic fungus Beauveria bassiana than other species.[17] 
This resistance against various pathogens is believed to be derived from harmonine ((R)-5), 
the defense compound of the Asian lady beetle.[27]  
 
1.1.3 Harmonine - the Defense Alkaloid of H. axyridis  
The aliphatic, long-chain diamine harmonine ((R)-5) was first found in five lady beetle 
species[26] and only in 2002 discovered to also be the major defense compound of 
H. axyridis[28]. The first material which was also used for initial structural elucidation was 
isolated from H. leis conformis of which 500 individuals were crushed. An acid-base 
extraction yielded a basic compound, which was acetylated and purified using column 
chromatography.[26, 51] To clarify the structure of the acetylated alkaloid HR-MS, IR and 
NMR techniques were applied. The position of the double bond was determined by 
epoxidation and also by oxidative cleavage followed by MS-analysis.[26] The complete 
structural confirmation and thereby the first racemic synthesis of rac-5 was reported by 
Braconnier et al.[52] Starting from 1,6-hexanediol and 1,8-octanediol, they achieved the total 
synthesis of harmonine (rac-5) in 15 steps with an overall yield of 6.5%. Since first analyses 
have already proven that harmonine (5) is an optically active molecule, Braconnier et al. also 
determined the absolute configuration of the alkaloid 5 exploiting the lanthanide-induced 
shifts of diastereomeric Mosher-amides (MTPA-amides) in 1H-NMR. With an empirical 
comparison of 1H-NMR shifts of amines of known absolute configuration in the presence of 
europium and of the shifts of harmonine under the same conditions, it was possible to assign 
the (R)-configuration for harmonine ((R)-5).[52]  
The first enantioselective synthesis of harmonine ((R)-5) was reported in 1991 by Enders 
et al.[53] and is outlined in Scheme 1.1. They developed a convergent synthesis starting from 
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diol 8 and Ȧ-hydroxy chloride 11. The latter was converted into the Į,Ȧ-disubstituted 
halide 12.  
 
 
Scheme 1.1: Simplified representation of the enantioselective synthesis of harmonine ((R)-5) 
by Enders et al.[53]  
 
To build up the alkyne moiety a five step sequence was employed. First, the diol 8 was 
heated with hydrobromic acid to give the mono-halide, which was oxidized and directly 
protected with 1,2-ethanediol to yield 9. Finally, coupling with lithium acetylide-
ethylenediamine complex introduced the alkyne residue. Then 10 and 12 were coupled in the 
presence of n-BuLi at -20 °C to give the skeleton 13 in 58 % yield. Next, the chloride at C-1 
was transferred into a primary azide. At C-17 deprotection of the aldehyde was directly 
followed by its conversion into the SAMP hydrazone. (S)-14 was then hydrogenated over 
Lindlar’s palladium catalyst to yield selectively the (9Z)-double bond (4% E-isomer) and the 
primary amino group. Methyllithium was employed for the nucleophilic addition to the 
carbon atom of the C=N-bond and the reaction was quenched with methyl chloroformate to 
give the protected hydrazino amine. Finally, an excess of lithium in liquid ammonia removed 
the chiral auxiliary and a subsequent deprotection of the resulting (R,Z)-15 yielded harmo-
nine ((R)-5) in 13 steps and an overall yield of 5% (ee  97%).[53]  
This long and costly synthesis has been the only source of synthetic harmonine ((R)-5) for 
years. However, during the completion of this thesis another synthesis was developed. In this 
synthesis, a Z-selective cross metathesis (Z/E > 90%) or a Wittig reaction was used as key 
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step to build up the carbon chain and the chiral center was introduced by use of D-alanine.[54] 
After the successful outcome and publication[55] of the synthetic procedure detailed in this 
thesis (see chapter 3.2.1 and 3.2.2), the next synthesis of harmonine ((R)-5) using a cross-
metathesis reaction was reported. Abel et al. managed to exclusively form the Z-isomer 
employing a Z-selective Grubbs catalyst with low catalyst loading (2.6% of catalyst).[56]  
Although a lot of research has been carried out on lady beetle defense systems in general, the 
biosynthesis of various alkaloids including harmonine ((R)-5) is not yet completely 
elucidated. The structural diversity of coccinellid alkaloids might be misleading though since 
most of them are simply build up from a chain of carbon atoms including one or more 
nitrogen atoms. This fact suggests a common biosynthetic origin related to a polyacetate 
pathway.[57, 58] To prove this hypothesis feeding experiments with C. septempunctata[59] and 
A. bipunctata[60] using CH314COONa/14CH3COONa were conducted, that showed incor-
poration of the precursors into the alkaloids, strongly suggesting a polyacetate origin. In 
general, however, these feeding experiments showed poor incorporation rates. Therefore, 
already established in vitro incubation assays[61] were modified to allow further biosynthetic 
studies of lady beetle alkaloids,[62] which revealed that glutamine is the most efficient 
nitrogen donor, the biosynthesis takes place in the fat body of the lady beetles, and that a fatty 
acid pathway is involved in the biosynthesis of lady beetle alkaloids.[62]  
To study the biosynthesis of harmonine ((R)-5) in vitro incorporation experiments with 
labeled [3H3] myristic acid, [3H3] stearic acid and [2H17] stearic acid were conducted by 
Haulotte et al.[57] They showed that stearic acid (16) could be incorporated at a much higher 
rate indicating that it is the biosynthetic precursor of harmonine ((R)-5). The 17-fold 
deuterated stearic acid delivered a closer insight into the formation of the amine at C-17. 
Since 3 deuterium atoms were lost during the incorporation process the biosynthesis of 
((R)-5) was outlined as shown in Scheme 1.2.[57]  
Haulotte et al. proposed that at first stearic acid (16) is converted into oleic acid (17). The 
latter is oxidized at C-17 (loss of two deuterium atoms) and transformed into an imine 19 
which can undergo imine-enamine tautomerism (loss of a third deuterium atom). The 
enamine is finally stereospecifically reduced to give harmonine ((R)-5).[57]  
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Scheme 1.2: Biosynthesis of harmonine ((R)-5) proposed by Haulotte et al.[57]  
 
The ecological function, properties, and biological activities of harmonine ((R)-5) have been 
repeatedly studied over the past years. The bitter tasting alkaloid was found to be a feeding 
deterrent for ants (Myrmica rubra) at concentrations of 10-4 M indicating that ((R)-5) 
functions as protection against possible predators.[52] Recently, parasitic microsporidia related 
to Nosema thompsoni have been reported to be present in the hemolymph of H. axyridis. 
While these microsporidia are harmful to other coccinellid species and might be another 
aspect which contributes to the dominance of H. axyridis over native species, H. axyridis is 
not infected by the microsporidia.[30] In this context ((R)-5) was proposed to protect the Asian 
lady beetle from self-infection.[63]  
However, ((R)-5) seems to be even more potent than these findings suggest: it demonstrates 
activity against 12 bacterial strains, it is active against the yeast Candida albicans and against 
four different fast-growing mycobacteria strains including Mycobacterium tuberculosis. 
Furthermore, harmonine ((R)-5) demonstrates multi-stage antimalarial activity by inhibiting 
the growth of the protozoan parasite Plasmodium falciparum (IC50 values of 4.8 and 
7.6 mM).[27] ((R)-5) is also cytotoxic to five human tumor cell lines and displays inhibitory 
activity against acetylcholinesterase, neuraminidase, and prolylendopeptidase suggesting that 
it might be used as anti-Alzheimer medication.[28] Regarding all of these recent developments 
harmonine ((R)-5) is considered as a promising lead in drug development and for agricultural 
use (yellow biotechnology).[64]  
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1.2 Bioactivity Studies 
As already outlined above, harmonine ((R)-5) displays an enormous range of different 
biological activities worth further evaluation. The assay-systems applied during the imple-
mentation of this thesis are introduced hereafter.  
 
1.2.1 Acetylcholinesterase ௅ Catalytic Function and Importance 
Alam et al. described inhibitory activity of harmonine ((R)-5) on acetylcholinesterase 
(AChE).[28] This finding prompted the establishment of an assay system for further studies.  
The neurotransmitter acetylcholine (21) (ACh; structure shown in Scheme 1.3) is responsible 
for various physiological processes in the peripheral and central nervous system. Among 
others, it controls sensory perception, sleep/wake cycles and arousal. In the periphery 
ACh (21) regulates the heart rate, smooth muscle activity and the motility of the 
gastrointestinal tract.[65, 66] These effects are mediated through activation of two different 
families of cell-surface receptors; the muscarinic receptor subtypes (mAChR, Fig. 1.4 A red) 
and the nicotinic receptor subtypes (nAChR, Fig. 1.4 A blue). The nAChRs are part of the 
ligand-gated ion channel superfamily and mediate fast neurotransmission. mAChRs are 
G-protein-coupled receptors and react slower through second messenger systems. Both 
receptor types exist in various subtypes that can be found in the synaptic cleft bound to the 
pre- and postsynaptic membrane.[66] Along with the vital enzyme AChE they are responsible 
for the transmission of action potentials across the synaptic cleft.[67]  
The functioning of a cholinergic synapse is illustrated in Figure 1.4 A: In the presynaptic, 
cholinergic neuron choline-acetyltransferases (ChAT) catalyze the production of ACh (21) 
from choline (22) and acetyl-coenzyme A. Then vesicular ACh transporters (vAChT) pack 
ACh (21) into synaptic vesicles, which are releasing 21 into the synaptic cleft when triggered 
by action potentials.[66, 68] The released ACh (21) can now bind to pre- or postsynaptic 
receptors and control various processes through inhibition of adenylate cyclase (AC), activa-
tion of the inositol-1,4,5-trisphosphate (IP3) pathway[66] or through higher permeability of 
Na+, K+, and Ca2+.[66] To terminate the transmission of action potentials AChE hydrolyzes the 
neurotransmitter 21. The resulting choline (22) is taken back up by the presynaptic neuron 
through high-affinity choline transporters (ChT).[66, 68]  
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Figure 1.4: Acetylcholinesterase. A) Repre-
sentation of a cholinergic synapse and the 
synaptic cleft with the biochemical processes 
taking place therein. (modified from Jones et 
al.[66]) B) Schematic representation of the 
binding sites and the active site of AChE. 
(reproduced from Soreq et al.[68]) C) Diagram 
of the catalytic subunit of the AChE from the 
pacific electric ray (Torpedo californica) with 
ACh (21) in the active site. (reproduced from 
Silmann et al.[69])  
 
Purified AChEs from the electric organs of electric fish (Electrophorus and Torpedo) are 
structurally comparable to those present in vertebrates[70, 71] and allowed various studies of 
the arrangement of subunits and the mode of action of these enzymes.[71] A model of the 
catalytic subunit of an AChE from Torpedo californica is shown in Figure 1.4 C. Early 
studies pointed out that two subsites ௅ the esteratic or catalytic site and the anionic or choline 
binding site ௅ build up the active site of AChE (Fig. 1.4 B).[68, 72] The active site is located in 
a narrow and deep gorge which is lined by 14 conserved aromatic residues. This residues 
contribute to the choline binding site and to the peripheral binding site.[69] The esteratic site 
provides the catalytic triad which consists of serine, histidine and glutamate and lies at the 
bottom of the gorge.[73] This triad classifies AChEs as serine hydrolases, however, with a 
gluatamate residue instead of the usual aspartate residue.[68, 72] 
The main function of AChE is the termination of receptor-mediated neurotransmission at 
cholinergic synapses by hydrolyzing ACh (21) (Scheme 1.3).[67] To fulfill this task, AChE 
functions with a very high activity and a turnover number >104 s-1,[67, 74] which is close to the 
rate of diffusion-controlled reactions.[71]  
B
A 
C 
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Scheme 1.3: AChE mediated hydrolysis of ACh. (modified from Soreq et al.[68]) 
 
The quarternary ammonium group of ACh (21) interacts with the choline binding site of the 
enzyme while the acetate-group is transferred to the hydroxyl group of serine (stabilized by 
the histidine and glutamate residue of the triad) at the eseratic site of the enzyme. Choline 
(22) is released from the newly formed acetyl-enzyme intermediate and through a subsequent 
hydrolysis the initial state of the AChE is recreated (Scheme 1.3).[68]  
This important role of AChE made the enzyme an attractive target for drug development. 
Already in the early 1970s post-mortem studies of the brains of Alzheimer’s disease patients 
revealed that these patients showed among others reduced choline (22) uptake and reduced 
ACh (21) release.[75] The resulting “cholinergic deficit hypothesis” explained many appearing 
symptoms by a general lack of neuronal ACh (21) and suggested drug development based on 
an inhibition of AChE to restore higher levels of the neurotransmitter 21.[76] Nowadays it is 
understood that many other processes are contributing to the disorder[77] but AChE inhibition 
still plays a major role in drug development.[78]  
 
1.2.2 Leishmaniasis and the Leishmania Parasites  
The antiparasitic activity of (R)-5 against P. falciparum has been reported[27] and initiated the 
evaluation of its activity against L. major, one of the causative agents of leishmaniasis.  
Leishmaniasis can be described as a complex and diverse disease caused by more than 20 
species of the protozoan genus Leishmania, which are transmitted to the human host during 
the bite of female sandflies (Phlebotominae). Depending on the transmitted parasite various 
forms of the disease can occur.[79, 80] The three major clinical forms are cutaneous (CL), 
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mucocutaneous (MCL), and visceral leishmaniasis (VL)[81] that can be found in at least 98 
countries worldwide[82] with 350 million people at risk of infection.[83, 84]  
CL is nonfatal but patients show skin lesions at the site of the sandfly bite,[81, 85] which may 
become large and permanent but are usually painless.[86] MCL can be characterized by the 
development of metastatic lesions leading to the destruction of mucous membranes.[87] The 
severest and frequently fatal form VL is accompanied by fever, anemia, weight loss, 
splenomegaly, and hepatomegaly.[81, 85]  
The life cycle of the protozoan parasites exhibits two principal stages and is retained through 
transmission between sandflies and human hosts (detailed in Fig. 1.5).  
 
                       
Figure 1.5: Life cycle of Leishmania parasites. 1) Procyclic promastigotes differentiate into 
infective metacyclic promastigotes in the sandfly gut. 2) During blood meal, promastigotes 
are regurgitated and enter the mammal body. 3) Phagocytes take up the promastigotes, which 
4) differentiate into amastigotes. 5) Amastigotes proliferate, 6) rupture the host cell and infect 
other phagocytes. 7) When a sandfly is sucking blood from an infected host, it takes up 
infected phagocytes. The amastigotes develop into promastigotes in the midgut of the sandfly 
and the cycle starts anew. (modified from Kaye et al.[88])  
 
In the gut of the sandfly, mobile and flagellated promastigotes process through various 
distinct stages (metacyclogenesis) until the noninfective, procyclic form is transformed into 
an infective, nondividing, metacyclic form with virulence capabilities. These metacyclic 
promastigotes migrate to the stomodeal valve - ready for transmission to the human host 
phagocyte 
phagolysosome 
intracelullar amastigote 
amastigotes 
procyclic promastigotes 
metacyclic  
promastigotes 
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during the blood meal. As soon as human macrophages phagocytize the promastigotes, they 
start to transform into immobile, nonflagellated amastigotes. These live as intracellular 
parasites in the human macrophages until a sandfly takes up and digests infected 
macrophages. The released amastigotes develop again into procyclic promastigotes in the 
sandfly midgut.[81, 88]  
With over 50 000 deaths recorded annually,[83] leishmaniasis was estimated to have the 
second highest mortality of tropical, infectious diseases.[79, 89] Poverty, ecological factors 
associated with poverty[90, 91] and poor nutrition increase the risk of disease progression and 
mortality.[90, 92]  
The medical treatments obtainable to this day were reviewed among others by Hussain 
et al.[93] and Sangshetti et al.[94] They demonstrate that very few drugs are available, which 
exhibit severe to life-threatening side effects. Furthermore, first resistances have been repor-
ted in these reviews. The mechanism of action of the approved antileishmanial drugs is still 
under investigation and not completely clarified yet.[93]  
One of the most convenient treatments of leishmaniasis is miltefosine (24). This 
alkylphosphocholine drug is still the only orally available treatment.[95, 96] The main organ 
targeted by side effects is the gastrointestinal tract, however, in animal studies 24 revealed 
embryotoxic and fetotoxic properties and is therefore not recommended for use during 
pregnancy.[97] Another drug in use, the aminoglycoside antibiotic paromomycin (25) needs to 
be injected intramuscular,[98] which results in injection-site pain as the principal adverse 
effect.[99] Ototoxicity and nephrotoxicity are known to occur occasionally.[96] 
 
 
Figure 1.6: Two examples of approved drugs against leishmaniasis. 
 
Since severe side effects and extremely high treatment costs are common among 
antileishmanial drugs[98, 99] and resistant Leishmania strains have been reported, the search for 
new and safer lead compounds continues.[96, 100]  
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2 Objectives and Scope of this Thesis  
The Asian lady beetle H. axyridis attracted much attention over the past decades. As an 
invasive species, the beetles began to establish and to spread worldwide threatening the 
native lady beetles wherever they occur. The enormous invasive success derives from various 
factors, among others from their chemical protection against pathogens[17] and predators[13]. 
Their defense compound, which is synthesized de novo, is harmonine ((R)-5). (R)-5 displays 
not only interesting ecological functions but also several biological activities worth testing.  
The purpose of this thesis was to contribute to the still incomplete body of knowledge of 
harmonine ((R)-5) by analytical, chemical and biological means. In detail this thesis had the 
following scope and specific aims that should be addressed:  
x  As a prerequisite for further studies “beetle material” was needed. Since H. axyridis 
is an invasive species and is no longer commercially available, the first aim of this 
thesis was to build up a reliable beetle rearing. Therefore, a cultivation of bean plants 
and a breeding of Acyrthosiphon pisum as food source should be established.  
 
x  After the successful establishment of the beetle rearing, a fast and sensitive method to 
examine the composition of the hemolymph should be developed. Previously 
unknown compounds should be identified and characterized using GC-MS (EI) and 
AcN-CI-MS/MS techniques.  
 
x Harmonine ((R)-5) displays promising biological activities which evoke a constant 
need of (R)-5. To satisfy this demand, a short, flexible and reasonable synthesis 
should be developed. This synthesis should be designed to deliver not only the 
racemic form of harmonine (rac-5) but also both enantiomers ௅ the natural occurring 
(R)-harmonine ((R)-5) and the non-natural (S)-harmonine (ent-(S)-5) ௅ as well as 
possible biosynthetic precursors and related derivatives.  
 
x  The efficiently synthesized compounds should be subsequently tested in different 
biological assays to identify new biological activities. Furthermore, the importance of 
the different functional groups and the stereochemistry for the biological activity of 
harmonine ((R)-5) should be examined. As assay systems microbial growth inhibition 
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assays, AChE inhibition assays and antileishmanial assays were chosen. The 
biological results should be complemented with docking studies and modeling.  
 
Hence, this thesis should be conducive to the knowledge of the defense alkaloid harmonine 
((R)-5) by not only providing synthetic access to all enantiomers of (R)-5 and derivatives but 
also by delivering new insights into biological activities and structure-activity relationships.  
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3 Results and Discussion  
To expand the knowledge regarding H. axyridis and harmonine ((R)-5) various measures 
were adopted during the implementation of this thesis. In general they can be differentiated 
into analysis, synthesis, and bioactivity studies. Hereafter, the results are discussed in 
previously stated order.  
 
 
3.1 Hemolymph Analysis of H. axyridis  
3.1.1 Beetle Rearing: the Prerequisite  
As a prerequisite for the analysis of H. axyridis’ hemolymph an adequate beetle rearing had 
to be established. The body of literature about beetle rearing is rather diverse and sometimes 
under-reported. To establish a successful long-term breeding the procedure described by 
Krengel et al.[101] was modified. Since H. axyridis is invasive and not marketed anymore, a 
stock of 250 - 300 adult beetles was permanently maintained (exact rearing conditions see 
chapter 6.3). The starting point were field collected fourth instar larvae reared on moth eggs 
(Lepidoptera: Gelechiidae: Sitotroga). The cannibalistic behavior of higher instars is 
relatively pronounced. Therefore, less than 15 larvae were kept in a box and food and water 
was constantly supplied to reduce cannibalistic incidents. After pupation, the newly hatched 
beetles were promptly separated into two different groups:  
x Around 80% of the beetles were fed with Sitotroga eggs and kept in groups of around 
30 individuals (group-S). 
x The other 20% were kept in groups of up to 20 individuals and fed with pea aphids 
(A. pisum) sitting on bean plants three times a week. Old plant material was removed 
regularly to avoid mould and infection of the beetles (group-A). 
Except for the different food, both beetle groups were treated equally and eggs were collected 
three times a week. Newly hatched larvae were kept in bigger groups, fed with Sitotroga eggs 
and only split up into groups of less than 15 when they reached the third instar. After 
pupation and hatching, the beetles were separated again into group-S or -A (ratio 80/20) and 
the cycle started anew.  
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The two different rearing groups were kept to allow a comparative study of H. axyridis’ 
hemolymph composition and to identify feed-dependent differences if existing. 
 
3.1.2 GC-MS Analysis of the Hemolymph  
To analyze the compounds present in H. axyridis’ hemolymph GC-MS (EI) was employed. 
The GC-MS technique was chosen because it is not only fast and reproducible but also a very 
sensitive method to separate and detect even minor compounds. Furthermore, various data 
bases containing plenty of (EI)-MS spectra of authentic reference standards are available that 
facilitate the identification of substance classes or even specific compounds.  
Since the major defense compound harmonine ((R)-5)[28] is a diamine and therefore not 
volatile enough for GC-MS analysis a suitable derivatization reagent had to be selected. The 
obvious requirements for the derivatization reagent were reproducibility, complete 
derivatization to yield only one specific product and a broad functional group acceptance. 
Underlying the proposed biosynthesis of (R)-5[57] amines and alcohols should be the main 
functional groups present in the hemolymph. Therefore, N-methyl-bis(trifluoroacetamide) 
(MBTFA) was chosen as standard derivatization reagent. This acylation reagent had already 
proven to be convenient for GC-MS detection of (R)-5. Sloggett et al.[102] and Kijita et al.[103] 
used MBTFA-derivatized full body (or egg) extracts of various lady beetle species to study 
intraguild predation through the presence of foreign alkaloids. Furthermore, MBTFA forms 
only a neutral, volatile acylamide as by-product, which does not interfere with the analytes.  
Prior to the collection of the hemolymph all beetles had unlimited access to water to facilitate 
the sample collection. For each hemolymph analysis at least five beetles were used 
(biological replicates) to confirm the results. Additionally the hemolymph of each beetle was 
split in two halves directly after the collection (technical replicate) to confirm the 
reproducibility of the procedure as such. To allow comparability between different analyses 
DCM with n-bromodecane (50 μg ml-1) as internal standard was used as the solvent.  
Since all larvae were kept on Sitotroga eggs, only beetles from group-A, which preyed on 
aphids for at least three months were used for analysis.  
 
Results and Discussion 
 
20 
 
The GC-MS chromatograms of a hemolymph sample of group-S (Fig. 3.1 A) and of group-A 
(Fig. 3.1 B) after derivatization with MBTFA are shown in Figure 3.1. Besides the standard 
(11.8 min) only one major peak was prominent in both samples. The concentration of this 
peak did not differ significantly between both feed groups.  
 
 
Figure 3.1: Comparison of the hemoplymph composition via GC-MS after derivatization 
with MBTFA. n-Bromodecane served as internal standard (RT = 11.8). A) TIC chromato-
gram of the hemolymph of a group-S beetle fed exclusively on Sitotroga eggs with detail 
magnification (20fold) of minor compounds (upper black box). B) TIC chromatogram of the 
hemolymph of a group-A beetle fed exclusively on A. pisum with detail magnification 
(20fold) of minor compounds (lower black box). 
 
A detail magnification from minute 25 to 33 revealed, however, the presence of various 
minor components in both hemolymph samples. The profile of these minor compounds was 
comparable but not completely identical (Fig. 3.1 black boxes).  
To identify the substances present in the hemolymph samples the MS spectra were analyzed. 
Four MS spectra typical for the substance classes found are displayed in Figure 3.2.  
A 
B 
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Figure 3.2: A) Structure of derivatized harmonine ((R)-5-MBTFA) with characteristic 
fragmentation points. B) Comparison of the fragmentation pattern of hemolymph compounds 
after derivatization with MBTFA (GC-MS, EI). The blue arrows display a mass loss of 
14 amu and the green arrows show a mass loss of typical MBTFA derived fragments. The 
characteristic fragment indicating double bonds (55 amu) is drawn in red.  
 
The major compound (RT = 27.6, upper spectrum) was identified to be double-derivatized 
harmonine ((R)-5-MBTFA). The spectrum did not only show a characteristic fragmentation 
pattern for MBTFA-derivatives but corresponded also exactly to the spectrum published by 
Sloggett et al.[102] The substance eluting at RT = 27.4 displayed a similar spectrum to 
A 
B 
RT: 27.6; MBTFA-harmonine ((R)-5-MBTFA) 
RT: 27.4; MBTFA-dehydro-harmonine 26-MBTFA 
RT: 28.9; heptacosene (27) 
RT: 25.0; tricosane (28) 
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(R)-5-MBTFA. The MS fragment of 55 amu indicated at least one double bond and iterative 
mass losses of 14 amu the presence of a long alkyl chain. Strikingly was the 2 amu difference 
of the higher mass fragments compared to the fragments of (R)-5-MBTFA. This mass 
difference together with all other similarities suggested a harmonine-like structure with an 
additional double bond. The further structural elucidation of this dehydro-harmonine 26 is 
detailed in chapter 3.1.3.  
For the other two compound types found in the hemolymph two representative spectra are 
shown (Fig. 3.2). The second last MS spectrum (peak eluting at RT = 28.9) exhibited the 
typical fragment of 55 amu indicating a certain degree of unsaturation as well as repeated 
mass losses of 14 amu. Furthermore, the relative abundance of the fragments was decreasing 
with increasing mass of the fragment. Together these facts indicated the presence of (mono)-
unsaturated hydrocarbons in the hemolymph samples.[104] The lower spectrum (peak eluting 
at RT = 25.0) showed a typical MS spectrum for a saturated long-chain hydrocarbon. The 
saturated hydrocarbons were easily identified by comparison of their retention times with 
those of a C7 - C30 hydrocarbon-standard. Additionally, the NIST MS spectral data base and 
massbank.jp were used. All identified compounds of the hemolymph samples are 
summarized in Table 3.1.  
 
Table 3.1: Summary of compounds found in the hemolymph of H. axyridis. 
RT [M]+· double bond molecular formula compound 
25.0 324 - n-C23H48 tricosane (28) 
26.8 350 + C25H50 pentacosene (29) 
27.1 352 - n-C25H52 pentacosane (30) 
27.4 “472” + C22H34F6N2O2 26-MBTFA 
27.6 474 + C22H36F6N2O2 (R)-5-MBTFA 
28.9 378 + C27H54 heptacosene (27) 
30.7 406 + C29H58 nonacosene (31) 
32.3 432 + C31H60 untriacontadiene (32)
32.5 434 + C31H62 untriacontene (33) 
 
Since radical sites can migrate along the chain in unsaturated compounds, the fragmentation 
patterns of alkenes are similar, and normal MS spectra are not sufficient to determine the 
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position of the double bond. The first attempt to completely identify the unsaturated 
hydrocarbons was a literature research about known long-chain hydrocarbons in H. axyridis. 
This research revealed the use of long-chain saturated and unsaturated hydrocarbons for 
substrate marking and navigation of aggregation behavior in winter. The beetles mark the 
surface with different blends of hydrocarbons. These blends underlie seasonal changes and 
evoke different behavior of the beetles. The quantification, as well as the characterization of 
the hydrocarbons, was published by Durieux et al.[105] The analysis of beetle markings in 
June and July revealed that 28, 29, 27 and 31 are the more abundant hydrocarbons in the 
substrate marking. This finding correlated with the obtained spectra (beetles were reared at 
22 °C) and strongly suggested that the hydrocarbons found in the hemolymph sample had the 
same structure as published previously, and that they were not originally part of the 
hemolymph but rather represent contaminants from the insect cuticle (hemolymph collection 
by cutting a leg). The structures of compounds found in the hemolymph sample are shown in 
Figure 3.3.  
 
 
Figure 3.3: Likeliest structures of compounds found in H. axyridis’ hemolymph sample after 
derivatization with MBTFA (except for 26-MBTFA which is discussed in detail in chap-
ter 3.1.3).  
 
With the hydrocarbons most likely being cuticular contaminants and not part of the 
hemolymph they were excluded from further analyses. The remaining hemolymph 
composition did not show any difference between the two feed groups. In general, the 
hemolymph was rather clean. Besides of (R)-5-MBTFA only the dehydro-harmo-
nine 26-MBTFA was found.  
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3.1.3 AcN-CI-MS/MS Analysis of hemolymph compound 26  
To determine the position of the second double bound in dehydro-harmonine 26 acetonitrile 
chemical ionization tandem mass spectrometry (AcN-CI-MS/MS) was used. This chemical 
ionization MS technique exploits acetonitrile as reagent gas and has been reported to facili-
tate the determination of double bond positions in monoene fatty acid methyl esters 
(FAME)[106] and in polyunsaturated FAME.[107-109]  
Under AcN-CI-MS conditions, acetonitrile reacts with an ion of itself followed by 
decomposition. The resulting, diagnostically useful ion ([CH2=C=N=CH2]+) was identified as 
1-(methyleneimino)-1-ethenylium (MIE) and reacts rapidly with double bonds to form 
[M+54]+ ions. Upon collision-induced dissociation of the [M+54]+ adducts, two reproducible 
fragments are observed: the methyl ester end containing ion (Į-ion) and the hydrocarbon end 
containing ion (Ȧ-ion). Typically, monoenes experience bond cleavage at the allylic carbon 
of the double bond while dienes undergo cleavage at the vinylic carbon atom.[107]  
Prior to AcN-CI-MS/MS analysis, the hemolymph was derivatized with MBTFA as described 
in chapter 6.4.2. Furthermore, the hemolymph sample was used as a whole since the molecule 
of interest was the minor hemolymph component (averaged: 26-MBTFA/ (R)-5-MBTFA = 
0.004).  
The section of the AcN-CI-MS/MS spectrum of MBTFA-dehydro-harmonine 26-MBTFA 
containing the characteristic MS2 ions is shown in Figure 3.4. Two characteristic fragments 
of 303 amu and 345 amu were present. They allowed narrowing the positions of the double 
bonds down to being either at carbon 6 and 9 (26b-MBTFA) or at carbon 9 and 12 
(26a-MBTFA). Furthermore, a fragment of 317 amu was dominant in the spectrum. This 
fragment arose from bond cleavage at the allylic carbon of the double bond. In FAME dienes 
mostly cleavage at the vinylic carbon is observed, however, minor peaks typical of monoene-
type cleavages are also visible.[108] 26-MBTFA features bulky functional groups at both sides 
of the molecule. These might have governed the normal hydrocarbon fragmentation pattern 
towards enhanced bond cleavage at the allylic carbon atom.  
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Figure 3.4: The 2 possible structures of 26-MBTFA with typical bond cleavage positions and 
characteristic ions are shown. The more likely structure is highlighted in blue. Furthermore, 
one of the proposed [M+54]+-ions (resulting from 26a-MBTFA; modified from Van Pelt et 
al.[108] and Michaud et al.[110]) and the relevant section of the AcN-CI-MS/MS spectrum of 
MBTFA-dehydro-harmonine 26-MBTFA are displayed.  
 
Unfortunately, the exact position of the second double bond of dehydro-harmonine 26 could 
not be assigned, since the molecule is too symmetric for AcN-CI-MS/MS analysis. The 
emerging Į-ion of structure 26a-MBTFA showed the same mass as the Ȧ-ion of 26b-MBTFA 
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and vice versa. The fragment 317 could also emerge from both structures (Fig. 3.4). Since 
only a few per mille of 26 are present in the hemolymph, structural elucidation through NMR 
was not possible. Based on the circumstances that ǻ9,12-unsaturation is a very common 
motive in nature and also existing in the omnipresent linoleic acid, a linoleic acid like 
structure with ǻ9,12-unsaturation could be assumed for 26. With this, 26a-MBTFA is more 
likely to be the correct structure of the dehydro-harmonine 26 found in the hemolymph. For 
an impeccable structural elucidation the total synthesis of dehydro-harmonine 26 is the next 
step that should be accomplished. 
  
Results and Discussion 
 
27 
 
3.2 Syntheses 
Although harmonine ((R)-5) has been isolated[26] and synthesized[52-54] previously, there is 
still a need for an efficient and rapid synthesis of harmonine ((R)-5) as well as for derivatives 
and possible biosynthetic precursors. Since the mode of action is still unknown, larger 
quantities of (R)-5 and related molecules are needed, in particular for bioassays and structure-
activity studies. Especially at the beginning of this thesis only one time-consuming and 
lengthy synthesis of (R)-5 was known.[53] Therefore the major aim of the following synthesis 
was not only to provide a quick and reliable access to harmonine ((R)-5) but also to generate 
a flexible synthetic route delivering derivatives and both enantiomers of 5 without the need of 
expensive catalysts or auxiliaries. The general concept of the synthesis was planned with a 
customizable key step enabling enantiomeric modifications and allowing necessary 
flexibility.  
The retrosynthetic analysis of 5 is shown in Scheme 3.1. 5 could be obtained through 
functional group interconversion from isopropyl (9Z)-17-hydroxyoctadec-9-enoate (34). 34 
itself could be generated following a Wittig-type reaction protocol starting from (9-iso-
propoxy-9-oxononyl)triphenylphosphonium bromide (35) and 9-methyloxonan-2-one (36). 
The Wittig salt 35 could be easily prepared through functional group interconversion from 
commercially available bromoacid 37. The lactone 36 is available through a Baeyer-Villiger 
oxidation of methyl-cyclooctanone 38 which itself could be prepared using commercially 
available cyclooctanone 39.  
 
 
Scheme 3.1: Retrosynthetic analysis of harmonine (5); R = isopropyl.  
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The straightforward synthesis to rac- (rac-5), (R)- ((R)-5), and (S)-harmonine (ent-(S)-5)1 as 
well as to harmonine-like compounds for structure-activity studies is described.  
 
3.2.1 Synthesis of rac-Harmonine (rac-5) and OH-Analog rac-48  
Initially the precursors for the assembly of the carbon backbone had to be synthesized. The 
Ȧ-methylated lactone rac-36 could be obtained in large quantities starting from commercially 
available cyclooctanone (39) following a protocol published by van Buijtenen et al.[111] 
(Scheme 3.2). First, 39 was methylated using methyl iodide (MeI). To avoid multiple alky-
lation reactions, low temperatures and only a minor excess of MeI were used. Under this 
reaction conditions the desired methyl-cyclooctanone 38 was obtained with high yield (up to 
97%). The double alkylated product and 39 were only present in negligible quantities which 
allowed the usage of 38 without an additional purification step. Subsequently a Baeyer-
Villiger oxidation employing meta-chloroperoxybenzoic acid (m-CPBA) as oxidant yielded 
rac-36. This reaction was improved with regard to the known protocol.[111] Although the 
duration is still long, the reaction time was reduced by 3 days and the yields were increased. 
 
 
Scheme 3.2: Synthesis of the precursors for the Wittig-type reaction. Reagents and 
conditions: (a) (i) DIPA, BuLi, THF, 30 min, 0 °C; (ii) MeI, 15 min, -78 °C; (iii) rt, 
overnight, (97%); (b) m-CPBA, CHCl3, 11 d at rt then 1 d reflux, (58%); (c) 2-propanol, 
H2SO4, 19 h, reflux, (86%); (d) PPh3, toluene, 4 d, reflux, (77%).  
 
The second precursor ௅ the phosphonium salt 35 ௅ could be prepared starting from Ȧ-bromo-
nonanoic acid 37 (Scheme 3.2). 37 was converted into the isopropyl ester 40 exploiting a 
                                                 
1 The stereochemistry of the synthesized substances is indicated using (S)- or (R)- or rac- in front of the assigned 
number.  
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classical esterification procedure (e.g. described in Yang et al.[112]). To shift the equilibrium 
towards the ester, a Dean-Stark apparatus was used to remove the released water. The 
isopropylester was chosen because it should allow minimization of side reactions during the 
following Wittig olefination. 40 was then reacted with PPh3 to yield the desired phosphonium 
salt 35 in good quantities and high purity.[113]  
With both precursors in hand, the actual synthesis of racemic harmonine (rac-5) could be 
conducted. The straightforward synthetic strategy is shown in Scheme 3.3.  
 
O
O
rac-36
OH
O
O
OH
HO
N3
N3
NH2
H2N
rac-5
Ph3P O
Br
7
O
35
rac-34 rac-41
rac-42
rac-41
a (iii)
a (ii)
a (i)
b
c d
 
Scheme 3.3: Synthetic sequence to rac-harmonine (rac-5). Reagents and conditions: (a) (i) 
DiBAL-H, MeOH, toluene, í78 °C; (ii) KHMDS, THF, í78 °C; (iii) í78 °C to rt in 1 h, 1 h 
rt, (23-29%, Z/E > 98/2); (b) LiAlH4, THF, 4.5 h, rt, (98%); (c) PPh3, DPPA, DIAD, THF, 
4 h, rt, (76%); (d) LiAlH4, THF, 4 h, rt, (quant).  
 
The carbon backbone of rac-5 was established via reductive olefination of rac-36 and 
phosphonium salt 35. The used “one-pot Wittig-type” procedure was first reported in 1980 by 
Boland et al.[114] and exhibits various advantages over a normal two step reaction procedure 
(isolation and purification of hemiacetals with subsequent Wittig reaction): Obviously, it is 
one step shorter and has therefore also one purification procedure less minimizing possible 
losses of substance. Furthermore, there is no need to handle unstable hemiacetals or 
aldehydes.  
The proposed reaction mechanism[114] of the “Wittig-type one-pot” reaction is detailed in 
Scheme 3.4. The use of DiBAL-H at temperatures below -65 °C allows the reduction of 
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lactone rac-36 to the cyclic aluminum salt 43, which undergoes ring opening at temperatures 
above -40 °C to form the free hydroxy aldehyde 44. The hydroxyl group is protected as an 
aluminum alkoxide. In the presence of a suitable ylide, 44 readily reacts to form the desired 
olefin rac-34.  
 
 
Scheme 3.4: Proposed mechanism for the “Wittig-type one-pot reaction” illustrated with 
9-methyloxonan-2-one (rac-36) as reagent.[114]  
 
The Wittig part of this one-pot reaction plays a pivotal role when it comes to formation of the 
Z- (or E-) alkene. Since high Z-selectivity was desirable, a non-stabilized ylide was used. 
Non-stabilized ylides react faster, favor the kinetically controlled formation of the 
cis-oxaphosphetane (OPA, 46, Fig. 3.5) intermediate and thereby the formation of 
Z-alkenes.[115]  
As it is widely known, the base used for the creation of the ylide, is essential to obtain high 
Z-selectivity. Although the Wittig-reaction was discovered more than 60 years ago, the exact 
mechanism has been controversial for a long time. While formerly the opinion was 
widespread that betaine-structures 45 are the first intermediate formed during the Wittig-
reaction[116] the notions have changed these days. Various proposed mechanisms including 
evidences for these mechanisms were reviewed by Byrne and Gilheany.[115]  
 
 
Figure 3.5: Schematic representation of a betaine 45 and a cis-OPA 46.  
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They clearly state that there should be made a distinction between the well-established 
“Li+ salt-free” and the up till now disputed “Li+ present” Wittig mechanism. They claim that 
under Li+ salt-free conditions all Wittig reactions occur under kinetic control. During the 
reaction an irreversible [2+2] cycloaddition of ylide and aldehyde is the first step that yields 
OPA. A following stereospecific cyclo-reversion yields the final product and phosphine 
oxide. The stereochemistry of the alkene is thereby defined by the stereochemistry of the 
OPA. Betaines or formerly proposed diradical species have been proven not to be present at 
any time of the reaction.[115]  
In the mechanistically not yet completely clarified Wittig reactions in the presence of Li+, 
reduced Z-selectivity is always observed. This arises probably from an effect of Li+ on the 
formation of OPA. Furthermore, in some exceptional cases a non-correspondence between 
the Z/E-ratios of the alkene and the OPA was observed. This so-called “stereochemical drift” 
is mostly linked to the presence of Li+ in the reaction mixture and favors the E- over the 
Z-isomer.[115]  
The reduced Z-selectivity in presence of Li+ ions could be also observed during the 
accomplishment of this thesis. The “Wittig-type one-pot” reaction was conducted with 
various reaction conditions to improve the yield and the Z/E-ratio of the formed isopropyl 
ester rac-34. The reductive part with DiBAL-H was kept constant, while the bases used for 
the Wittig part were varied. The results are summarized in Table 3.2 and clearly demonstrate 
that KHMDS was the most suitable base for the Wittig reaction showing moderate yields and 
an excellent Z/E-ratio.  
 
Table 3.2: Used reagents for ylide preparation during the “Wittig-type one-pot” reaction, ob-
tained Z/E-ratios and yields.  
reagent Z/E-ratio yield [%] 
n-BuLi 80/20  Z/E  86/14 23 - 29 
KHMDS > 98/2 26 
NaHMDS 98/2 13 
 
Although the yields never exceed the 30%, this was not a serious drawback since the pre-
cursors could easily be obtained in abundance from commercially available substances. The 
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major aim of this reaction step was to create a distinguished excess of the Z-isomer for 
bioactivity studies, which was impeccably achieved.  
The obtained isomer ratio was determined using GC-MS (exact method see chapter 6.1). The 
TIC chromatograms are shown in Figure 3.6 and clearly demonstrate the advantages of 
KHMDS over n-BuLi in terms of Z-selectivity.  
 
 
Figure 3.6: GC-MS chromatograms for Z/E-ratio determination of rac-34. A) rac-34 
prepared with n-BuLi; Z/E = 80/20. B) rac-34 prepared with KHMDS; Z/E  98/2.  
 
The next step in the sequence to harmonine (rac-5) was a reduction of rac-34 using LiAlH4 
(LAH) (procedure modified from Ooi et al.[117]). This reducing agent allowed the quantitative 
generation of the racemic diol rac-41 (Scheme 3.3). A subsequent Mitsunobu reaction 
utilizing triphenylphosphine (PPh3), diphenyl phosphorazidate (DPPA) and diisopropyl 
azodicarboxylate (DIAD) converted rac-41 into the diazide rac-42 (modified from Jiao et 
al.[118]). Finally another reduction step with an excess of LAH afforded the desired product 
rac-5, which was extracted as a salt, in quantitative yield (modified from Jiao et al.[118]).  
In total racemic harmonine (rac-5) could be prepared with an overall yield of 22% in only 
four reaction steps starting from the lactone rac-36 and the phosphonium salt 35.  
The reaction sequence shown in Scheme 3.3 could be easily altered to furnish a possible bio-
synthetic precursor of harmonine (5), the (9Z)-18-aminooctadec-9-en-2-ol (rac-48)2, in only 
two reaction steps. This OH-analog rac-48 was of special interest for biological assays and 
structure-activity studies since it is structurally very similar to rac-5 with only one different 
functional group.  
                                                 
2 (9Z)-18-aminooctadec-9-en-2-ol (rac-48) is from now on called OH-analog 
A B 
(Z) (Z) 
(E) 
(E) 
Results and Discussion 
 
33 
 
The synthetic sequence to the OH-analog rac-48 starting from isopropyl ester rac-34 is 
outlined in Scheme 3.5. Initially, the conversion of rac-34 into the amide rac-47 was 
conveniently achieved using magnesium nitride in MeOH at 80 °C.[119]  
 
 
Scheme 3.5: Synthetic sequence to the OH-analog rac-48. Reagents and conditions: (a) 
Mg3N2, MeOH, 80 °C, 1 d, (87%); (b) LiAlH4, THF, 45 °C, 20 h, (95%).  
 
This so far relatively unknown procedure was chosen because it displays various decisive 
advantages over commonly used methods like the preparation of saturated ammonia 
solutions. Most importantly the use of toxic, gaseous ammonia was not necessary anymore, 
which also simplified the reaction set-up enormously. The required ammonia was prepared in 
situ from the reaction of magnesium nitride with a protic solvent such as MeOH. The release 
of ammonia could be simply observed by a distinctive color change. The initially brown 
reaction slurry turned white during the formation of magnesium salts. To ensure a complete 
reaction it was important to use thick-walled, tightly sealed glass vessels which could 
withstand the pressure built up from released ammonia and superheated MeOH.[119]  
A subsequent reduction of the amide rac-47 with LAH yielded the desired OH-analog rac-48 
in nearly quantitative yield (procedure modified from Csíki et al.[120]). Taken together rac-48 
could be obtained with an overall yield of 83% starting from the isopropyl ester rac-34.  
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3.2.2 Enantioselective Synthesis: (R)- ((R)-5) and (S)-Harmonine ((S)-5)  
The synthesis of racemic harmonine (rac-5) could be readily modified to allow the generation 
of the natural occurring (R)-harmonine ((R)-5) as well as the synthesis of its non-natural 
enantiomeric (S)-harmonine (ent-(S)-5). Up until now the preparation of the (S)-enantiomer 
ent-(S)-5 has never been described before and was achieved for the first time during the 
implementation of this thesis.  
The racemic lactone rac-36 served as starting material for the synthesis of both enantiomers. 
A kinetically controlled, enantioselective saponification of rac-36 allowed the generation of 
the (S)-lactone (S)-36 (ee > 99.5%) as well as the (R)-hydroxy acid (R)-49 (ee > 99%) 
(Scheme 3.6).  
 
 
Scheme 3.6: Enzymatic, enantioselective saponification of rac-36. Reagents and conditions: 
(a) HLE, NaH2PO4, NaOH, 16 h, rt; (S)-36: 43%, ee  99.5%; (R)-49: 39%, ee  99%. 
 
For this crucial key step, a procedure described by Fouque et al.[121] was modified. First, the 
lactone rac-36 was suspended in a NaH2PO4-buffer (0.1 M) at pH = 7.2. Then horse liver 
esterase (HLE) was added as a lyophilized powder. With the addition of HLE, the hydrolysis 
started immediately. During the whole reaction the pH had to be kept constant by the 
dropwise addition of diluted NaOH (0.5 M) to avoid spontaneous hydrolysis and thereby 
racemization. The substrate/enzyme ratio could be lowered in regard to the previously 
published procedure. While Fouque et al.[121] used a ratio of 1/1 (w/w), the enzyme amount 
could be drastically reduced. An initial ratio of 10/1 (w/w) was found to be sufficient for 
complete reaction. To speed up the reaction procedure, an additional portion of HLE could be 
added (final ratio 8.3/1 (w/w)).  
The progress of the hydrolysis was monitored using a GC-MS equipped with a chiral 
ȕ-6TBDM-cyclodextrin column (Fig. 3.7 A). This column together with a newly developed 
method allowed a baseline separation of the lactone 36 enantiomers present in the reaction 
mixture and thereby a detailed evaluation of the reaction progress.  
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After complete hydrolysis of the (R)-lactone (R)-36, the reaction rate slowed down 
drastically. No hydrolysis of the (S)-lactone (S)-36 was observed.  
 
 
Figure 3.7: Enantiomeric GC analysis of (S)-36 (A) and (R)-49 (B) on a ȕ-6TBDM-
cyclodextrin column. A) 1) Initial conditions: racemic lactone rac-36. 2) 98% hydrolysis of 
(R)-lactone (R)-36. 3) Isolated lactone (S)-36 (ee  99.5%). B) 1) Derivatized, racemic 
hydroxy acid rac-49(der) (derivatized with TMS-diazomethane/MSTFA). 2) Derivatized, 
isolated (R)-49(der) (ee > 99%). (modified from Nagel et al.[55])  
 
To develop an appropriate GC-MS method for the determination of the enantiomeric excess 
(ee) of the (R)-hydroxy acid (R)-49, the racemic hydroxy acid rac-49 was needed. Therefore, 
the racemic lactone rac-36 was dissolved in a mixture of THF and aqueous LiOH solution. 
The reaction mixture was stirred overnight, acidified with 3% HCl and extracted with DCM. 
The resulting, crude rac-49 was initially derivatized with TMS-diazomethane, the solvent 
was evaporated and then the crude ester was derivatized with N-trimethylsilyl-N-methyl 
trifluoroacetamide (MSTFA). The obtained derivatized hydroxy acid rac-49(der) was used 
for the development of a GC-MS method (Fig. 3.7 B). Both methods developed for the 
determination of the ee of the (S)-lactone (S)-36 and the (R)-hydroxy acid (R)-49 can be 
found in detail in chapter 6.1.  
In total, (S)-36 and (R)-49 could be obtained with good yields and excellent ee ((S)-36: 43%, 
ee > 99.5%, (R)-49: 39%, ee  99%).  
The optically pure (S)-lactone (S)-36 was now used to prepare the naturally occurring 
(R)-harmonine ((R)-5) (Scheme 3.7). For this, the same sequence of reactions was used as 
previously described in chapter 3.2.1 for the racemic harmonine (rac-5). The usage of the 
A B 
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Mitsunobu reaction protocol as the second last step involves the inversion of the stereocenter 
to finally result in the required (R)-configuration. In conclusion (R)-harmonine ((R)-5) could 
be obtained with an overall yield of 18% starting from the phosphonium salt 35 and the 
lactone (S)-36. All spectral data of (R)-5 were identical to literature values.[28, 53, 56] 
 
 
Scheme 3.7: Synthetic route to (R)- ((R)-5) and (S)-harmonine ((S)-5). Reagents and 
conditions: (a) (i) DiBAL-H, MeOH, toluene, í78 °C; (ii) n-BuLi, THF, í78 °C; (iii) í78 °C 
to rt in 1 h, 1 h rt, (23%, Z/E > 85/15); (b) LiAlH4, THF, 4.5 h, rt, (98%); (c) PPh3, DPPA, 
DIAD, THF, 4 h, rt, (81%); (d) LiAlH4, THF, 4 h, rt, (quant); (e) (i) TMS-diazomethane, 
DCM/MeOH, 1.5 h, rt; (ii) AcOH; (iii) imidazole, TBDMSCl, DCM, 16.5 h, rt, (84%); (f) (i) 
DiBAL-H, MeOH, toluene, í78 °C; (ii) KHMDS, THF, í78 °C; (iii) í78 °C to rt in 1 h, 1 h 
rt, (29%, Z/E > 98/2); (g) (i) LiAlH4, THF, 4 h, rt; (ii) 40% HF, AcN, 2 h, rt, (73%); (h) PPh3, 
DPPA, DIAD, THF, 4 h, rt, (87%); (i) LiAlH4, THF, 4 h, rt, (95%). 
 
For the preparation of the non-natural (S)-harmonine (ent-(S)-5) the chiral (R)-hydroxy acid 
(R)-49 was used as starting material.  
At first, the overall reaction concept applied for the synthesis of (R)-5 and rac-5 should not 
be altered. Therefore, a re-lactonization of the hydroxy acid (R)-49 to the (R)-lactone (R)-36 
was attempted. The used methods and results are summarized in Table 3.3.  
For macrolactone formation from the corresponding hydroxy acid it is important to achieve a 
rapid lactonization to overcome polymerization.[122] The first entry (Table 3.3) displays a 
lactonization attempt with slightly modified Yamaguchi macrolactonization conditions 
employing the 2,4,6-trichlorobenzoyl chloride (TCBC) to form a mixed anhydride, which 
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could be attacked from the intramolecular alcohol function. Since these reaction conditions 
did not show any product formation (NMR, GC-MS) an approach following the protocol of 
Shiina et al.[123] was tested. In this case, the mixed anhydride was prepared with 2-methyl-6-
nitrobenzoic anhydride (MNBA). The reaction resulted in the formation of traces of the 
desired product (R)-36 but also in the formation of dimeric or trimeric large ring lactones. 
The reaction conditions were varied several times but the amount of (R)-36 could not be 
increased.  
 
Table 3.3: Macrolactonization methods used for the preparation of (R)-lactone (R)-36.  
Reagents no. of attempts (R)-36 a side products a
TCBC, Et3N, DMAP[124] 1 / reagents  
MNBA, DMAP[123] 5 traces “dimer”b 
ethoxyacetylene, [RuCl2(p-cymene)]2, 
p-TsOH[125] 
2 ~ 50% “dimer”b, (R)-49 
a Substances and amounts were determined via GC-MS from the crude reaction mixture. 
b Dimeric or trimeric lactones were observed showing a similar fragmentation pattern as the 
monomeric lactone. The molecular ion was not visible. The exact ring size was not 
determined.  
 
Therefore a different method was applied (Table 3.3 entry 3). First the ethoxyvinyl ester was 
prepared from the hydroxy acid (R)-49 and ethoxyacetylene in the presence of a ruthenium 
catalyst. The catalyst had to be removed and afterwards the solution was added dropwise to a 
highly diluted solution of p-TsOH in 1,2-dichloroethane.[125] This procedure afforded the 
desired lactone (R)-36 in around 50% yield. However, the hydroxy acid (R)-49 and dimeric 
products were always observed.  
Since all lactonization methods would lead to a substantial substance loss, the overall reaction 
concept to (S)-harmonine ((S)-5) was slightly altered (Scheme 3.7). At first, the hydroxy acid 
(R)-49 was converted into the TBDMS-protected hydroxy methyl ester (R)-50 in a one-pot 
reaction. The ester (R)-50 could easily be used in the “Wittig-type one-pot” reaction to form 
the protected isopropyl ester (R)-51. (R)-51 was then reduced with LAH and subsequently 
deprotected with HF to yield the (R)-diol (R)-41. At that point, the same sequence of 
reactions was used as described for the synthesis of the racemic harmonine (rac-5). In 
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summary, (S)-harmonine ((S)-5) could be obtained with an overall yield of 15% starting from 
the hydroxy acid (R)-49 and the phosphonium salt 35.  
All spectral data of (S)-5 (except for the optical rotation) were identical to literature va-
lues.[28, 53, 56] As expected, the optical rotation showed a similar numeric value with the 
opposite sign.  
 
3.2.3 Synthesis of the short-chain Harmonine Derivative: C17-Harmonine 
(rac-58)  
Finally the complete reaction sequence should be used to obtain a short-chain derivative of 
(R)-5. This shorter harmonine derivative was mainly synthesized because it should give 
interesting insights into the chain length dependency of the biological activities of harmonine 
((R)-5).  
 
 
Scheme 3.8: Synthesis of the short-chain phosphonium salt 54. Reagents and conditions: (a) 
2-propanol, H2SO4, 19 h, reflux, (83%); (b) PPh3, toluene, 4 d, reflux, (61%). 
 
For the alteration of the carbon backbone the C8-phosphonium salt 54 was prepared (Scheme 
3.8). 54 was only one carbon atom shorter than the previously used phosphonium salt 35. In 
general, the same procedure was conducted as detailed in chapter 3.2.1. The isopropyl group 
was again chosen to minimize side reactions during the following “Wittig-type one-pot” 
reaction.  
Interestingly C8-phosphonium salt 54 proved to be hygroscopic, which aggravated the 
process of drying as well as the handling of the syrup-like compound.  
The following Wittig-type reaction was performed between the racemic lactone rac-36 and 
the C8-phosphonium salt 54 (Scheme 3.9). Due to the slightly elevated amount of moisture in 
54, the ylide preparation was not complete and the yield of the “Wittig-type one-pot” reaction 
decreased to some extent. The resulting C17-isopropyl ester rac-55 was then subjected to the 
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same sequence of reactions (see chapter 3.2.1, Scheme 3.3) as previously described yielding 
the C17-harmonine derivative rac-58.  
 
Scheme 3.9: Outline of the synthetic sequence to C17-harmonine (rac-58). Reagents and 
conditions: (a) (i) DiBAL-H, MeOH, toluene, í78 °C; (ii) KHMDS, THF, í78 °C; (iii) 
í78 °C to rt in 1 h, 1 h rt, (15%, Z/E > 97/3); (b) LiAlH4, THF, 4.5 h, rt, (98%); (c) PPh3, 
DPPA, DIAD, THF, 4 h, rt, (90%); (d) LiAlH4, THF, 4 h, rt, (quant). 
 
C17-harmonine rac-58 could be prepared with an overall yield of 13% starting form lactone 
rac-36 and C8-phosphonium salt 54. Because of the shorter carbon chain containing the 
primary amino group of rac-58, the position of the cis-configured double bond was shifted 
from ǻ9 to ǻ8. The back part of the molecule carrying the second amino group and the 
stereocenter was completely identical to racemic harmonine rac-5. Consequently, biological 
assays should allow to study the influence of the length of the carbon backbone without any 
other structural influences.  
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3.3 Determination of Biological Activities  
The synthesized substances were tested in diverse bioassays to allow the elucidation of 
structure-activity relationships in harmonine ((R)-5) and to discover interesting new 
biological activities.  
With the synthesized compounds the importance of the features summarized in Figure 3.8 
was tested and evaluated:  
 
          
Figure 3.8: Modified structural features in the synthesized compounds.  
 
At first, the role of the stereocenter of (R)-harmonine ((R)-5) should be clarified. Therefore, 
(R)-, (S)-, and rac-harmonine (5) were assayed. An importance of the stereocenter would 
suggest that the biological activity observed for harmonine (5) is due to a specific interaction 
with enzymes or receptors. Since most active sites of enzymes are structurally conserved and 
highly specific, changes in stereochemistry of an inhibitor or substrate should alter the 
observed activity. Next, the impact of the functional groups should be tested. A comparison 
of the biological activities of rac-harmonine (rac-5), OH-analog rac-48 and diol rac-41 could 
give important hints to functional group dependency of the observed activity. Finally, also the 
importance of the chain length of the carbon skeleton should be elucidated. Therefore, 
biological activities of rac-harmonine (rac-5) and C17-harmonine rac-58 were compared. A 
chain length dependency of the biological activities could also point towards effects of 
harmonine (5) on important enzymes of the assayed organisms.  
  
functional groups: 
NH2 ļ OH 
chain length: 
C18 ļ C17 
stereochemistry: 
(R) ļ (S) ļ rac 
functional groups: 
NH2 ļ OH 
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3.3.1 Determination of Microbial Growth Inhibition  
Initially, the antibacterial properties of various synthesized compounds were tested using a 
microbial growth inhibition assay. Therefore, bacteria were cultivated in LB medium, plated 
and the agar was pierced to allow the application of the substances. In this assay the 
compounds diffuse into the agar and the bacteria are exposed to a concentration gradient 
during their growth. Depending on the antibacterial activity (and the concentration) of the 
substance the occurring inhibition zones vary in size.  
For the microbial growth inhibition assay Escherichia coli and Bacillus subtilis were chosen. 
B. subtilis is one of the well-known representatives of Gram-positive and E. coli of Gram-
negative bacteria. The bacteria types can be differentiated through Gram staining.[126] A 
Gram-positive and a Gram-negative bacterium were used to cover both of the most important 
bacterial groups in this assay. 
The efficiency of (R)-harmonine ((R)-5) against E. coli and B. subtilis was already proven by 
Röhrich et al.[27] who determined the minimal inhibitory concentration for E. coli to be 
89 ȝM and 44 ȝM for B. subtilis.  
Considering these data, solutions of the substances with concentrations of 0.1 mM and 
10 mM in MeOH were prepared. MeOH was used because all of the substances are not water 
soluble under neutral conditions. To ensure that MeOH had no effect on the bacterial growth, 
each plate had one negative control in the form of pure MeOH. For the negative control a 
growth inhibition zone was never observed (Figure 3.9; hole (8)). The accuracy of each assay 
was assured by the use of a positive control. For this, ampicillin (1 mM) was applied.  
All substances tested in the microbial growth inhibition assays are listed in Table 3.4. In 
preliminary tests, solutions with a concentration of 0.1 mM showed no growth inhibition. 
Therefore, only 10 mM solutions were used afterwards. Since the inhibition zones were not 
exactly circular, the diameter was measured from three different directions and averaged out. 
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Table 3.4: Tested substances in microbial growth inhibition assays with E. coli and 
B. subtilis. All compounds were dissolved in MeOH (c = 10 mM), except for ampicillin 
which was dissolved in water (c = 1 mM). The average diameters of the inhibition zones are 
given in cm (± SEM). “-“ indicates no detected inhibition zone and “/“ substance not tested.  
 E. coli BW25113 B. subtilis DSM10 
(R)-harmonine ((R)-5) 2.2 ± 0.09 
2.2 ± 0.10 
2.2 ± 0.11 
- 
- 
- 
- 
0.8 ± 0.05 
2.1 ± 0.05 
1.4 ± 0.05 
2.6 ± 0.10 
(S)-harmonine ((S)-5) 2.6 ± 0.10 
rac-harmonine (rac-5) 2.6 ± 0.10 
rac-isopropyl ester rac-34 / 
(S)-diol (S)-41 / 
rac-diol rac-41 - 
rac-diazide rac-42 - 
1.4 ± 0.05 
2.8 ± 0 
1.3 ± 0.05 
OH-analog rac-48 
C17-harmonine rac-58 
ampicillin (positive control) 
 
 
 
Figure 3.9: Microbial growth inhibition assays on LB-agar. Used substances and conditions: 
(1) rac-5; (2) (R)-5; (3) (S)-5; (4) rac-58; (5) rac-48; (6) rac-42; (7) rac-41; (8) MeOH 
(negative control); (9) ampicillin (positive control); Test substances: 10 mM in MeOH; 
ampicillin: 1 mM in H2O; A) E. coli; B) B. subtilis.   
A B 
1 
 
4 
 
7 
1 
 
4 
 
7 
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After the application of the test substances the plates were incubated for 24 hours at 37 °C 
and then the diameter of the growth inhibition zones was determined (Table 3.4). The applied 
rac-isopropyl ester rac-34 as well as (S)-diol (S)-41, rac-diol rac-41, and rac-diazide rac-42 
showed no growth inhibitory effect at all. Interestingly, the growth inhibition zones of both 
harmonine (5) enantiomers and of the racemic harmonine (rac-5) had the exact same size in 
the E. coli growth inhibition assay (Figure 3.9 A). In the assay using B. subtilis the diameters 
of the inhibition zones caused by the harmonine (5) enantiomers and the racemate were also 
identical (Figure 3.9 B). This fact reveals that the antibacterial activity of harmonine (5) is 
not dependent on the orientation of the amino group at C-17. The inhibition zone induced by 
the OH-analog rac-48 was distinctly smaller in both bacterial assays, indicating that the 
antibacterial properties of rac-48 are not as pronounced as the antibacterial properties of 
harmonine (5). An inhibiting effect by C17-harmonine rac-58 could also be observed. The 
inhibition zone measured for E. coli had nearly the same size as the ones for the harmo-
nine (5) enantiomers. With B. subtilis only a slightly larger inhibition zone could be 
measured. Consequently, the observed antibacterial activity of rac-58 is comparable to the 
activity of harmonine (5).  
The diameters of the growth inhibition zones were measured again after another incubation at 
37 °C for 24 hours and showed the same size as previously determined.  
 
 
Figure 3.10: Graphical summary of the structural features moderating growth inhibition of E. 
coli and B. subtilis. “red”: changes show no effect on growth inhibition; “green”: changes 
effect growth inhibition.  
 
All in all the structural dependency of the microbial growth inhibition can be summarized as 
shown in Figure 3.10. While chain length and stereochemistry do not matter when it comes 
to bacterial growth inhibition, the functional groups are of great importance. Substitution of 
one amino group through an alcohol function reduces the biological activity drastically. The 
replacement of both amino functions leads to a complete loss of inhibitory activity.  
These observations suggest that the microbial growth inhibitory activity of harmonine (5) and 
its derivatives is a more general effect on the used bacteria.  
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A stronger response of B. subtilis to the harmonine enantiomers (5), the racemate rac-5 as 
well as to rac-48 and rac-58 was noticed in this assay. This effect could generally arise from 
a greater susceptibility of Gram-positive bacteria ௅ like B. subtilis ௅ to the growth inhibitory 
and also killing effects of most antibacterial agents resulting at least partly from the absence 
of a protecttive outer membrane.[127]  
 
3.3.2 Studies for the Determination of AChE-Inhibitory Activity  
Alam et al.[28] reported 47% inhibition of the enzyme acetylcholinesterase (AChE) through a 
40 ȝg ml-1 (R)-harmonine ((R)-5) solution. Although they did not provide further information 
about the used solvent, the origin of the enzyme or the general assay procedure, this 
observation represented a good starting point for the development of a new structure-activity 
relationship assay system.  
Consequently, the biological activity of (R)-harmonine ((R)-5) as well as the properties of the 
synthesized enantiomer (S)-5 and the derivatives were evaluated using AChE. This vital 
enzyme plays an important role in the transmission of action potentials across the synaptic 
cleft. It is responsible for the hydrolysis of the neurotransmitter ACh and thereby the 
termination of the current synaptic transmission.[68] A malfunction of ACh release or uptake 
can lead to severe diseases like dementia or the Alzheimer’s disease. Through the 
development of AChE inhibiting drugs the course of the disease should be stopped or slowed 
down drastically.  
With this assay the inhibitory properties of (R)-harmonine ((R)-5) were further qualified, the 
IC50 values of all synthesized compounds were established and new insights into the structure 
dependent activity of harmonine-like molecules were obtained.  
For the determination of the IC50 values of the synthetic compounds a colorimetric AChE 
assay kit (AAT Bioquest Inc.) was used. This kit contains AChE isolated from the electric 
organ of Electrophorus electricus and was primarily developed to detect the presence of 
AChE in tissue or blood samples. However, through some modifications of the protocol this 
kit could be conveniently used to determine the inhibitory activity of the synthesized 
substances (detailed method described in chapter 6.5.2).  
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The quantification of AChE activity is based on Ellman’s method (Scheme 3.10): In principal 
the AChE mediated hydrolysis of acetylthiocholine (59) is measured by the reaction of the 
product thiocholine (60) with the DTNB ion 61. The resulting 5-thio-2-nitro-benzoate ion 
(63) displays a bright yellow color. This last reaction step is thereby sufficiently rapid to not 
be rate limiting. The absorption intensity of 63 can be measured with a photometer and is 
proportional to the formation of thiocholine (60), thus AChE activity.[128]  
 
 
Scheme 3.10: Reaction mechanism proposed for Ellman’s method.[128]  
 
The AChE inhibition assays were conducted as descried in chapter 6.5.2. To introduce the 
synthesized substances into the assay system small amounts of MeOH had to be used. Since 
the aqueous assay buffer had a pH of 7.4 (manufacturer’s information) some test substances 
could not be sufficiently dissolved. The introduction of MeOH had only minor effects on the 
enzyme. The longevity of AChE was shortened, which had no impact on the conducted 
assays since only the enzymatic reaction speed within the linear range (0 - 20 min) was 
needed for IC50 determination. The overall enzyme activity was only slightly reduced through 
the presence of MeOH and was effectively compensated by MeOH addition to positive 
control and blanks, too.  
To determine the IC50 value of (R)-harmonine ((R)-5) preliminary tests were conducted, that 
involved the use of methanolic (R)-harmonine ((R)-5) solutions of a broad range of different 
concertations. This range was necessary to ensure complete inhibition as well as no inhibition 
of AChE. Based on these results a preliminary IC50 value could be calculated as described by 
Järvinen et al.[129]  
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The actual assay concentrations of (R)-harmonine ((R)-5) were then developed in accordance 
to the preliminary IC50 value to obtain accurate results. A graph containing the photo-
metrically measured absorbance changes per minute plotted against the logarithmic 
concentrations of (R)-harmonine ((R)-5) allowed the determination of the IC50 value 
(Fig. 3.11).  
 
 
Figure 3.11: Concentration-dependency curve of (R)-harmonine (R)-5 with sigmoidal dose-
response fitting (variable slope, n = 3, ± SEM). Concentration of (R)-5: ȝM. 
 
The obtained IC50 value of (R)-harmonine ((R)-5) as well as the IC50 values of the other test 
substances are listed in Table 3.5. The graphs can be found in Appendix A.8.  
All IC50 values were determined for an enzyme concentration of 100 mU and of 50 mU to 
add a further control. Under ideal assay conditions the IC50 values obtained for both enzyme 
concentrations should be identical. This requirement was fairly fulfilled.   
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Table 3.5: Determined IC50-values for two different AChE concentrations. “-.“ indicates no 
inhibition.  
 IC50 [ȝM]  
50 mU 100 mU 
(R)-harmonine ((R)-5) 14.6 ± 1.10 12.8 ± 1.12 
(S)-harmonine ((S)-5) 22.6 ± 1.11 27.7 ± 1.10 
rac-harmonine (rac-5) 30.6 ± 1.21 36.1 ± 1.21 
OH-analog rac-48 “245.8 ± 3.77” a 56.5 ± 1.18 a 
rac-diol rac-41 -a -a 
C17-harmonine rac-58 61.4 ± 1.23 73.3 ± 1.16 
a These values could not be precisely determined because of solubility problems at higher 
concentrations.  
 
The determined IC50 values of (R)-, (S)-, and rac-harmonine (5) were in a similar range and 
showed no considerable difference. This was an interesting result since most enzymes are 
highly specialized and changes in stereochemistry of substrates/inhibitors should alter the 
existing interactions and thereby the activity/IC50 values drastically. For AChE it was proven 
that a change of the stereochemistry of inhibiting phosphotriesters[130] or chemical warfare 
nerve agents[131] evokes different inhibition or inactivation rates.  
Since the stereochemistry of harmonine (5) does apparently not matter for AChE inhibition, it 
is reasonable to suggest that the interactions between harmonine (5) and AChE do not involve 
binding to the active center or specific binding pockets but are more to the peripheral parts of 
the enzyme. At these parts, the interactions might be less conserved and stereochemical 
changes of the inhibitor do probably not evoke different reactions of the enzyme. In this case, 
the inhibitory activity of harmonine (5) could arise from a simple blockage of the active 
center. Since the active center is situated in a narrow and deep gorge (chapter 1.2.1, 
Fig. 1.4 B) an inhibitor blocking the entrance of this gorge or slightly changing the 
conformation of the enzyme could stop the catalytic reaction.  
Furthermore, it is proposed that AChE can only function with such a high efficiency because 
there are alternative entrances (additional to the main door of the gorge) leading to the active 
site. These doors allow the passage of water and small ions and would therefore smoothen the 
overall reaction procedure and the entering of reactants. For these doors a gating mechanism 
is described which is explained as a temporary side chain movement of specific amino acid 
Results and Discussion 
 
48 
 
residues.[132] A binding of harmonine (5) could therefore also block one of the amino acids 
responsible for gate opening/closing.  
In general, harmonine (5) shows only moderate inhibition of AChE compared to other well-
known inhibitors.[129]  
The IC50 value of the racemic C17-harmonine rac-58 was determined to be slightly higher 
than the one for harmonine (5), however on a similar scale. This might suggest that the chain 
length of the carbon backbone is important but that the shortage of only one carbon atom is 
not enough to completely prevent interactions.  
Unfortunately, the IC50 value of the OH-analog rac-48 could only be approximated. The 
obtained concentration-dependency curve of rac-48 is shown in Figure 3.12 and the critical 
range is marked in gray.  
 
 
Figure 3.12: Complete concentration-dependency curve of OH-analog rac-48 with sigmoidal 
dose-response fitting (variable slope, n = 3, ± SEM) (12 data points). Concentration of 
rac-48: nM. 
 
The values in the grey rectangle were obtained for the highest used concentrations of rac-48. 
At these concentrations rac-48 was not completely soluble under the assay conditions. 
Therefore, the initial absorbance was higher than usually. Over time rac-48 started to 
dissolve and the absorbance decreased. This fact afforded a contrary effect to the assay 
during which the increase in absorbance was measured. Close to the point of complete 
inhibition of AChE, the obtained slopes of the absorbance increase were extremely small and 
were therefore covered by the decreasing absorbance due to solvation of rac-48. The 
measured absorbance appeared smaller than it actually was and “simulated” complete 
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inhibition. Especially with an enzyme concentration of 50 mU, which only gave small slopes, 
severe problems like the complete loss of the sigmoidal curve shape needed for calculation 
were encountered. The IC50 value obtained for this concentration is consequently not 
accurate. To get an approximate IC50 value of an enzyme concentration of 100 mU the 
highest concentration was left out of calculation (Fig. A.8.4; Appendix). The obtained value 
is, however, smaller than it would actually be and feigns thereby better inhibition.  
The rac-diol rac-41 showed already during the preliminary testing (high concentrations) 
absolutely no inhibition. The absorbance curve for this test is shown in Figure 3.13. For the 
diol rac-41 even worse solubility was observed. In the obtained curves the solubility 
problems are mirrored in the high observed absorbance compared to the positive control.  
 
 
Figure 3.13: Absorbance curve of (9Z)-octadec-9-ene-1,17-diol (rac-41) with linear fitting 
(0 - 20 min; red line) and positive control (n = 3, ± SEM). In-well-concentrations of c1 = 
6 10-3 μmol μl-1 and c2 = 2.8·10-3 μmol μl-1. Positive control: 100 mU enzyme with 5 ȝl 
MeOH.  
 
The structural dependency observed for AChE inhibition can be summarized as shown in 
Figure 3.14. The stereochemistry of harmonine (5) again does not seem to play an important 
role when it comes to AChE inhibition. However, replacement of the functional groups as 
well as a variation of the chain length affects the inhibitory activity.   
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Figure 3.14: Graphical summary of the structural features influencing AChE inhibition. 
“red”: changes do not alter activity; “green”: changes effect activity.  
 
Taken together these observations, the mechanism of AChE inhibition shows moderate 
selectivity (based on the lack of activity differences of the enantiomers of harmonine (5)).  
 
3.3.3 Proof of Antileishmanial Activity  
The synthesized compounds which proved to be the most active ones so far were also tested 
against the causative agent of cutaneous leishmaniasis ௅ L. major. Annually around 800 000 ௅ 
1.3 million new infections of CL are estimated to occur.[133] The available chemotherapy is 
thereby not only limited but also accompanied by severe side effects. Resistances of the 
parasites against the available medication are also regularly reported.[134] With the ongoing 
search for new and safer drugs, naturally derived compounds are screened to identify and 
develop new antileishmaniasis treatments.  
The activity of (R)-harmonine ((R)-5) against the malaria causing parasite P. falciparum was 
already reported[27] and prompted the evaluation of (R)-5’s activity against L. major.  
Antileishmanial assays were kindly performed by Dr. Anita Masic and Martina Schultheis in 
the laboratories of the former research group of Dr. Uta Schurigt (Institute for Molecular 
Infection Biology, Würzburg).  
At first the naturally occurring (R)-harmonine ((R)-5) was tested against the parasite. The 
AlamarBlue assay with L. major promastigotes and the Britelite assay with Luciferase-
transgenic L. major amastigotes were performed (detailed in chapter 6.5.3). The IC50 value of 
(R)-5 against L. major promastigotes was determined to be 14.2 ȝM and against L. major 
amastigotes 2.4 ȝM (Table 3.6). Miltefosine (24) ௅ the current drug in use ௅ exhibited IC50 
values of 36.2 ȝM (promastigotes) and 33.0 ȝM (amastigotes).[135] In comparison to these 
values, (R)-harmonine ((R)-5) showed antileishmanial activity already at distinctly lower 
concentrations and thereby higher potency than 24.  
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Table 3.6: Antileishmanial activity of (R)-harmonine ((R)-5) in comparison to the commonly 
used drug miltefosine (24). (Nagel et al.[55])  
 IC50 [ȝM]    
L. major 
promastigotes 
L. major 
amastigotes 
BMDM SI b 
(R)-harmonine ((R)-5) a 14.2 2.4 36.5 15.2 
miltefosine (24) 36.2 33.0 65.5 2.0 
a isolated from H. axyridis  
b SI: IC50 for BMDM/IC50 for L. major  
 
To examine the cytotoxic effect of (R)-5 and 24 against host cells, bone marrow derived 
macrophages (BMDM) were used. The IC50 values against BMDM were determined to be 
36.5 ȝM for (R)-5 and 65.5 ȝM for 24. The cytotoxicity of an antileishmanial drug against 
host cells divided through its antileishmanial efficacy is defined as selectivity index (SI). In 
general, SIs > 20 are considered to be magnificent.[136] In this assay, (R)-harmonine ((R)-5) 
demonstrates a very good SI = 15.2 towards L. major while miltefosine (24) shows only a SI 
of 2.0.  
A further investigation of the antileishmanial effect of (R)-harmonine ((R)-5) was possible via 
transmission light microscopy. To determine the cell morphological changes of L. major 
promastigotes, they were treated with (R)-5 for 6 h, 10 h, and 24 h (Fig. 3.15). Changes of the 
cell morphology were rapidly visible. After 6 h upon (R)-5 treatment rounding of the cells 
was induced and after 10 h first dead cells were observed. After 24 h only dead cells were 
visible. In the DMSO treated control L. major promastigotes showed no significant changes. 
After 6 h and 10 h of cultivation, the characteristic flagellated parasite with its slender shape 
was observed (Fig. 3.15).  
To study the type of cell death induced by (R)-harmonine ((R)-5) a flow cytometric approach 
was used. For this approach the different mechanisms of necrosis (unregulated cell death) and 
apoptosis (programmed cell death) were exploited. While during necrosis the membrane 
integrity is lost and DNA is exposed to the surrounding environment, apoptotic cells 
translocate phosphatidylserine (PS) to the outside of the cellular membrane. A double 
staining with Annexin V-fluorescein isothiocyanate (AV, binds PS) and propidium iodide 
(PI, binds DNA)[137] can therefore be used to differentiate all four possible Leishmania cell 
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death phenotypes: alive (AVí/PIí), early necrotic (AVí/PI+), early apoptotic cells (AV+/ 
PIí), and late necrotic/late apoptotic (AV+/PI+).[137, 138]  
 
 
Figure 3.15: Observation of (R)-harmonine ((R)-5) induced cell death in L. major pro-
mastigotes. L. major promastigotes were treated with 1% DMSO (control) or 30 ȝM 
(R)-harmonine ((R)-5) solution for 6 h, 10 h, and 24 h. Double staining (Annexin V, PI) was 
performed to determine the cell death phenotype (dot-blots, left). Diff-Quick staining allowed 
investigation of cell morphological changes via transmission light microscopy (pictures, 
right). Scale bars: 10 ȝm. Number in quadrants: cells [%] showing early necrotic, late 
necrotic, or apoptotic cell death. (modified from Nagel et al.[55])  
 
In general, cell death during treatment with (R)-5 increased over time. In total, after 6 h 
26.2% and after 10 h 40.3% of cells were dead (PI staining, Fig. 3.15). The successful PI-
staining indicates binding to the DNA, loss of membrane integrity and thereby the early 
necrotic cell death type. After 10 h a population of 24.5% early necrotic cells was detected 
(Fig. 3.15). In the 24 h treatment, (R)-harmonine ((R)-5) induced early necrotic cell death in 
31.6% and late necrotic/late apoptotic cell death in 51.1% of all treated cells. In total, 82.8% 
of cells were dead. Under normal growth conditions 73.4% of all cells were viable.  
These results clearly indicate that (R)-harmonine ((R)-5) induces necrosis in L.major 
promastigotes. The increase of late necrotic/late apoptotic cells after 24 h results from the 
rupture of the cell membrane during necrosis. After loss of cell membrane integrity, AV can 
bind to PS of the dead parasites.  
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For structure-activity relationship studies more substances were tested against the 
promastigote form of the Leishmania parasite. The determined IC50 values are summarized in 
Table 3.7.  
 
Table 3.7: Antileishmanial activity of (R)-, (S)-, rac-harmonine (5), and OH-analog rac-48. 
 L. major promastigotes; IC50 [ȝM] 
(R)-harmonine ((R)-5) 8.6 
(S)-harmonine ((S)-5) 9.1 
rac-harmonine (rac-5) 13.2 
OH-analog rac-48 32.1 
 
To evaluate the importance of the amino group orientation at the stereocenter, the two 
harmonine (5) enantiomers as well as the racemate rac-5 were tested against L. major 
promastigotes using the AlamarBlue assay. The obtained IC50 values showed no considerable 
difference. All three IC50 values were below the determined IC50 value for miltefosine (24) 
(36.2 ȝM), which shows that even the racemic harmonine (rac-5) is more active in vitro than 
the current drug in use.  
The IC50 value of the OH-analog rac-48 was determined to be 32.1 ȝM. This means that 
rac-48 is again less active than the harmonine enantiomers (5) but its activity against the 
promastigote form is still comparable to 24.  
In general, the pronounced activity of all enantiomers of harmonine (5) and the OH-analog 
rac-48 against L. major was shown for the first time during the implementation of this thesis 
and is an encouraging result for antileishmanial drug development. The indifference of the 
stereochemistry is thereby especially interesting since complex or costly stereocontrol of 
chemical synthesis does not seem to be necessary to achieve antileishmanial activity.  
When it comes to structure-activity relationship the general picture observed so far is again 
confirmed (Fig. 3.16). Interestingly, the stereochemistry does not play an important role 
when it comes to antileishmanial activity. An exchange of an amino group through a hydroxy 
group at the carbon backbone nevertheless reduces the activity slightly.  
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Figure 3.16: Graphical summary of the structural features moderating antiparasitic activity 
against L. major. “red”: changes do not alter activity; “green”: changes effect activity, 
“brown”: effect not tested.  
 
Unfortunately, the impact of the chain length of the carbon backbone could not be examined 
so far. The research group of the collaborators was closed before an assay with 
C17-harmonine rac-58 could be conducted. As perspective, this assay can hopefully be 
completed with the help of another research group working with the L. major parasites.  
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3.3.4 Modeling and Docking Studies  
The search for a connection between the biological activities of the harmonine enantiomers 
(5) against AChE (chapter 3.3.2) and against the Leishmania parasite (chapter 3.3.3) was 
initiated following two key observations:  
At first, the IC50 values of the harmonine enantiomers (5) as well as of the OH-analog rac-48 
were comparable in scale in both tested assay systems. Besides, a similar behavior to structu-
ral changes of the introduced inhibitors was visible.  
The hypothesis that both activities are connected with each other was promoted by the proof 
of the presence of an AChE in Trypanosoma evansi by subcellular localization and confocal 
microscopy.[139] This protozoan parasite causes surra in animals but is not pathogenic to 
humans. The non-neuronal role of AChE in T. evansi respectively the Trypanosomatidae 
family is not yet completely understood. However, Mijares et al.[139] proposed that AChE is 
mostly located in the glycosome and that it is responsible for the regulation of the flow of 
Ca2+ between this organelle and the cytosol. Since the Leishmania parasites belong to the 
same family the presence of an AChE or a carboxylesterase with similar structure and 
function was assumed. Hereafter, the search for the “leishmanial AChE” as well as modeling 
and docking studies proving the inhibitory activity of the harmonine enantiomers (5) are 
presented.  
 
3.3.4.1 Identification of “AChE-like proteins” in L. major  
At first the “AChE-like proteins” in L. major had to be identified. Therefore, the protein 
sequence of a known AChE from the model organism Caenorhabditis elegans 
(NP_510660.1) was blasted against the protein sequence of L. major. The BLAST identified 
two possible candidates: a conserved hypothetical protein (XP_001681951.1) and a putative 
ecotin (XP_001681950.1). Both sequences showed relatively low identities and query covers. 
Interestingly, the identical parts of the sequences were at important and conserved sites of the 
AChE sequence. Most matches could be found from amino acid 129 - 228 (conserved 
hypothetical protein) or from amino acid 124 - 238 (putative ecotin). In this sequence region, 
amino acids which are part of the substrate binding pocket as well as the serine from the 
catalytic triad are located.  
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This fact suggested that even with substandard identities and query covers two good 
candidates were found. Since both candidates showed matches with the important, catalytic 
or substrate binding part of the AChE, they were both considered for docking studies.  
 
3.3.4.2 Modeling of possible Candidates and Docking Studies  
Modeling and docking studies of the two possible “leishmanial AChE” candidates were 
kindly performed by PD Dr. Wolfgang Brandt (Leibniz Institute of Plant Biochemistry, 
Halle). The exact approach is described in chapter 6.5.4. 
For the putative ecotin (XP_001681950.1) no reasonable models could be created. For the 
conserved hypothetical protein (XP_001681951.1), however, an interesting model could be 
obtained (Fig. 3.17). This model was based on homology modeling. After search for 
templates in the protein database[140] and various refinement steps, a model resembling the 
template 1qz3 (Fig. 6.3, chapter 6.5.4) appeared as most fitting. Interestingly, this template 
can be complexed with hexadecanesulfonate which is structurally comparable to harmo-
nine (5).  
 
 
Figure 3.17: Model of the sequence XP_001681951.1 with bond harmonine. The amino 
groups interact with E406 (surface; no specificity of the chiral carbon) and with D739 
(bottom, probably near the active site).  
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The model of the full sequence of the conserved hypothetical protein bound with harmonine 
(5) is shown in Figure 3.17. This model already suggests that harmonine (5) is bound to 
aspartate 739 at the bottom of the visible gorge of the protein and with this probably near the 
active site.  
A more detailed view (Fig. 3.18) clearly shows that harmonine (5) is able to form two salt 
bridges (dashed lines) with aspartate 739 and glutamate 406. The glutamate residue is located 
near the surface of the protein and the amino group at the chiral center of 5 is probably 
interacting with it. Near the surface of the protein no space limitations can be found. 
Therefore, the stereochemistry of harmonine (5) is not important and the (S)- as well as the 
(R)-enantiomer of 5 are able to form a salt bridge with glutamate.  
 
 
Figure 3.18: The most favored docking arrangement of harmonine (5) (interaction 
energy: -47.5 kcal mol-1). Interactions based on the hydrophobic effect (F404, V400, V401, 
L695, V536) are identifiable. Furthermore, the ligand’s length is ideal to form two salt 
bridges with E406 and D739. 
 
The non-polar middle part of 5 is probably interacting with various non-polar amino acids 
such as leucine, valine, and phenylalanine. Obviously the length of the carbon backbone 
plays an important role for the observed interactions. Even though harmonine (5) is not 
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bound to the active center it fits perfectly into the gorge forming two salt bridges at either 
side. 
This assumption was confirmed by the model of the conserved hypothetical protein bound to 
the short-chain C17-harmonine rac-58 (Fig. 3.19 and Fig. A.9.2, Appendix). It is clearly 
visible that rac-58 is too short to fit perfectly. With the C17-backbone only one salt bridge can 
be formed - either with aspartate or with glutamate. The hydrophobic interactions were 
nevertheless present. In total, the shortage of one carbon atom reduced the calculated 
interaction energy from -47.5 kcal mol-1 with harmonine (5) to -40.1 kcal mol-1 (with D739) 
or -39.2 kcal mol-1 (with E406) with C17-harmonine rac-58.  
 
 
Figure 3.19: Favored docking arrangement of C17-harmonine (rac-58) (interaction 
energy: -40.1 kcal mol-1). Interactions based on the hydrophobic effect (F404, V400, V401, 
L695, V536) are present. However, the length of the ligand is too short to form two salt 
bridges but only one with D739. 
 
Even though these modeling studies confirmed that harmonine (5) is not bound to the active 
center it was nicely shown that the interactions between 5 and this putative “leishmanial 
AChE” are strong, defined and near the active center. Therefore a possible blockage of the 
substrate on its way to the active center of the AChE and/or the enforced retention of the 
enzyme conformation are possible inhibition mechanisms (see also chapter 3.3.2). 
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The desired linkage between the observed AChE-inhibitory activity as well as the determined 
antileishmanial activity of harmonine (5) and its derivatives could be nicely established. With 
this model of the possible “leishmanial AChE” and the docking studies explaining perfectly 
the observed structure-activity relationship in both biological assay systems, the presence of 
an AChE or at least a carboxylesterase with structural similarity can be suggested in L.major. 
In the future, the C17-harmonine rac-58 can hopefully be tested against L. major to confirm 
these above discussed results.  
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4 Summary  
The Asian lady beetle Harmonia axyridis gained enormous attention over the past years. This 
vivid, carnivorous beetle is natively distributed in the Asian range[31, 37] and shows a vora-
cious feeding behavior of coccids, aphids and mites[39] which qualified H. axyridis as a sui-
table biological control agent. However, over time populations began to establish and already 
more than two decades ago H. axyridis became an invasive species threatening and decima-
ting the native lady beetle populations wherever it occurred.[44, 50] The enormous invasive 
success derives from various factors: First of all, the cannibalistic Asian lady beetles act as 
aggressive inraguild predators dominating other lady beetle species.[10] Second, H. axyridis is 
less likely to be eaten by coccinellid predators[13] and is more resistant to pathogens[17]. This 
resistance most likely derives from harmonine ((R)-5), the defense compound of H. axyridis.  
This long-chain, aliphatic alkaloid (R)-5 is present in the hemolymph and displays a variety 
of interesting biological properties. For example, harmonine ((R)-5) is active against 12 diffe-
rent bacterial strains, against the yeast Candida albicans and against four fast-growing myco-
bacteria strains including Mycobacterium tuberculosis.[27] (R)-5 demonstrates multi-stage 
antimalarial activity by inhibiting the growth of the protozoan parasite P. falciparum[27] and is 
also cytotoxic to five human tumor cell lines[28].  
Although H. axyridis and harmonine ((R)-5) have been studied over the past years, many 
details and connections are not clarified yet. The main objective of this thesis was to contri-
bute to the body of knowledge about this beetle and harmonine ((R)-5) in particular by 
analytical, chemical and biological means.  
Analysis of H. axyridis‘ hemolymph (chapter 3.1) 
To study the hemolymph composition of H. axyridis a beetle rearing was established starting 
from field collected specimens. The beetles were kept on two different food sources (moth 
eggs (Sitotroga) or pea aphids (A. pisum)) to examine their effect on the hemolymph 
composition. After hemolymph collection, the samples were derivatized using MBTFA and 
analyzed via GC-MS. The GC-MS technique was chosen because it is a fast, reproducible, 
and very sensitive method to separate and detect even minor compounds. In the hemolymph 
samples were, however, only very few compounds detected. In general, the hemolymph 
composition of both feed groups was comparable and showed no considerable differences. 
Harmonine ((R)-5) was the major component in both feed groups. Besides (R)-5, conta-
minants from the cuticula were identified as well as one minor component present in only 
Summary 
 
61 
 
4 ‰ compared to (R)-5. This minor component showed a similar fragmentation pattern as 
(R)-5 along with a 2 amu difference in molecular mass and was consequently identified as 
dehydro-harmonine 26 with one additional double bond. To elucidate the structure of the 
previously unknown hemolymph compound 26 the AcN-CI-MS/MS technique was applied. 
This technique exploits acetonitrile as reagent gas and allows the localization of double bonds 
especially in fatty acid methyl esters. Since 26 is too symmetric for this technique, the 
position of the double bond could not be unambiguously assigned, however, a ǻ9,12-dehydro-
harmonine structure is assumed. To confirm the structure, a synthesis of 26 and a comparison 
of the natural and the synthetic compound would be the next step.  
Synthesis of rac-, (R)-, and (S)-harmonine (5), OH-analog rac-48 and the short chain 
derivative C17-harmonine rac-58 (chapter 3.2)  
Since harmonine ((R)-5) displays a lot of interesting biological activities, a constant demand 
for synthetic material can be observed. However, at the beginning of this thesis only one 
lengthy synthesis[53] was known to provide synthetic (R)-5. Within this work, a short and 
efficient synthetic method was developed to obtain the natural (R)-harmonine ((R)-5) as well 
as the racemic form rac-5 and the previously undescribed non-natural enantiomer 
(S)-harmonine (ent-(S)-5). Based on a “Wittig-type one-pot” reaction as key step a flexible 
approach was designed to allow the synthesis of a whole spectrum of compounds starting 
from commercially available cyclooctanone (39) and Ȧ-bromononanoic acid (37).  
Cyclooctanone (39) was easily converted into the racemic lactone rac-36 and the bromo acid 
37 into the corresponding Wittig salt 35. The “Wittig-type one-pot” reaction of both com-
pounds yielded the carbon skeleton of harmonine (5) with high Z-selectivity (Z/E  98/2). 
Through subsequent functional group modifications, harmonine (rac-5) was readily available. 
To obtain both harmonine enantiomers (5), horse liver esterase was used for enantioselective, 
enzymatic saponification of the lactone rac-36. This yielded the (S)-lactone (S)-36 and the 
(R)-hydroxy acid (R)-49 with excellent ee ((S)-36: ee  99.5%, (R)-49: ee  99%) and good 
yields. The optically pure precursors were then used to synthesize the natural harmonine 
((R)-5) and the (S)-harmonine (ent-(S)-5).  
This flexible synthetic protocol was subsequently altered to gain access to the possible bio-
synthetic intermediate, the OH-analog rac-48, as well as to the short chain derivative 
C17-harmonine rac-58. Both substances were designed to provide insights into structure-
activity relationships. The synthetic strategy is shown in Scheme 4.1.  
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Scheme 4.1: Schematic representation of the synthetic protocol used to generate the harmo-
nine enantiomers (5) as well as the OH-analog rac-48 and C17-harmonine rac-58. 
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Bioactivity and structure-activity relationship studies of the synthesized compounds 
(chapter 3.3)  
The previously synthesized compounds were used to determine the biological activities of 
harmonine (5) as well as to study structure-activity relationships. At first, microbial growth 
inhibition assays with the Gram-negative bacterium E. coli and the Gram-positive bacterium 
B. subtilis were conducted. These assays confirmed an antibacterial activity of both 
harmonine enantiomers (5) and showed that C17-harmonine rac-58 is equally active. The OH-
analog rac-48 showed a lower antibacterial activity. In terms of structure-activity 
relationships, this assay led to the conclusion that neither the stereochemistry of the amino 
group at C-17 of harmonine (5) nor the chain length of the carbon backbone is important for 
the antibacterial activity. The replacement of the amino groups through one or two alcohol 
functions reduces the activity drastically.  
Next, the acetylcholinesterase (AChE) inhibitory activity of the synthesized compounds was 
evaluated. In general, both harmonine enantiomers (5) showed the same, moderate AChE 
inhibitory activity. The C17-harmonine rac-58 showed a slightly reduced activity, but on the 
same scale. The inhibitory activity of rac-48 could only be approximated due to solubility 
problems under the assay conditions but is, however, lower than the activities of 5 and 
rac-58. The inhibitory effect on AChE seems to be more specific than the antibacterial effect. 
Since the stereochemistry of the amino group is again not important, an interaction of the 
compounds with the periphery of the enzyme is assumed.  
The most active compounds could also be tested against the Leishmania parasite L. major 
with the help of the research group of Dr. Uta Schurigt. During the accomplishment of this 
thesis the antileishmanial activity of (R)-harmonine ((R)-5) was demonstrated for the first 
time. The determined IC50 value was considerably lower than the one obtained for miltefo-
sine (24), the current drug in use. Again, both harmonine enantiomers (5) showed the same 
activity and rac-48 was slightly less active.  
Due to the discovery of non-neuronal AChEs in the Trypanosomatidae family[139] the 
possibility of a “leishmanial AChE” was examined. Candidates were selected using BLAST 
and subsequently modeled with the help of PD Dr. Wolfgang Brandt. Docking studies with 
the obtained model confirmed that harmonine (5) binds close to the active center of the 
possible “leishmanial AChE” with the amino group at C-17 in the periphery of the enzyme 
nicely explaining the observed structure-activity relationships.  
In conclusion, an efficient synthesis of the harmonine enantiomers (5) was developed and, 
inter alia, their antileishmanial activity was proven for the first time.  
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5 Zusammenfassung  
Der asiatische Marienkäfer Harmonia axyridis hat im Laufe der letzten Jahre enorme Auf-
merksamkeit auf sich gezogen. Dieser karnivore Käfer ist im asiatischen Raum beheima-
tet[31, 37] und vertilgt große Mengen an Blattläusen, Schildläusen und Milben.[39] Dies führte 
zu seinem großflächigen Einsatz in der biologischen Schädlingsbekämpfung. Mit der Zeit 
siedelten sich allerdings erste H. axyridis Populationen an, welche bereits vor 20 Jahren 
begannen invasiv zu werden und sich weltweit zu verbreiten.[44, 50] Für die einheimischen 
Marienkäferarten stellt H.axyridis dabei eine große Bedrohung dar, da er deren Bestände 
beträchtlich dezimiert.[44, 50] Der außergewöhnliche, invasive Erfolg von H. axyridis ist auf 
mehrere Faktoren zurückzuführen: Zunächst dominiert der kannibalische asiatische 
Marienkäfer trophische Wechselwirkungen mit natürlichen Gegenspielern (intraguild 
predator).[10] Weiterhin wird H. axyridis seltener von Fressfeinden attakiert[13] und ist 
resistenter gegenüber Krankheitserregern[17]. Diese Resistenzen lassen sich auf Harmonin 
((R)-5), die sich in der Hämolymphe befindliche Abwehrsubstanz von H. axyridis 
zurückführen.  
Das langkettige, aliphatische Alkaloid (R)-5 weist eine Vielzahl interessanter biologischer 
Eigenschaften auf. So ist Harmonin ((R)-5) unter anderem wirksam gegen 12 verschiedene 
Bakterienstämme, zeigt Aktivität gegen Candida albicans und vier Mykobakterien Stämme; 
Mycobacterium tuberculosis eingeschlossen.[27] Des Weiteren inhibiert (R)-5 auch das 
Wachstum des Parasiten P. falciparum und demonstriert damit anti-Malaria Aktivität.[27] 
Gegen fünf humane Krebszelllinien erweist sich Harmonine ((R)-5) als zytotoxisch.[28]  
Obwohl H. axyridis und Harmonin ((R)-5) in den letzten Jahren mehrfach untersucht wurden, 
sind immer noch viele Zusammenhänge ungeklärt. Das Hauptaugenmerk dieser Dissertation 
lag deshalb darauf, den gegenwärtigen Wissensfundus über Harmonin ((R)-5) mittels analy-
tischer, chemischer und biologischer Methoden zu erweitern.  
Analyse der Hämolymphe von H. axyridis (Kapitel 3.1)  
Zunächst wurde die Zusammensetzung der Hämolymphe von H. axyridis untersucht. Dazu 
wurde eine verlässliche Käferzucht etabliert. Um einen möglichen Effekt der Futtermittel auf 
die Hämolymph-Zusammensetzung zu studieren, wurden die Käfer entweder auf Motteneiern 
(Sitotroga) oder auf Erbsenblattläusen (A. pisum) gehalten. Nach der Entnahme der Hämo-
lymphe wurden die Proben mit MBTFA derivatisiert und mittels GC-MS analysiert um 
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schnelle und reproduzierbare Ergebnisse zu erhalten und selbst die Identifikation von 
Minderkomponenten zu ermöglichen. Im Allgemeinen konnten in der Hämolymphe nur 
wenige Verbindungen detektiert werden und die Zusammensetzungen beider Fütterungsgrup-
pen war annähernd identisch. Harmonin ((R)-5) war in beiden Proben die Hauptkomponente. 
Neben (R)-5 wurden noch Verunreinigungen von der Cuticula sowie eine der wenigen 
Minderkomponenten (4 ‰ verglichen mit (R)-5) identifiziert. Diese zeigte im MS Spektrum 
ein dem Harmonin ((R)-5) ähnliches Fragmentierungsmuster sowie eine geringe Massen-
differenz der größeren Fragmentionen von 2 amu. Um die Struktur dieser als Dehydro-
Harmonin 26 bestimmten Hämolymph-Verbindung aufzuklären wurde die AcN-CI-MS/MS 
Technik angewendet, welche Acetonitril als Reaktandgas verwendet und die Lokalisierung 
von Doppelbindungen ௅ vor allem in Fettsäuremethylestern ௅ ermöglicht. Die symmetrische 
Struktur von 26 erlaubte allerdings keine exakte Bestimmung der Lage der Doppelbindung. 
Man kann jedoch davon ausgehen dass es sich um eine ǻ9,12-Dehydro-Harmonin-Struktur 
handelt. Zur Bestätigung der Struktur von 26 ist eine Synthese unabdingbar.  
Synthese von rac-, (R)-, und (S)-Harmonin (5), OH-Analogon rac-48 und dem kurz-
kettigen Derivat C17-Harmonin rac-58 (Kapitel 3.2) 
Da Harmonin ((R)-5) viele interessante biologische Aktivitäten aufweist, besteht eine kons-
tante Nachfrage nach synthetischem Material. Zu Beginn dieser Dissertation gab es allerdings 
nur eine aufwändige und teure Synthese,[53] die diesem Bedürfnis nicht vollständig nachkom-
men konnte.  
Im Rahmen dieser Arbeit wurde eine kurze und effektive Synthese entwickelt um das 
natürlich vorkommende (R)-Harmonin ((R)-5) sowie die racemische Form rac-5 und das bis-
lang noch nicht dargestellte unnatürliche Enantiomer (S)-Harmonin (ent-(S)-5) zu erhalten. 
Basierend auf einer „Wittig-ähnlichen One-Pot“ Reaktion wurde eine flexible Synthese 
ausgearbeitet, die die Herstellung eines ganzen Substanzspektrums ausgehend von kommer-
ziell erhältlichem Cyclooctanon (39) und Ȧ-Bromnonansäure (37) ermöglichte. 
Zunächst wurde aus Cyclooctanon (39) das racemische Lacton rac-36 und aus der Brom-
nonansäure 37 das korrespondierende Wittig-Salz 35 hergestellt. Die „Wittig-ähnliche One-
Pot“ Reaktion beider Verbindungen ergab das Kohlenstoffgerüst des Harmonins (5). Die 
Doppelbindung wurde dabei mit hoher Z-Selektivität dargestellt (Z/E  98/2). Durch nachfol-
gende Modifikationen der funktionellen Gruppen konnte Harmonin rac-5 einfach erhalten 
werden.  
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Schema 5.1: Schematische Darstellung des Syntheseprotokolls zur Gewinnung der Harmonin 
Enantiomere (5), sowie des OH-Analogons rac-48 und des C17-Harmonins rac-58.  
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Um beide Harmonin Enantiomere (5) zu erhalten wurde Pferdeleberesterase zur enantio-
selektiven Verseifung des Lactons rac-36 eingesetzt. Diese ergab das (S)-Lacton (S)-36 und 
die (R)-Hydroxysäure (R)-49 in guten Ausbeuten und mit exzellentem Enantiomerenüber-
schuß ((S)-36: ee  99.5%, (R)-49: ee  99%). Die optisch reinen Ausgangsstoffe wurden 
anschließend zur Synthese des natürlichen Harmonins ((R)-5) und des (S)-Harmo-
nins (ent-(S)-5) eingesetzt.  
Das flexible Syntheseprotokoll konnte einfach modifiziert werden um eine mögliche, bio-
synthetische Zwischenstufe (OH-Analogon rac-48) sowie ein kurzkettiges Harmonin-Derivat 
(C17-Harmonin rac-58) zu erhalten. Beide Substanzen wurden synthetisiert um Erkenntnisse 
über die Struktur-Wirkbeziehungen von Harmonin ((R)-5) zu erlangen. Eine Zusammen-
fassung der Synthesestrategie ist in Schema 5.1 gezeigt.  
Bioaktivitätsstudien und Struktur-Wirkbeziehungs-Studien der synthetisierten Verbin-
dungen (Kapitel 3.3)  
Die synthetisierten Verbindungen wurden nun zur Bestimmung der biologischen Aktivitäten 
des Harmonins (5) sowie zur Analyse von Struktur-Wirkbeziehungen eingesetzt. Zunächst 
wurden Hemmhoftests mit E. coli und B. subtilis, als Modelle für Gram-positive beziehungs-
weise Gram-negative Bakterienstämme, durchgeführt. Diese bestätigten die antibakterielle 
Wirkung der Harmonin Enantiomere (5) und zeigten, dass C17-Harmonin rac-58 ähnlich aktiv 
ist. Lediglich das OH-Analogon rac-48 zeigte eine geringere Aktivtät. In Bezug auf die 
durchgeführten Hemmhoftests ist ersichtlich, dass weder die Stereochemie der Aminogruppe 
an C-17 des Harmonins (5) noch die Kettenlänge des Kohlenstoffgrundgerüsts Einfluss auf 
die antibakterielle Aktivität haben. Der Austausch einer oder beider Aminogruppen durch 
Alkoholfunktionen reduziert die Aktivität allerdings deutlich.  
Weiterhin wurde die Acetylcholinesterase-hemmende (AChE) Wirkung der Verbindungen 
evaluiert. Im Allgemeinen zeigten die Harmonin Enantiomere (5) erneut die gleiche, mode-
rate Aktivität. C17-Harmonin rac-58 wies eine ähnliche, allerdings leicht geringere Aktivität 
auf. Die inhibitorische Aktivität von rac-48 konnte nur abgeschätzt werden, da sich dieses 
unter Assay-Bedingungen nicht vollständig löste. Sie war allerdings geringer als die 
ermittelten Aktivitäten für 5 und rac-58. Die AChE-inhibierende Wirkung des Harmonins (5) 
scheint spezifischer zu sein als sein antibakterieller Effekt. Da die Stereochemie der 
Aminogruppe an C-17 des Harmonins (5) allerdings nicht von Bedeutung ist, wird eine 
Interaktion der Verbindungen mit der Peripherie des Enzyms angenommen.  
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Die aktivsten Verbindungen konnten mit Hilfe der Forschungsgruppe von Frau Dr. Uta 
Schurigt ebenfalls auf ihre Wirkung gegen den Humanparasiten L. major getestet werden. Im 
Rahmen dieser Dissertation wurde zum ersten Mal die anti-Leishmaniose Wirkung von 
(R)-Harmonin ((R)-5) gezeigt. Der bestimmte IC50 Wert war dabei deutlich geringer als der 
ermittelte Wert des momentan verwendeten Medikaments Miltefosin (24). Beide Harmonin 
Enantiomere (5) waren gleich effektiv gegen L. major; rac-48 wies eine geringere Aktivität 
auf.  
Da in der Trypanosomatidae Familie nicht-neuronale AChEs nachgewiesen werden konn-
ten,[139] wurde das Vorhandensein einer „Leishmania-AChE“ überprüft. Mögliche Kandidaten 
wurden mittels BLAST ermittelt und mit Hilfe von PD Dr. Wolfgang Brandt modelliert. 
Docking Studien mit dem erhaltenen Modell bestätigten, dass Harmonin (5) nahe des aktiven 
Zentrums der möglichen „Leishmania-AChE“ bindet, aber auch dass sich die Aminogruppe 
an C-17 in der Peripherie des Enzyms befindet. Dieses Ergebnis erklärt ausgezeichnet die 
beobachteten Struktur-Wirkbeziehungen sowohl in den AChE-Assays als auch in den 
Leishmanien-Assays.  
Im Rahmen dieser Dissertation wurde somit eine effektive Synthese beider Harmonin 
Enantiomere (5) entwickelt und, unter anderem, deren anti-Leishmaniose Wirkung erstmals 
gezeigt.  
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6 Materials and Methods  
 
6.1 General Information 
The NMR spectra were recorded with a Bruker AV 400 spectrometer (Bruker, Rheinstetten/ 
Karlsruhe, Germany) operating at 400 MHz (1H) or 100 MHz (13C). All chemical shifts (ɷ) 
are reported in ppm and referenced to the residual solvent peak (CDCl3: 7.27 (1H), 77.0 
(13C)). For structural elucidation COSY, HSQC and HMBC spectra were used.  
Infrared spectra (700 – 4000 cm-1, resolution: 2 cm-1) were recorded using a Bruker Equinox 
55 FTIR spectrophotometer in transmission mode.  
GC-MS analysis of synthesized compounds or of hemolymph samples were conducted with a 
Trace MS connected to a Trace GC 2000 Series (ThermoQuest, Austin, TX, USA) and an 
Alltech DB5 column (30 m × 0.25 m, 0.25 μm) with helium as carrier gas (1.5 ml min-1) and 
EI (70 eV) for ionization. 1 μl of the sample was automatically injected with an A200SE 
(CTCAnalytics, Zwingen, Switzerland). The data were acquired using the software package 
Finnigan Xcalibur 2.07. The following methods were used:  
Hemolymph Analysis: 50 °C (3 min) - 7.5 °C min-1 - 280 °C (4 min) - 10 °C min-1 - 300 °C 
(1 min), inlet T: 250 °C, split flow: 15 ml min-1, split ratio: 10:1  
Z/E Determination: 50 °C (2 min) - 1 °C min-1 - 280 °C - 30 °C min-1 - 300 °C (5 min), 
inlet T: 250 °C, split flow: 15 ml min-1, split ratio: 10:1  
Synthesis I:  60 °C (1 min) - 7 °C min-1 - 250 °C - 30 °C min-1 - 300 °C (2 min), 
inlet T: 250 °C, split flow: 20 ml min-1, split ratio: 13:1 
Synthesis II:  50 °C (2 min) - 10 °C min-1 - 280 °C - 30 °C min-1 - 300 °C (5 min), 
inlet T: 250 °C, split flow: 15 ml min-1, split ratio: 10:1 
Volatile Compounds:  45 °C (2 min) - 5 °C min-1 - 180 °C - 30 °C min-1 - 300 °C (2 min), 
inlet T: 250 °C, split flow: 15 ml min-1, split ratio: 10:1 
For the determination of the enantiomeric excess of chiral compounds an ITQ 900 (Thermo 
Fisher Scientific, Waltham, MA, USA) connected to a Trace GC Ultra (Thermo Fisher Scien-
tific, Waltham, MA, USA) equipped with a Hydrodex-ɴ-6TBDM column (25 m × 0.25 m) 
was used. Helium was used as carrier gas (1.0 ml min-1) and EI (70 eV) for ionization. An 
Materials and Methods 
 
70 
 
A200SE (CTCAnalytics, Zwingen, Switzerland) automatic sampler injected 1 μl of the 
sample. For data acquisition the software package Finnigan Xcalibur 2.07 was used.  
ee Lactone:  100 °C (20 min) - 15 °C min-1 - 200 °C (2 min), inlet T: 200 °C, 
split flow: 10 ml min-1, split ratio: 10:1 
ee Hydroxy acid:  60 °C (5 min) - 0.1 °C min-1 - 120 °C (5 min) - 40 °C min-1 - 200 °C 
(3 min), inlet T: 200 °C, split flow: 10 ml min-1, split ratio: 10:1 
To detect molecular ions of synthetic compounds the same device was used in CI mode (CI 
gas: methane) equipped with a Restek RTX-200MS (30 m x 0.25 mm, 0.25 ȝm; Restek, Bad 
Homburg, Germany) column. Helium was used as carrier gas (1.0 ml min-1). 
CI positive:  50 °C (2 min) - 10 °C min-1 - 230 °C (2 min), inlet T: 240 °C, split 
flow: 14 ml min-1, split ratio: 9:1 
The HPLC-MS spectra were obtained using a Finnigan LTQ (Thermo Electron Company, 
Waltham, MA, USA) MS in APCI mode connected to a Purospher STAR RP 18 column 
(250 mm × 4 mm, 5 μm). Flow rate: 1 ml min-1. Solvents: A: H2O + 0.1% formic acid, B: 
AcN + 0.1% formic acid.  
LC Method:  20% B (0 min - 5 min, isocratic) - 100% B (5 min - 36 min, 
gradient) - 100% B (36 min - 41 min, isocratic) - 20% B (41 min - 
42 min, gradient) - 20% B (42 min - 50 min, isocratic)  
HR-MS spectra were either recorded with a QExactive Plus MS (Thermo Fisher Scientific, 
Waltham, MA, USA)) running with a RP-18 column (150 mm × 2.1 mm, 120 Å) or through 
direct injection into the ESI source (capillary T = 275 °C) or with a Hewlett Packgard 
6890 GC equipped with a Phenomenex ZB5HT column (30 m × 0.25 m, 0.25 μm) and linked 
to a Masspec MS02 (Mircomass, UK) (ionization: EI, 70 eV). 
The optical rotation of enantiopure compounds was determined with a JASCO P1030 polari-
meter at a specific wavelength of 589 nm (T = 22 - 24 °C).  
For thin layer chromatography silica gel 60 F254 on aluminum sheets (Merck, Darmstadt, 
Germany) was used. The separated compounds were detected using Hanessian’s stain, 
potassium permanganate stain or vanillin.  
Preparative column chromatography was conducted with silica gel (40 - 63 μm, Macherey-
Nagel, Düren, Germany) or Lichroprep RP-18 silica gel (40 - 63 μm, Merck, Darmstadt, 
Germany).  
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Solvents were purchased in HPLC grade and used without further purification. Except for 
diethyl ether, which was distilled prior to use. Anhydrous solvents were purchased as such.  
Horse liver esterase was obtained as lyophilized powder (0.5-1.0 U/mg, Sigma Aldrich, 
Schnelldorf, Germany). 
H. axyridis larvae (third and fourth instar) were collected in spring in Jena, Germany or in 
Mitwitz, Germany. The larvae – and later beetles – were kept in Gerda boxes (20 cm × 
20 cm × 9,5 cm, Westmark, Lennestadt-Elspe, Germany) equipped with a fine-meshed net for 
air circulation in a climate chamber (Vötsch Industrietechnik, Type VB 1014/S, Balingen, 
Germany). Sitotroga eggs (Katz Biotech AG, Baruth, Germany) or pea aphids (A. pisum) 
reared on bean plants (Broad Bean “The Sutton”, Hazera Seeds UK Ltd., Rothwell, UK) in 
rotho boxes (23 cm × 22,5 cm × 27,5 cm, Rotho Kunststoff AG, Würenlingen, Switzerland) 
were used as feed.  
Dissections were conducted with a StemiDV4 microscope (Carl Zeiss Lichtmikroskopie, 
Göttingen, Germany), spring steel tweezers and micro scissors. Hemolymph samples were 
dried using an eppendorf Concentratorplus (Eppendorf AG, Hamburg, Germany). The default 
derivatization reagent was N-methyl-bis(triflouroacetamide) (Sigma-Aldrich, St. Louis, MO, 
USA).  
For microbial growth inhibition assays LB-agar (Lennox) and LB-medium (Lennox) (both 
Carl Roth GmbH + Co. KG, Karlsruhe, Germany) were used.  
AChE inhibition assays were conducted in crystal-clear 96 well microplates (Greiner Bio-one 
GmbH, Kremsmünster, Austria). Amplite Colorimetric Acetylcholinesterase Assay Kit (AAT 
Bioquest Inc., Sunnydale, CA, USA) and a Spectra MAX 190 (Molecular Devices LLC., 
Sunnyvale, CA, USA) were used to determine the enzymatic activity. IC50 values were 
calculated using GraphPad Prism 5.04 software (nonlinear regression, log(inhibitor) vs. 
response – variable slope; Fitting method: least squares (ordinary) fit) and graphs were 
illustrated using Origin8.   
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6.2 Syntheses 
Most of the following syntheses in chapter 6.2.1, 6.2.2 and 6.2.4 were already published in 
“Efficient synthesis of (R)-harmonine – the toxic principle of the multicolored Asian lady 
beetle (Harmonia axyridis)” (authors: Nagel, N. C. et al.)[55] and are subsequently cited 
thereof.  
 
6.2.1 Synthesis of rac-Harmonine (rac-5)  
6.2.1.1 Synthesis of 2-Methylcyclooctan-1-one (rac-38)  
Diisopropylamine (18.0 ml, 127.3 mmol) was dissolved in dry THF 
(230 ml) under argon atmosphere and cooled to 0 °C. n-BuLi (1.6 M in 
hexane, 86.6 ml, 138.6 mmol) was added dropwise and the reaction 
mixture was stirred at 0 °C for another 30 minutes before cyclooctanone 
(39) (15.9 g, 125.9 mmol) dissolved in dry THF (75 ml) was added. The 
solution was again stirred for 30 minutes, cooled to -78 °C and MeI 
(11.0 ml, 176.4 mmol) was added. After 15 minutes, the cooling bath was removed, the 
reaction mixture was allowed to warm to room temperature and stirred for 17 hours. Then it 
was poured into saturated NH4Cl solution (150 ml) and extracted with Et2O (150 ml). The 
phases were separated and the organic phase was first washed with saturated Na2CO3 solution 
(150 ml), HCl (1 M, 100 ml) and saturated MgCl2 solution (150 ml) and then dried over 
MgSO4. The solvent was removed under reduced pressure yielding the crude 2-methyl-
cyclooctan-1-one (rac-38) which was used without further purification (17.1 g, 121.9 mmol, 
97%).[111] 
HRMS m/z calcd for C9H16O 140.1199 [M]+·, found 140.1201  
IR (thin film, cm-1) Ȟ 2930 (s), 2858 (m), 1704 (s), 1448 (m), 1373 (m), 1242 (w), 1160 (w), 
1122 (w), 1082 (w) 
1H NMR (400 MHZ, CDCl3) į 2.65 – 2.53 (m, 1 H, H-2), 2.43 – 2.33 (m, 2 H, H-8), 1.96 – 
1.88 (m, 2 H, H-3a/H-7a), 1.80 – 1.71 (m, 1 H, H-7b), 1.70 – 1.56 (m, 2 H, H-3b/H-5a), 
1.56 – 1.29 (m, 4 H, H-4a/H-5b/H-6), 1.26 – 1.13 (m, 1 H, H-4b), 1.02 (d, 3J9,8 = 7.0 Hz, 3 H, 
H-1’)  
O
rac-38
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13C NMR (100 MHz, CDCl3) į 220.3 (C-1), 45.2 (C-2), 40.3 (C-8), 33.1 (C-3), 26.9 (C-6), 
26.5, 25.6, 24.5 (C-4/C-5/C-7), 16.8 (C-1’) 
MS (GC-MS, EI) m/z (%) 140 ([M]+·, 20), 112 (40), 98 (76), 83 (100), 67 (38), 55 (62) 
 
6.2.1.2 Synthesis of 9-Methyloxonan-2-one (rac-36)  
2-Methylcyclooctan-1-one (rac-38) (2.2 g, 15.88 mmol) was dissolved 
in chloroform (20 ml) and m-CPBA (5.2 g, 30.17 mmol) was added at 
room temperature. The solution was stirred for 11 days. Then, 
additional m-CPBA (548 mg, 3.18 mmol) was added and the reaction 
mixture was heated to reflux for 24 hours. The solution was cooled to 
room temperature, filtered over Celite and the solvent was removed 
under reduced pressure. The residue was dissolved in Et2O (20 ml) and washed with saturated 
Na2S2O3 solution (2 × 20 ml), saturated Na2CO3 solution (2 × 20 ml) and saturated MgCl2 
solution (20 ml). The ethereal phase was dried over MgSO4 and the solvent was removed 
under reduced pressure. After purification by column chromatography on silica gel using 
DCM as eluent, (rac-36) was obtained as colorless liquid (1.4 g, 9.20 mmol, 58%). Rf = 0.62 
(DCM).[111] 
HRMS m/z calcd for C9H16O2 156.1150 [M]+·, found 156.1156  
IR (thin film, cm-1) Ȟ 2929 (s), 2857 (m), 1710 (s), 1461 (w), 1410 (w), 1375 (w), 1258 (s), 
1100 (w), 940 (w)  
1H NMR (400 MHZ, CDCl3) į 5.07 (mc, 1 H, H-9), 2.25 (mc, 2 H, H-3), 1.93 (mc, 1 H, 
H-5a), 1.82 – 1.74 (m, 1 H, H-8a), 1.72 – 1.64 (m, 1 H, H-4a), 1.67 – 1.55 (m, 2 H, H-7a/ 
H-4b), 1.55 – 1.43 (m, 3 H, H-8b/H-6a/H-5b), 1.37 – 1.27 (m, 2 H, H-7b/H-6b), 1.25 (d, 
3J9,8 = 6.5 Hz, 3 H, H-1’)  
13C NMR (100 MHz, CDCl3) į 175.6 (C-2), 71.6 (C-9), 35.7 (C-3), 35.1 (C-8), 29.4 (C-6), 
25.0 (C-5), 23.9 (C-4), 21.9 (C-7), 20.7 (C-1’)  
MS (GC-MS, EI) m/z (%) 156 ([M]+·, 0.8), 138 (18), 113 (48), 97 (77), 95 (43), 83 (77), 67 
(100) 
 
  
Materials and Methods 
 
74 
 
6.2.1.3 Synthesis of Isopropyl 9-Bromononanoate (40) 
9-Bromononanoic acid (37) (5.2 g, 21.92 mmol) was dissolved in 
dry 2-propanol (50 ml) and sulfuric acid (1 ml) was added. The 
flask was equipped with a Dean-Stark apparatus and the solution 
was heated to reflux for 19 hours. After the solution cooled down 
to room temperature, 2-propanol was removed under reduced 
pressure, the residue was dissolved in Et2O (20 ml) and the organic solution was washed with 
saturated Na2CO3 solution (20 ml), distilled water (20 ml) and saturated NaCl solution 
(20 ml). The ethereal solution was dried over MgSO4, the solvent was removed and the crude 
product was purified by column chromatography on silica gel (DCM). After removal of the 
solvent 40 was obtained as a colorless oil (5.23g, 18.73 mmol, 86%). Rf = 0.70 (DCM).[55] 
HRMS m/z calcd for C12H23O2BrNa, C12H23O281BrNa 301.0774, 303.0753 [M + Na]+·, 
found 301.0776, 303.0753  
IR (thin film, cm-1) Ȟ 2979 (m), 2932 (s), 2857 (m), 1731 (s), 1466 (m), 1374 (m), 1256 (m), 
1181 (m), 1145 (w), 1110 (s), 964 (w)  
1H NMR (400 MHz, CDCl3) į 5.00 (sp, 3J1’,2’ = 3J1’,2” = 6.2 Hz, 1 H, H-1’), 3.40 (t, 3J9,8 = 
6.9 Hz, 2 H, H-9), 2.26 (t, 3J2,3 = 7.6 Hz, 2 H, H-2), 1.85 (mc, 2 H, H-8), 1.61 (mc, 2 H, H-3), 
1.42 (mc, 2 H, H-7), 1.34 – 1.28 (m, 6 H, H-6 – H-4), 1.22 (d, 3J2’,1’ = 3J2”,1’ =6.2 Hz, 6 H, 
H-2’/H-2”)  
13C NMR (100 MHz, CDCl3) į 173.3 (C-1), 67.3 (C-1’), 34.6 (C-2), 33.9 (C-9), 32.7 (C-8), 
29.0, 29.0 (C-5/C-4), 28.5 (C-6), 28.1 (C-7), 24.9 (C-3), 21.8 (C-2’, C-2”)  
MS (GC-MS, EI) m/z (%) 280, 278 ([M]+·, 0.04), 265 (0.08), 263 (0.08), 239 (14), 237 (14), 
221 (48), 219 (48), 157 (58), 139 (100), 121 (34), 97 (38), 73 (16), 61 (38), 55 (40) 
 
6.2.1.4 Synthesis of (9-Isopropoxy-9-oxononyl)triphenylphosphonium Bromide (35) 
Isopropyl 9-bromononanoate (40) (2.89 g, 10.35 mmol) was 
dissolved in dry toluene (65 ml) and PPh3 (2.71 g, 
10.35 mmol) was added. The solution was refluxed for 
24 hours under argon, cooled to room temperature and the 
supernatant was transferred to a new flask. There again PPh3 
(1.36 g, 5.18 mmol) was added and the solution was stirred under reflux for 3 days. After 
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cooling to room temperature, the supernatant was discarded and both bottom layers were 
combined and purified by column chromatography on silica gel (DCM/MeOH 14:1). The 
solvents were removed under reduced pressure and 35 was obtained as a sticky syrup (4.33 g, 
8.00 mmol, 77%). Rf = 0.51 (DCM/MeOH 14:1).[55] 
HRMS m/z calcd for C30H38O2P 461.2604 [M]+, found 461.2601  
IR (thin film, cm-1) Ȟ 3057 (w), 2977 (w), 2855 (s), 2802 (w), 1720 (s), 1587 (w), 1522 (w), 
1485 (m), 1104 (m), 856 (s), 842 (s)  
1H NMR (400 MHZ, CDCl3) į 7.88 – 7.76 (m, 9 H, Har-6/Har-2/Har-4), 7.74 – 7.67 (m, 6 H, 
Har-5/Har-3), 4.96 (sp, 3J1’,2’ = 3J1’,2” = 6.2 Hz, 1 H, H-1’), 3.82 – 3.71 (m, 2 H, H-1), 2.19 (t, 
3J2,3 = 7.5 Hz, 2 H, H-8), 1.68 – 1.56 (m, 4 H, H-3/H-2), 1.52 (mc, 2 H, H-7), 1.30 – 1.21 (m, 
6 H, H-6 - H-4), 1.20 (d, 3J2’,1’ = 3J2”,1’ = 6.2 Hz, 6 H, H-2”/H-2’)  
13C NMR (100 MHz, CDCl3) į 173.3 (C-9), 134.9, 134.9 (Car-4), 133.7, 133.6 (Car-6/Car-2), 
130.5, 130.4 (Car-5/Car-3), 118.7, 118.1 (Car-1), 67.3 (C-1’), 34.6 (C-8), 30.3, 30.2 (C-3), 
28.9, 28.9, 28.7 (C-6 – C-4), 24.8 (C-7), 22.9, 22.6 (C-1), 22.6, 22.6 (C-2), 21.8 (C-2’/C-2”) 
 
6.2.1.5 Synthesis of Isopropyl (9Z)-17-Hydroxyoctadec-9-enoate (rac-34)  
A cold solution (-78 °C) of 9-methyloxonan-2-one 
(rac-36) (78 mg, 0.5 mmol) in dry toluene (2.7 ml) was 
treated within 10 min with DiBAL-H (0.6 ml, 0.6 mmol, 
1 M in hexane). Stirring was continued for another 
40 minutes and excess of DiBAL-H was quenched by 
addition of dry MeOH (5 μl). Next, the cold solution 
was transferred into a cold solution (-78 °C) of the 
phosphorous ylid, prepared from (9-isopropoxy-9-oxononyl)triphenylphosphonium bromide 
(35) (325 mg, 0.6 mmol) in dry THF (3.5 ml) and KHMDS (120 mg, 0.6 mmol). The reaction 
mixture was warmed to room temperature during 1 hour. Stirring was carried on for 1 hour 
and the mixture was hydrolyzed by the addition of 5% HCl (2.6 ml). The layers were 
separated and the aqueous phase was extracted with Et2O (2 × 5 ml). The combined organic 
extracts were washed with 5% HCl (20 ml), saturated NaHCO3 solution (20 ml) and water 
(20 ml). After removal of the solvents under reduced pressure, the crude product was purified 
by column chromatography on silica gel using hexane/ethyl acetate (5:1) for elution. 
Removal of the solvents yielded (rac-34) as a colorless oil (49 mg, 0.13 mmol, 26%, 
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Z/E > 98/2; Ylid preparation with n-BuLi: 29%, Z/E 80/20 ). Rf = 0.18 (hexane/ethyl 
acetate 5:1).[55] 
HRMS m/z calcd for C21H40O3 340.2978 [M]+·, found 340.2985  
IR (thin film, cm-1) Ȟ 3401 (br, m), 2977 (m), 2964 (m), 2925 (s), 2854 (s), 1732 (s), 1655 
(w), 1465 (m), 1374 (m), 1247 (m), 1181 (m), 1145 (m), 1109 (s)  
1H NMR (400 MHZ, CDCl3) į 5.40 – 5.31 (m, 2 H, H-10/H-9), 5.01 (sp, 3J1’,2’ = 3J1’,2” = 
6.2 Hz, 1 H, H-1’), 3.79 (tq, 3J17,18 = 3J17,16 = 6.1 Hz, 1 H, H-17), 2.26 (t, 3J2,3 = 7.7 Hz, 2 H, 
H-2), 2.04 – 1.96 (m, 4 H, H-11/H-8), 1.61 (mc, 2 H, H-3), 1.48 – 1.38 (m, 2 H, H-16), 1.36 – 
1.27 (m, 16 H, H-15 – H-12/H-7 – H-4), 1.23 (d, 3J2’,1’ = 3J2”,1’ = 6.3 Hz, 6 H, H-2’/H-2”), 
1.19 (d, 3J18,17 = 6.2 Hz, 3 H, H-18)  
13C NMR (100 MHz, CDCl3) į 173.4 (C-1), 129.8 (C-10/C-9), 68.1 (C-17), 67.3 (C-1’), 39.4 
(C-16), 34.7 (C-2), 29.7, 29.5, 29.2, 29.1, 29.1, 25.7 (C-15 – C-12/C-7 – C-4), 27.2, 27.2 
(C-11/C-8), 25.0 (C-3), 23.5 (C-18), 21.9 (C-2’/C-2”)  
MS (GC-MS, EI) m/z (%) 340 ([M]+·, 0.3), 322 (1.5), 279 (26), 123 (37), 109 (56), 95 (87), 
81 (98), 67 (92), 55 (100), 43 (80), 41 (71)  
 
6.2.1.6 Synthesis of (9Z)-Octadec-9-ene-1,17-diol (rac-41)  
LiAlH4 (99 mg, 2.62 mmol) was suspended at 0 °C in 
dry THF (7.5 ml) and the ester rac-34 (297 mg, 
0.87 mmol) was added slowly. The reaction mixture was 
allowed to come to room temperature and stirred for 
4.5 hours. Et2O (9 ml) and water (10 ml) were added, the 
phases were separated and the aqueous layer was 
extracted with Et2O (3 × 10 ml). The combined organic extracts were washed with water 
(30 ml) and dried over Na2SO4. The solvent was removed under reduced pressure and the 
residue was purified by column chromatography on silica gel using hexane/ethyl acetate (1:1) 
for elution. After removal of the solvents, rac-41 was obtained as slightly yellow oil (243 mg, 
0.85 mmol, 98%). Rf = 0.35 (hexane/ethyl acetate 1:1).[55] 
HRMS m/z calcd for C18H36O2 284.2715 [M]+·, found 284.2705  
IR (thin film, cm-1) Ȟ 3332 (br, m), 3004 (w), 2926 (s), 2854 (s), 1654 (w), 1462 (m), 1373 
(m)  
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1H NMR (400 MHZ, CDCl3) į 5.40 – 5.30 (m, 2 H, H-10/H-9), 3.79 (tq, 3J17,18 = 3J17,16 = 
5.9 Hz, 1 H, H-17), 3.63 (t, 3J1,2 = 6.6 Hz, 2 H, H-1), 2.06 – 1.95 (m, 4 H, H-11/H-8), 1.95 – 
1.80 (br, 2 H, O-H), 1.56 (tt, 3J2,3 = 3J2,1 = 6.7 Hz, 2 H, H-2), 1.49 – 1.38 (m, 2 H, H-16), 
1.38 – 1.25 (m, 18 H, H-15 – H-12/H-7 – H-3), 1.18 (d, 3J18,17 = 6.0 Hz, 3 H, H-18)  
13C NMR (100 MHz, CDCl3) į 129.9, 129.8 (C-10/C-9), 68.2 (C-17), 63.0 (C-1), 39.3 
(C-16), 32.7 (C-2), 29.7, 29.7, 29.5, 29.4, 29.4, 29.2, 29.1 (C-14 – C-12/C-7 – C-4), 27.1 
(C-11/C-8), 25.7 (C-15/C-3), 23.4 (C-18)  
MS (GC-MS, EI) m/z (%) 284 ([M]+·, 0.6), 266 (10), 149 (6), 135 (14), 124 (24), 110 (56), 96 
(84), 95 (82), 82 (85), 81 (98), 67 (98), 55 (100)  
 
6.2.1.7 Synthesis of (9Z)-1,17-Diazidooctadec-9-ene (rac-42)  
(9Z)-Octadec-9-ene-1,17-diol (rac-41) (218 mg, 
0.77 mmol) was dissolved in dry THF (13 ml) and cooled 
to 0 ºC. PPh3 (836 mg, 3.19 mmol), DPPA (0.97 ml, 
4.51 mmol) and DIAD (0.85 ml, 4.29 mmol) were 
successively added with stirring and the reaction mixture 
was allowed to warm to room temperature. After 4 hours 
the solvent was removed and the reaction product was purified by column chromatography 
on silica gel using hexane/DCM (3:1) for elution. Removal of solvents afforded rac-42 as a 
colorless oil (195 mg, 0.58 mmol, 76%). Rf = 0.30 (hexane/DCM 3:1).[55]  
HRMS m/z calcd for C18H34N6Na 357.2737 [M + Na]+, found 357.2737  
IR (thin film, cm-1) Ȟ 3004 (w), 2928 (s), 2855 (s), 2094 (s), 1653 (w), 1459 (m), 1378 (w), 
1249 (s)  
1H NMR (400 MHZ, CDCl3) į 5.42 – 5.30 (m, 2 H, H-10/H-9), 3.42 (tq, 3J17,18 = 3J17,16 = 
6.5 Hz, 1 H, H-17), 3.26 (t, 3J1,2 = 7.0 Hz, 2 H, H-1), 2.07 – 1.94 (m, 4 H, H-11/H-8), 1.61 (tt, 
3J2,3 = 3J2,1 = 7.0 Hz, 2 H, H-2), 1.57 – 1.28 (m, 20 H, H-16 – H-12/H-7 – H-3), 1.25 (d, 
3J18,17 = 6.6 Hz, 3 H, H-18)  
13C NMR (100 MHz, CDCl3) į 129.9, 129.8 (C-10/C-9), 58.0 (C-17), 51.5 (C-1), 36.2 
(C-16), 29.7, 29.6, 29.4, 29.3, 29.2, 29.1, 29.1 (C-14 – C-12/C-7 – C-4), 28.8 (C-2), 27.2, 
27.1 (C-11/C-8), 26.7 (C-3), 26.1 (C-15), 19.5 (C-18)  
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6.2.1.8 Synthesis of (9Z)-Octadec-9-ene-1,17-diamine (rac-5)  
LiAlH4 (177 mg, 3.95 mmol) was suspended with 
stirring in dry THF (11 ml) and cooled to 0 ºC. A 
solution of (9Z)-1,17-diazidooctadec-9-ene (rac-42) 
(165 mg, 0.49 mmol) in dry THF (5 ml) was added 
dropwise and the suspension was warmed to room 
temperature. After stirring for 4 hours water (30 ml) 
and CHCl3 (30 ml) were added, the layers were separated and the aqueous phase was 
extracted with CHCl3 (6 × 30 ml). The organic extracts were combined and solvents were 
removed under reduced pressure. The product was taken up in MTBE (80 ml) and 2% HCl 
(80 ml). The layers were separated, the aqueous phase was carefully extracted with MTBE 
(3 × 20 ml) and the combined organic extracts were washed with 2% HCl (30 ml). The 
aqueous solutions were combined and MTBE (40 ml) and NH3 (25% aqueous solution, 
80 ml) were added. After separation of the two layers, the aqueous phase was extracted with 
MTBE (3 × 60 ml). The combined organic extracts were dried over Na2SO4 and the solvent 
was evaporated under reduced pressure to yield (rac-5) as colorless oil (139 mg, 0.49 mmol, 
quant.).[55]  
HRMS m/z calcd for C18H39N2 283.3108 [M + H]+, found 283.3106  
IR (thin film, cm-1) Ȟ 3320 (m), 3004 (w), 2921 (s), 2851 (s), 1639 (w), 1564 (m), 1468 (m), 
1430 (w), 1390 (m), 1331 (m)  
1H NMR (400 MHZ, CDCl3) į 5.38 – 5.27 (m, 2 H, H-10/H-9), 2.85 (tq, 3J17,18 = 3J17,16 = 
6.0 Hz, 1 H, H-17), 2.66 (t, 3J1,2 = 7.0 Hz, 2 H, H-1), 2.04 – 1.91 (m, 4 H, H-11/H-8), 1.50 – 
1.38 (m, 6 H, H-2, N-H2), 1.36 – 1.21 (m, 20 H, H-16 – H-12/H-7 – H-3), 1.03 (d, 3J18,17 = 
6.2 Hz, 3 H, H-18)  
13C NMR (100 MHz, CDCl3) į 129.8, 129.8 (C-10/C-9), 46.9 (C-17), 42.1 (C-1), 40.1 
(C-16), 33.7 (C-2), 29.7, 29.6, 29.6, 29.4, 29.4, 29.2, 29.2 (C-14 – C-12/C-7 – C-4), 27.1 
(C-11/C-8), 26.8 (C-3), 26.3 (C-15), 23.8 (C-18)  
MS (HPLC, APCI) m/z (%) 283 ([M + H]+, 100), 264 (8)  
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6.2.2 Synthesis of (R)-Harmonine ((R)-5)  
6.2.2.1 Enzymatic hydrolysis of 9-Methyloxonan-2-one (rac-36)  
Racemic 9-methyloxonan-2-one (rac-36) (3.50 g, 22.4 mmol) was 
suspended in NaH2PO4 buffer (0.1 M, pH = 7.2, 100 ml) and stirred for 
15 minutes. Then horse liver esterase (350 mg, lyophilized powder) was 
added and the pH was kept constant by dropwise addition of 0.5 M 
NaOH during the whole reaction time. After 12 hours, another portion 
of horse liver esterase (70 mg) was added and stirring was continued for 
4 hours. Then Celite (3.50 g) and ice (7.00 g) were added, the suspension was stirred for 
5 minutes and the solids were filtered off. The filter cake was washed with Et2O (2 × 50 ml). 
The layers of the filtrate were separated and the aqueous phase was extracted with Et2O (3 × 
50 ml). The combined organic extracts were washed with saturated NaHCO3 solution 
(100 ml) and dried over Na2SO4. Evaporation of the solvent yielded (9S)-9-methyloxonan-2-
one ((S)-36) as a colorless liquid.[55]  
(9S)-9-Methyl-oxonan-2-one ((S)-36): Yield: 1.51 g (9.67 mmol, 86% of (S)-enantiomer, 
ee  99.5%).  
ሾࢻሿ۲૛૜ + 31.8 (c 1.00, THF). All other spectral data were identical to rac-36. 
 
(8R)-8-Hydroxynonanoic acid ((R)-49)  
The water phase was covered with Et2O (100 ml) and 
2 M HCl (60 ml) was added. The layers were separated 
and the aqueous phase was extracted with Et2O (3 × 
100 ml). The combined organic extracts were washed 
with saturated NaCl solution (150 ml) and dried over 
Na2SO4. The solvent was removed under reduced pressure to yield (8R)-8-hydroxynonanoic 
acid ((R)-49) as a colorless wax.[55]  
(8R)-8-Hydroxynonanoic acid ((R)-49): Yield: 1.52 g (8.72 mmol, 78% of (R)-enantiomer, 
ee  99%).  
ሾࢻሿ۲૛૜ – 8.5 (c 1.00, THF).  
HRMS m/z calcd for C9H18O3Na 197.1148 [M + Na]+, found 197.1146  
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IR (thin film, cm-1) Ȟ 3391 (br, s), 2933 (s), 2858 (s), 1711 (s), 1462 (m), 1410 (m), 1376 (m), 
1261 (m), 1127 (m), 1103 (m)  
1H NMR (400 MHZ, CDCl3) į 5.25 (br, 2 H, O-H, COO-H), 3.81 (tq, 3J8,9 = 3J8,7 = 6.1 Hz, 
1 H, H-8), 2.36 (t, 3J2,3 = 7.5 Hz, 2 H, H-2), 1.65 (tt, 3J3,4 = 3J3,2 = 7.5 Hz, 2 H, H-3), 1.50 – 
1.40 (m, 3 H, H-7/H-6a), 1.40 – 1.30 (m, 5 H, H-6b/H-5/H-4), 1.20 (d, 3J9,8 = 6.1 Hz, 3 H, 
H-9)  
13C-NMR (100 MHz, CDCl3) į 179.0 (C-1), 68.2 (C-8), 39.2 (C-7), 33.9 (C-2), 29.2, 29.0 
(C-5/C-4), 25.5 (C-6), 24.6 (C-3), 23.5 (C-9)  
MS (GC-MS, EI) m/z (%) 174 ([M]+·, 0.1), 141 (18), 130 (30), 95 (26), 87 (60), 73 (100), 69 
(20), 55 (30), 45 (72)  
 
6.2.2.2 Subsequent synthesis steps to (R)-Harmonine ((R)-5)  
Isopropyl (17S,9Z)-17-hydroxyoctadec-9-enoate  
((S)-34):  
Prepared from (9S)-9-methyloxonan-2-one ((S)-36) 
(750 mg, 4.80 mmol) as described in chapter 6.2.1.5 
(ylide preparation with n-BuLi). After purification, 
(S)-34 was obtained as colorless oil (366 mg, 1.08 mmol, 
23%, Z/E > 85/15).[55]  
ሾࢻሿ۲૛૛ + 2.9 (c 1.00, CHCl3). All other spectral data were identical to rac-34. 
 
(17S,9Z)-Octadec-9-ene-1,17-diol ((S)-41):  
Prepared from isopropyl (17S,9Z)-17-hydroxyoctadec-9-
enoate ((S)-34) (295 mg, 0.87 mmol) as described in 
chapter 6.2.1.6. After column chromatography, (S)-41 
was obtained as a colorless oil (245 mg, 0.86 mmol, 
98%).[55]  
ሾࢻሿ۲૛૛ + 3.8 (c 1.00, CHCl3). All other spectral data were identical to rac-41. 
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(17R,9Z)-1,17-Diazidooctadec-9-ene ((R)-42):  
Prepared from (17S,9Z)-octadec-9-ene-1,17-diol ((S)-41) 
(200 mg, 0.70 mmol) as depicted in chapter 6.2.1.7. 
Purification by column chromatography afforded (R)-42 
as a colorless oil (189 mg, 0.57 mmol, 81%).[55]  
ሾࢻሿ۲૛૛ – 19.7 (c 1.06, CHCl3). All other spectral data were identical to rac-42. 
 
(17R,9Z)-Octadec-9-ene-1,17-diamine ((R)-5)/(R)-Harmonine:  
Prepared from (17R,9Z)-1,17-diazidooctadec-9-ene 
((R)-42) (161 mg, 0.48 mmol) as described in chapter 
6.2.1.8. Harmonine ((R)-5) was obtained as a slightly 
yellow oil (135 mg, 0.48 mmol, 99%).[55]  
ሾࢻሿ۲૛૝ – 3.4 (c 1.04, C6H6). Spectroscopic data were identical with rac-5.  
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6.2.3 Synthesis of (S)-Harmonine ((S)-5)  
6.2.3.1 Synthesis of Methyl (8R)-8-((tert-Butyldimethylsilyl)oxy)nonanoate ((R)-50) 
(8R)-8-Hydroxynonanoic acid ((R)-49) (558 mg, 
3.20 mmol) was dissolved in a DCM/MeOH (95 ml/ 
9.5 ml) mixture and the solution was stirred for 
2 minutes. Then, (TMS)-diazomethane solution (2.0 M 
in Et2O) was added dropwise until a slightly yellow 
color remained (~ 2.3 ml). The reaction mixture was 
stirred for 1.5 hours at room temperature. Acetic acid was added until the yellow color 
fainted and the solvents were removed under reduced pressure. The residue was dissolved in 
dry DCM (43 ml) and the solution was henceforward treated under an argon atmosphere. 
Imidazole (1.36 g, 20.00 mmol) was added, the reaction mixture was cooled to 0 °C and 
TBDMSCl (1.21 g, 8.00 mmol) was added in small portions. After additional stirring for 10 
minutes, the solution was allowed to warm to room temperature and was stirred for another 
17 hours before water (25 ml) and DCM (25 ml) were added. The aqueous phase was 
extracted with DCM (3 × 25 ml) and the combined organic extracts were washed with 
saturated NaCl solution (35 ml) and dried over MgSO4. The solvent was removed under 
reduced pressure and the residue was purified by column chromatography on silica gel 
(hexane/ethyl acetate 12:1) yielding methyl (8R)-8-((tert-butyl-dimethylsilyl)oxy)-nonanoate 
((R)-50) as a colorless oil (812 mg, 2.68 mmol, 84%). Rf = 0.44 (hexane/ethyl acetate 12:1).  
ሾࢻሿ۲૛૜ – 12.0 (c 1.00, THF)  
HRMS m/z calcd for C15H31O3Si 287.2042 [M-Me·]+, found 287.2054 
IR (thin film, cm-1) Ȟ 2957 (s), 2931 (s), 2857 (s), 1743 (s), 1463 (m), 1436 (m), 1374 (m), 
1361 (m), 1254 (s), 1198 (s), 1168 (s), 1134 (s), 1104 (s), 1068 (s), 1005 (s), 939 (s), 892 (m) 
1H NMR (400 MHZ, CDCl3) į 3.77 (mc, 1 H, H-8), 3.67 (s, 3 H, H-1‘), 2.31 (t, 2 H, H-2, 
3J2,3 = 7.5 Hz), 1.63 (mc, 2 H, H-3), 1.46 – 1.23 (m, 8 H, H-4 – H-7), 1.11 (d, 3 H, H-9, 3J9,8 = 
6.1 Hz), 0.89 (s, 9 H, H-3* - H-3***), 0.05, 0.05 (2 × s, 2 × 3 H, H-1*/H-1**) 
13C NMR (100 MHz, CDCl3) į 174.3 (C-1), 68.6 (C-8), 51.4 (C-1‘), 39.6 (C-7), 34.1 (C-2), 
29.3, 29.2, 25.6 (C-4/C-5/C-6), 25.9 (C-3* - C-3***), 24.9 (C-3), 23.8 (C-9), 18.2 
(C-2*), -4.4, -4.7 (C-1*/C-1**) 
MS (GC-MS, EI) m/z (%) 287 ([M-Me·]+·, 0.4), 245 (10), 213 (50), 159 (20), 107 (35), 89 
(32), 75 (100), 73 (65), 69 (69), 55 (57)  
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6.2.3.2 Synthesis of Isopropyl (17R,9Z)-17-((tert-Butyldimethylsilyl)oxy)octadec-9-enoate 
((R)-51)  
(8R)-8-((tert-Butyldimethylsilyl)oxy)nonanoate ((R)-50) 
(576 mg, 1.90 mmol) was reacted with (9-isopropoxy-9-
oxo-nonyl)triphenylphosphonium bromide (35) (1.24 g, 
2.28 mmol) following the “Wittig-type one-pot” reaction 
protocol described in chapter 6.2.1.5. The crude product 
was purified by column chromatography on silica gel 
using pure DCM as eluent. Removal of the solvent in 
reduced pressure yielded ((R)-51) as a colorless oil (248 mg, 0.55 mmol, 29%, Z/E > 98/2). 
Rf = 0.49 (DCM).  
ሾࢻሿ۲૛૚ ௅ 4.0 (c 1.00, CHCl3) 
HRMS m/z calcd for C27H54O3Si 454.3842 [M]+·, found 454.3854 
IR (thin film, cm-1) Ȟ 3007 (m), 2928 (s), 2856 (s), 1735 (s), 1699 (w), 1464 (m), 1374 (m), 
1253 (m), 1180 (w), 1134 (w), 1110 (m), 1066 (w), 1005 (w), 939 (w) 
1H NMR (400 MHZ, CDCl3) į 5.40 – 5.30 (m, 2 H, H-10/H-9), 5.01 (sp, 1 H, H-1‘, 
3J1‘,2‘/2‘‘ = 6.2 Hz), 3,77 (mc, 1 H, H-17), 2.26 (t, 2 H, H-2, 3J2,3 = 7.5 Hz), 2.02 (mc, 4 H, 
H-11/H-8), 1.66 – 1.56 (m, 2 H, H-3), 1.46 – 1.26 (m, 18 H, H-4 – H-7/H-12 – H-16), 1.23 
(d, 6 H, H-2‘/H-2“, 3J2‘/2‘‘,1‘ = 6.2 Hz), 1.12 (d, 3 H, H-18, 3J18,17 = 6.1 Hz), 0.89 (s, 9 H, 
H-3* - H-3***), 0.05, 0.05 (2 × s, 2 × 3 H, H-1*/H-1**)  
13C NMR (100 MHz, CDCl3) į 173.4 (C-1), 129.9, 129.8 (C-10/C-9), 68.7 (C-17), 67.3 
(C-1‘), 39.7 (C-16), 34.7 (C-2), 29.7, 29.7, 29.6, 29.3, 29.2, 29.1, 29.1, 25.8 (C-4 – C-7/C-12 
– C-15), 27.2, 27.2 (C-11/C-8), 25.9 (C-3* - C-3***), 25.0 (C-3), 23.8 (C-18), 21.9 (C-2‘/ 
C-2‘‘), 18.2 (C-2*), - 4.4, -4.7 (C-1*/C-1**)  
MS (GC-MS, EI) m/z (%) 454 ([M]+·, 0.02), 337 (48), 159 (16), 109 (10), 95 (19), 81 (21), 75 
(100), 73 (42), 69 (19), 67 (20), 55 (30)  
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6.2.3.3 Synthesis of (17R,9Z)-Octadec-9-ene-1,17-diol ((R)-41) 
LAH (55 mg, 1.44 mmol) was suspended in dry THF 
(2.4 ml) under an argon atmosphere and the slurry was 
cooled to 0 °C. Then, isopropyl (17R,9Z)-17-((tert-
butyldimethylsilyl)oxy)-octadec-9-enoate ((R)-51) 
(218 mg, 0.48 mmol) dissolved in 2.2 ml THF was 
added dropwise and the reaction mixture was warmed to room temperature. After 4 hours, 
water (7.3 ml) and Et2O (7.3 ml) were added, the layers were separated and the aqueous 
phase was extracted with Et2O (3 × 10 ml). The combined organic extracts were washed with 
water (20 ml), dried over MgSO2 and the solvent was evaporated under reduced pressure. The 
residue was dissolved in AcN (4.4 ml) and HF (40% aq, 85 μl) was added dropwise. The 
reaction mixture was stirred for 2.5 hours and then K2CO3 (847 mg, 6.13 mmol) was added. 
Water was poured into the reaction vessel until all solids were dissolved. The mixture was 
extracted with MTBE (4 × 20 ml), the organic extracts were combined and dried over 
MgSO2. Evaporation of the solvent yielded the crude product which was purified by column 
chromatography using hexane/ethyl acetate (1:1). The Diol ((R)-41) was obtained as a 
colorless oil (100 mg, 0.35 mmol, 73%).  
ሾࢻሿ۲૛૛ – 4.7 (c 1.00, CHCl3). All other spectral data were identical to rac-41 and (S)-41.  
 
6.2.3.4 Subsequent synthesis steps to (S)-Harmonine ((S)-5)  
(17S,9Z)-1,17-Diazidooctadec-9-ene ((S)-42):  
Prepared from (17R,9Z)-octadec-9-ene-1,17-diol ((R)-41) 
(28 mg, 0.10 mmol) according to the procedure described 
in chapter 6.2.1.7. After purification, ((S)-42) was ob-
tained as a colorless oil (29 mg, 0.09 mmol, 87%).  
ሾࢻሿ۲૛૛ + 18.8 (c 1.00, CHCl3). All other spectral data were identical to rac-42 and (R)-42.  
  
OH
HO
(R)-41
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(17S,9Z)-Octadec-9-ene-1,17-diamine ((S)-5):  
The reduction of (17S,9Z)-1,17-diazidooctadec-9-ene 
((S)-42) (25 mg, 0.08 mmol) using LAH (26 mg, 
0.70 mmol) was executed as described in chapter 
6.2.1.8. The desired (S)-harmonine ((S)-5) was obtained 
as a slightly yellow oil (20 mg, 0.07 mmol, 95%).  
ሾࢻሿ۲૛૝ + 2.9 (c 0.87, C6H6). All other spectral data were identical to rac-5 and (R)-5. 
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6.2.4 Synthesis of (Z)-18-Aminooctadec-9-en-2-ol (rac-48) 
6.2.4.1 Synthesis of (9Z)-17-Hydroxyoctadec-9-enamide (rac-47)  
Isopropyl (9Z)-17-hydroxyoctadec-9-enoate (rac-34) 
(237 mg, 0.70 mmol) was dissolved at 0 °C in MeOH 
(2.25 ml). Mg3N2 (353 mg, 3.48 mmol) was quickly added 
in one portion, the reaction vessel was carefully closed and 
the suspension was allowed to warm to room temperature. 
Stirring was continued for 1 hour. The reaction was heated 
to 80 ºC and stirring was continued for 24.5 hours. After 
cooling to room temperature, CHCl3 (25 ml) and water (25 ml) were added. The aqueous 
phase was neutralized with 3 M HCl, the layers were separated and the aqueous phase was 
extracted with CHCl3 (2 × 25 ml). The organic layers were combined and the solvent was 
removed under reduced pressure. The residue was purified by column chromatography on 
RP-18 silica gel using H2O/MeOH (1:9) for elution. CHCl3 was added and the solvents were 
removed under reduced pressure. This procedure was repeated three times with CHCl3 and 
three times with benzene to remove last traces of water. The residue was concentrated under 
high vacuum to yield rac-47 as a colorless, sticky oil. (182 mg, 0.61 mmol, 87%). Rf = 0.43 
(H2O/MeOH 1:9, RP-18).[55]  
HRMS m/z calcd for C18H36NO2 298.2741 [M + H]+, found 298.2734  
IR (thin film, cm-1) Ȟ 3358 (s), 3191 (br, m), 3003 (w), 2967 (w), 2924 (s), 2852 (s), 1703 
(w), 1659 (s), 1633 (s), 1468 (m), 1423 (m), 1412 (m)  
1H NMR (400 MHZ, CDCl3) į 5.68 (d, 2JNH,NH’ = 81.9 Hz, 2 H, N-H2), 5.40 – 5.27 (m, 2 H, 
H-10/H-9), 3.78 (tq, 3J17,18 = 3J17,16 = 5.7 Hz, 1 H, H-17), 2.20 (t, 3J2,3 = 7.5 Hz, 2 H, H-2), 
2.05 – 1.92 (m, 4 H, H-11/H-8), 1.84 (brs, 1 H, O-H), 1.62 (tt, 3J3,4 = 3J3,2 = 7.1 Hz, 2 H, 
H-3), 1.51 – 1.37 (m, 2 H, H-16), 1.37 – 1.23 (m, 16 H, H-15 – H-12/H-7 – H-4), 1.17 (d, 
3J18,17 = 6.1 Hz, 3 H, H-18)  
13C NMR (100 MHz, CDCl3) į 175.8 (C-1), 129.9, 129.8 (C-10/C-9), 68.0 (C-17), 39.3 
(C-16), 35.9 (C-2), 29.6, 29.6, 29.5, 29.5, 29.2, 29.2, 29.0 (C-14 – C-12/C-7 – C-4), 27.1, 
27.1 (C-11/C-8), 25.7 (C-15), 25.5 (C-3), 23.4 (C-18)  
MS (GC-MS, EI) m/z (%) 297 ([M]+·, 1), 279 (2), 262 (5), 207 (6), 109 (28), 95 (43), 81 (33), 
72 (64), 69 (34), 67 (54), 59 (98), 55 (100), 41 (68)   
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6.2.4.2 Synthesis of (9Z)-18-Aminooctadec-9-en-2-ol (rac-48)  
LiAlH4 (106 mg, 3.00 mmol) was suspended with 
stirring in dry THF (3 ml) and cooled to 0 ºC. (9Z)-17-
Hydroxyoctadec-9-enamide (rac-47) (168 mg, 
0.56 mmol), dissolved in dry THF (2 ml), was added 
dropwise. The reaction was allowed to warm to room 
temperature, stirred for 4 hours at room temperature and 
for 19.5 hours at 45 ºC. After cooling to room temperature, water (10 ml) and CHCl3 (10 ml) 
were added. The layers were separated and the aqueous phase was extracted with CHCl3 (5 × 
10 ml). The organic extracts were combined and the solvents were removed under reduced 
pressure. The residue was separated between MTBE (80 ml) and 2% HCl (80 ml). The 
aqueous phase was extracted with MTBE (3 × 20 ml) and the combined organic extracts were 
washed with 2% HCl (35 ml). Both aqueous solutions were combined and MTBE (50 ml) and 
NH3 (25% aqueous solution, 80 ml) were added. The layers were separated and the aqueous 
phase was extracted with MTBE (3 × 80 ml). The combined organic extracts were dried over 
Na2SO4 and the solvent was evaporated under reduced pressure yielding rac-48 as an oily, 
colorless wax (151 mg, 0.53 mmol, 95%).[55]  
HRMS m/z calcd for C18H38NO 284.2948 [M + H]+, found 284.2935  
IR (thin film, cm-1) Ȟ 3332 (br, m), 3004 (m), 2925 (s), 2853 (s), 1632 (m), 1572 (m), 1464 
(m), 1372 (m), 1315 (m)  
1H NMR (400 MHZ, CDCl3) į 5.38 – 5.28 (m, 2 H, H-10/H-9), 3.75 (tq, 3J17,18 = 3J17,16 = 
6.1 Hz, 1 H, H-2), 2.66 (t, 3J1,2 = 7.0 Hz, 2 H, H-18), 2.04 – 1.91 (m, 4 H, H-11/H-8), 1.82 – 
1.76 (m, 3 H, N-H2, O-H), 1.48 – 1.35 (m, 5 H, H-17/H-4a/H-3), 1.35 – 1.23 (m, 17 H, H-4b/ 
H-16 – H-12/H-7 – H-5), 1.15 (d, 3J18,17 = 6.1 Hz, 3 H, H-1)  
13C-NMR (100 MHz, CDCl3) į 129.8, 129.8 (C-10/C-9), 67.7 (C-2), 42.1 (C-18), 39.4 (C-3), 
33.6 (C-17), 29.6, 29.6, 29.5, 29.4, 29.4, 29.2, 29.1, (C-15 – C-12/C-7 – C-5), 27.1 (C-11/ 
C-8), 26.8 (C-16), 25.8 (C-4), 23.5 (C-1)  
MS (GC-MS, EI) m/z (%) 283 ([M]+·, 30), 268 (40), 250 (10), 238 (26), 222 (12), 210 (12), 
196 (20), 182 (35), 168 (38), 154 (92), 140 (40), 123 (18), 109 (32), 95 (86), 81 (87), 79 (53), 
67 (100), 55 (42)  
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6.2.5 Synthesis of C17-Harmonine (rac-58) 
Isopropyl 8-Bromooctanoate (53):  
Prepared from 8-bromooctanoic acid (52) (9.0 g, 40.34 mmol) as 
described in chapter 6.2.1.3. Isopropyl 8-bromooctanoate (53) 
was obtained as sweet smelling, colorless oil (8.9 g, 33.56 mmol, 
83%).  
HRMS m/z calcd for C11H21O2Br 264.0734 [M]+·, found 264.0725  
IR (thin film, cm-1) Ȟ 2979 (s), 2933 (s), 2858 (s), 1728 (s), 1466 (m), 1374 (m), 1238 (s), 
1181 (s), 1145 (m), 1109 (s), 964 (w)  
1H NMR (400 MHz, CDCl3) į 4.99 (sp, 3J1’,2’ = 3J1’,2” = 6.2 Hz, 1 H, H-1’), 3.39 (t, 3J8,7 = 
7.0 Hz, 2 H, H-8), 2.25 (t, 3J2,3 = 7.5 Hz, 2 H, H-2), 1.84 (mc, 2 H, H-7), 1.61 (mc, 2 H, H-3), 
1.43 (mc, 2 H, H-6), 1.37 – 1.29 (m, 4 H, H-5/H-4), 1.22 (d, 3J2’,1’ = 3J2”,1’ =6.2 Hz, 6 H, H-2’/ 
H-2”)  
13C NMR (100 MHz, CDCl3) į 173.2 (C-1), 67.3 (C-1’), 34.6 (C-2), 33.8 (C-8), 32.7 (C-7), 
28.8, 28.4 (C-5/C-4), 27.9 (C-6), 24.8 (C-3), 21.8 (C-2’, C-2”)  
MS (GC-MS, CI) m/z (%) 267, 265 ([M+H]+, 70), 252, 250 (14), 224, 222 (84), 206, 204 
(29), 143 (32), 125 (100), 97 (58), 55 (39)  
 
(8-Isopropoxy-8-oxooctyl)triphenylphosphonium Bromide (54):  
Compound 54 was prepared from isopropyl 8-bromooctanoate 
(53) (8.7 g, 32.92 mmol) and PPh3 (12.9 g, 49.38 mmol) as 
described in chapter 6.2.1.4. After purification, 54 was 
obtained as a slightly yellow, sticky syrup (10.6 g, 
20.07 mmol, 61%).  
HRMS m/z calcd for C29H36O2P 447.2447 [M]+, found 447.2437  
IR (thin film, cm-1) Ȟ 3054 (m), 2980 (s), 2934 (s), 2860 (s), 2795 (w), 1722 (s), 1622 (w), 
1587 (m), 1486 (w), 1466 (s), 1374 (m), 1185 (m), 1110 (s), 996 (m)  
1H NMR (400 MHZ, CDCl3) į 7.85 – 7.75 (m, 9 H, Har-6/Har-2/Har-4), 7.73 – 7.65 (m, 6 H, 
Har-5/Har-3), 4.93 (sp, 3J1’,2’ = 3J1’,2” = 6.2 Hz, 1 H, H-1’), 3.79 – 3.68 (m, 2 H, H-1), 2.17 (t, 
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3J2,3 = 7.5 Hz, 2 H, H-7), 1.66 – 1.56 (m, 4 H, H-3/H-2), 1.51 (mc, 2 H, H-6), 1.31 – 1.20 (m, 
4 H, H-5/H-4), 1.17 (d, 3J2’,1’ = 3J2”,1’ = 6.2 Hz, 6 H, H-2”/H-2’)  
13C NMR (100 MHz, CDCl3) į 173.2 (C-8), 135.0, 134.9 (Car-4), 133.6, 133.5 (Car-6/Car-2), 
130.5, 130.4 (Car-5/Car-3), 118.7, 117.9 (Car-1), 67.3 (C-1’), 34.4 (C-7), 30.2, 30.0 (C-3), 
28.7, 28.5 (C-5/C-4), 24.7 (C-6), 22.9, 22.5 (C-1), 22.5, 22.5 (C-2), 21.8 (C-2’/C-2”)  
 
Isopropyl (8Z)-16-Hydroxyheptadec-8-enoate (rac-55):  
This “Wittig-type one-pot reaction” between (8-isopro-
poxy-8-oxooctyl)triphenylphosphonium bromide (54) 
(3.0 g, 5.76 mmol) and 9-methyloxonan-2-one (rac-36) 
(750 mg, 4.80 mmol) was carried out as described in 
chapter 6.2.1.5 and yielded rac-55 as a colorless oil 
(219 mg, 0.67 mmol, 15%, (Z)/(E) > 97/3).  
HRMS m/z calcd for C20H38O3 326.2821 [M]+·, found 326.2808  
IR (thin film, cm-1) Ȟ 3418 (br, m), 3003 (m), 2974 (s), 2926 (s), 2855 (s), 1732 (s), 1657 (w), 
1465 (m), 1374 (m), 1254 (m), 1180 (m), 1145 (m), 1109 (s)  
1H NMR (400 MHZ, CDCl3) į 5.40 – 5.29 (m, 2 H, H-9/H-8), 5.01 (sp, 3J1’,2’ = 3J1’,2” = 
6.2 Hz, 1 H, H-1’), 3.79 (tq, 3J16,17 = 3J16,15 = 6.1 Hz, 1 H, H-16), 2.26 (t, 3J2,3 = 7.7 Hz, 2 H, 
H-2), 2.07 – 1.95 (m, 4 H, H-10/H-7), 1.61 (mc, 2 H, H-3), 1.50 (brs, 1 H, OH), 1.48 – 1.39 
(m, 2 H, H-15), 1.39 – 1.28 (m, 14 H, H-14 – H-11/H-6 – H-4), 1.23 (d, 3J2’,1’ = 3J2”,1’ = 
6.3 Hz, 6 H, H-2’/H-2”), 1.19 (d, 3J17,16 = 6.2 Hz, 3 H, H-17)  
13C NMR (100 MHz, CDCl3) į 173.4 (C-1), 129.9, 129.8 (C-9/C-8), 68.1 (C-16), 67.3 
(C-1’), 39.4 (C-15), 34.7 (C-2), 29.7, 29.5, 29.5, 29.2, 29.0, 28.9, 25.7 (C-14 – C-11/C-6 – 
C-4), 27.2, 27.1 (C-10/C-7), 25.0 (C-3), 23.5 (C-17), 21.8 (C-2’/C-2”)  
MS (GC-MS, EI) m/z (%) 326 ([M]+·, 0.3), 308 (2.2), 265 (28), 137 (20), 123 (34), 109 (48), 
95 (80), 81 (100), 67 (92), 55 (92), 45 (44)  
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(8Z)-Heptadec-8-ene-1,16-diol (rac-56):  
The reduction of isopropyl (8Z)-16-hydroxyheptadec-8-
enoate (rac-55) (150 mg, 0.46 mmol) was conducted as 
described in chapter 6.2.1.6. Diol rac-56 was obtained as a 
colorless oil (121 mg, 0.45 mmol, 98%).  
HRMS m/z calcd for C17H34O2 270.2559 [M]+·, found 270.2566  
IR (thin film, cm-1) Ȟ 3333 (br, m), 3004 (w), 2926 (s), 2854 (s), 1656 (w), 1463 (m), 1373 
(m), 1128 (w), 1057 (m)  
1H NMR (400 MHZ, CDCl3) į 5.42 – 5.29 (m, 2 H, H-9/H-8), 3.80 (mc, 1 H, H-16), 3.64 (t, 
3J1,2 = 6.6 Hz, 2 H, H-1), 2.06 – 1.97 (m, 4 H, H-10/H-7), 1.57 (mc, 2 H, H-2), 1.53 (brs, 2 H, 
O-H), 1.50 – 1.41 (m, 2 H, H-15), 1.41 – 1.27 (m, 16 H, H-14 – H-11/H-6 – H-3), 1.19 (d, 
3J17,16 = 6.1 Hz, 3 H, H-17)  
13C NMR (100 MHz, CDCl3) į 129.9 (C-9/C-8), 68.2 (C-16), 63.0 (C-1), 39.4 (C-15), 32.8 
(C-2), 29.7, 29.6, 29.5, 29.3, 29.2, 29.2 (C-13 – C-11/C-6 – C-4), 27.2 (C-10/C-7), 25.7, 25.7 
(C-14/C-3), 23.5 (C-17)  
MS (GC-MS, EI) m/z (%) 270 ([M]+·, 0.6), 252 (4.7), 135 (12), 121 (20), 110 (38), 95 (62), 
81 (100), 67 (98), 55 (98), 45 (31)  
 
(8Z)-1,16-Diazidoheptadec-8-ene (rac-57):  
Prepared from (8Z)-heptadec-8-ene-1,16-diol (rac-56) 
(71 mg, 0.26 mmol) as described in chapter 6.2.1.7. After 
column chromatography, rac-57 was obtained as a colorless 
oil (75 mg, 0.24 mmol, 90%).  
HRMS m/z calcd for C17H32N6Na 343.2581 [M + Na]+, found 343.2578  
IR (thin film, cm-1) Ȟ 3004 (w), 2929 (s), 2856 (s), 2095 (s), 1459 (m), 1379 (w), 1260 (s), 
1095 (m), 1018 (m)  
1H NMR (400 MHZ, CDCl3) į 5.42 – 5.31 (m, 2 H, H-9/H-8), 3.43 (mc, 1 H, H-16), 3.27 (t, 
3J1,2 = 6.8 Hz, 2 H, H-1), 2.08 – 1.97 (m, 4 H, H-10/H-7), 1.61 (tt, 3J2,3 = 3J2,1 = 6.8 Hz, 2 H, 
H-2), 1.55 – 1.29 (m, 18 H, H-15 – H-11/H-6 – H-3), 1.25 (d, 3J17,16 = 7.0 Hz, 3 H, H-17)  
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13C NMR (100 MHz, CDCl3) į 129.9, 129.8 (C-9/C-8), 58.0 (C-16), 51.5 (C-1), 36.2 (C-15), 
29.6, 29.6, 29.3, 29.1, 29.1, 29.0 (C-13 – C-11/C-6 – C-4), 28.8 (C-2), 27.1 (C-10/C-7), 26.7 
(C-3), 26.0 (C-14), 19.5 (C-17)  
 
(8Z)-Heptadec-8-ene-1,16-diamine (rac-58):  
The C17-harmonine (rac-58) was synthesized from (8Z)-
1,16-diazidoheptadec-8-ene (rac-57) (24 mg, 0.08 mmol) 
and LAH (22.7 mg, 0.60 mmol) as depicted in chapter 
6.2.1.8. Rac-58 was obtained as a slightly yellow oil 
(22 mg, quant.).  
HRMS m/z calcd for C17H37N2 269.2951 [M + H]+, found 269.2951  
IR (thin film, cm-1) Ȟ 3338 (m), 3005 (w), 2918 (s), 2850 (s), 1605 (s), 1461 (s), 1392 (m), 
1345 (m), 1320 (w)  
1H NMR (400 MHZ, CDCl3) į 5.41 – 5.30 (m, 2 H, H-9/H-8), 2.89 (mc, 1 H, H-16), 2.70 (t, 
3J1,2 = 7.0 Hz, 2 H, H-1), 2.06 – 1.96 (m, 4 H, H-10/H-7), 1.72 (brs, 4 H, N-H2), 1.46 (mc, 
2 H, H-2), 1.39 – 1.27 (m, 18 H, H-15 – H-11/H-6 – H-3), 1.07 (d, 3J17,16 = 6.2 Hz, 3 H, 
H-17)  
13C NMR (100 MHz, CDCl3) į 129.9 (C-9/C-8), 47.0 (C-16), 42.1 (C-1), 40.0 (C-15), 33.6 
(C-2), 29.7, 29.7, 29.6, 29.4, 29.3, 29.2 (C-13 – C-11/C-6 – C-4), 27.2 (C-10/C-7), 26.8 
(C-3), 26.4 (C-14), 23.8 (C-17)  
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6.3 Rearing of the Beetles  
H. axyridis were collected as fourth (or third) instar larvae and kept in groups of ~ 10 
individuals before pupation. Larvae were fed with Sitotroga eggs. Eppendorf tubes plugged 
with cotton were used as water supply. Feed and water were renewed twice a week (Monday 
and Friday). Each Friday, the larvae were provided with a slice of fresh apple.  
H. axyridis beetles were kept in groups of 20 - 30 sorted by their hatching dates. Sufficient 
water supply was also provided in Eppendorf tubes plugged with cotton. 80% of the beetles 
were fed with Sitotroga eggs twice a week (Monday and Friday) and 20 % were fed with pea 
aphids three times a week (Monday, Wednesday, Friday). On Fridays, all beetles were 
offered a slice of fresh apple. A piece of kitchen tissue was placed in each box to encourage 
oviposition.  
Eggs were collected three times a week and placed into separate boxes. Larvae were reared 
with separation of instars and in small groups.  
The boxes of the beetles were cleaned and disinfected every Monday. Therefore, the beetles 
were moved to new boxes. Larvae boxes were cleaned after pupation when the newly hatched 
beetles were moved to different boxes.  
Larvae and beetle boxes were kept together in a climate chamber to ensure a controlled 
environment (60% humidity, 22 °C (light), 19 °C (darkness), 16:8 (light:darkness)).  
 
6.4 Hemolymph Analysis  
6.4.1 Collection of the Hemolymph  
Prior to the collection of the hemolymph it was assured that the beetles had unlimited access 
to fresh water.  
The beetle was stuck with its elytra on adhesive tape placed under the microscope and held in 
place with a gloved hand. One of its hind legs was cut directly at the metathorax using a pair 
of micro scissors and the resulting droplet of hemolymph was collected with a pipette tip 
filled with 10 μl of MeOH. The content of the pipette tip was thoroughly washed into a GC 
vial filled with 50 μl of MeOH. These 60 μl were split into halves and the solvent and the 
water content of the hemolymph were removed using a Concentratorplus (program: Vaq, 
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30 min, 30 °C). The residue was dissolved in 100 μl DCM with n-bromodecane (50 μg ml-1) 
as standard.  
 
6.4.2 Derivatization and GC-MS Analysis 
The previously prepared hemolymph samples in 100 μl DCM with n-bromodecane were 
entirely transferred into smaller inserts and 4 μl of MBTFA were added. Then, the vials were 
placed into a preheated thermo-shaker and derivatized at 60 °C for 1 hour.  
GC-MS analyses were executed on a Trace MS using the method “hemolymph analysis” 
described in chapter 6.1. To avoid contamination from preceding samples, DCM blanks were 
measured between each hemolymph sample.  
 
6.4.3 Acetonitrile Chemical Ionization Tandem Mass Spectrometry 
The collection of the hemolymph was similarly conducted to the procedure described in 
chapter 6.4.1. However, for AcN-CI-MS/MS experiments, the hemolymph of one beetle was 
not split into halves but used as one sample. Furthermore, no standard was added. The 
procedure detailed in chapter 6.4.2 was used for the derivatization with MBTFA.  
All AcN-CI-MS/MS experiments were performed with the help of Dr. Tobias Engl in the 
former laboratory of Dr. Martin Kaltenpoth (Max Planck Research Group Insect Symbioses, 
Jena). The following equipment and method were used:  
CI-GC-MS analyses were conducted on a Varian 240MS ion-trap mass detector with internal 
ionization configuration coupled to a Varian 450GC (Varian, Inc., Palo Alto, CA, USA). For 
separation of the compounds a DB-5 ms column (30 m×0.25 mm ID; 0.25 ȝm df, Agilent, 
Santa Clara, CA, USA) was used.  
CI-GC-MS Method:  45 °C (3 min) - 7.5 °C min-1 - 280 °C (4 min) - 10 °C min-1 - 300 °C 
(1 min), inlet T: 250 °C, splitless  
Helium (1 ml min-1) served as carrier gas and AcN as reagent gas. The CI spectra were 
recorded with a mass range of m/z = 90-1000. MS/MS experiments of the [M+54]+ adducts 
were accomplished with the resonant waveform type for precursor ion excitation (m/z = 526), 
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an isolation window of m/z = 3, and 20 ms excitation time. The automatic “q” calculator was 
used for the product ion mass range and the determination of precursor ion excitation energy. 
An ion-trap temperature of 160 °C and a manifold temperature of 50 °C were used for all CI 
measurements. Data analyses were performed with a MS Workstation software (version 
6.9.3, Varian Inc., Palo Alto, CA, USA).[141] 
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6.5 Bioactivity Studies 
6.5.1 Microbial Growth Inhibition Assays 
The microbial growth inhibition assays were conducted with E. coli BW25113- and 
B. subtilis DSM 10. The substances which should be tested were dissolved in MeOH and the 
concentration was adjusted to 10 mM. MeOH was used as a negative control and Ampicillin 
(1 mM) as a positive control.  
First, precultures of E. coli and B. subtilis were prepared. 5 ml LB-medium were inoculated 
with bacteria from a cryostock and the cultures were grown for 17 hours at 37 °C (220 rpm). 
The optical density of the cultures was measured and was adjusted to OD600 = 1 with LB-
medium.  
2 ml of a preculture from the respective bacterial strain were mixed with 48 ml of LB-agar. 
Next, 2 plates (12 cm × 12 cm) were poured with 25 ml of agar in each plate and left to dry 
upside down for 2 hours. The agar was pierced with a metal stick to result in 3 × 3 holes with 
a diameter of 0.5 cm. Each hole was filled with 8 μl of one of the test compound solutions. 
The standard assay design is shown in the following scheme:  
 
Figure 6.1: Pipetting scheme of the Microbial Growth Inhibiton Assay (mirror-inverted to 
photographs). Ampicillin as positive control (green), MeOH as negative control (red), test 
compounds (blue).  
 
The plates were cultivated for 24 hours at 37 °C. Afterwards, the clear inhibition zones were 
measured in three different directions and the average was calculated.  
  
MeOH 
Ampicillin 
Samples 
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6.5.2 AChE Inhibition Assays  
All required stock solutions and the acetylthiocholine reaction mixture were prepared 
according to the technical information sheet obtained with the kit (chapter 6.1). However, the 
overall assay procedure was altered and is described hereafter: 
1. To determine the correct concentration range for the inhibition assay, preliminary tests 
were performed for each substance. Solutions of the possible inhibitor in MeOH were 
prepared using 6 different concentrations. The concentrations were calculated referring to the 
final concentration in the wells and were chosen to be within a broad range from 
9·10-4 mol l-1 to 6·10-7 mol l-1 (in-well-concentration). The enzyme solution was diluted to 
concentrations of 50 mU and 100 mU. Each plate contained 3 blank wells and 3 standard 
wells to facilitate comparability between plates. There were 3 replicates with 100 mU and 
3 replicates with 50 mU enzyme for each inhibitor concentration on each plate.  
Table 6.1: Filling of the wells in preliminary tests and AChE inhibition assays.  
Blank 5 μl MeOH, 50 μl buffer, 50 μl enzyme (100 mU) 
Standard 
5 μl MeOH, 50 μl acetylthiocholine reaction 
mixture, 50 μl enzyme (100 mU) 
Assay 100 
5 μl inhibitor solution, 50 μl acetylthiocholine 
reaction mixture, 50 μl enzyme (100 mU) 
Assay 50 
5 μl inhibitor solution, 50 μl acetylthiocholine 
reaction mixture, 50 μl enzyme (50 mU) 
The preliminary test was conducted as follows: The plate was put on ice and the whole assay 
was pipetted on ice with exclusion of light. First, MeOH or the inhibitor solution was pipetted 
in the wells directly followed by the enzyme solution or buffer. This mixture was incubated 
for 10 minutes on ice before the acetylthiocholine reaction mixture was added. The plate was 
again incubated for 5 minutes at room temperature and then the absorbance increase was 
monitored every minute for 1 hour using a microplate reader at 410 nm.  
2. For preliminary tests an approximate value of the IC50 was calculated using Microsoft 
Excel and the GraphPad Prism software: First, the mean of the blank values was calculated 
and subtracted from all other values. Then, the mean of the standard wells was divided by the 
mean of the standard wells of the first plate measured to obtain comparability between plates. 
All values were multiplied by this factor. The absorbance of each assay well was then plotted 
Materials and Methods 
 
97 
 
against the time and a linear regression curve fit of the data points from minute 0 to minute 
20 (linear range) resulted in the change of absorbance per minute (ǻabs./min). This change of 
absorbance was plotted against the logarithmic concentration of the possible inhibitor. A 
sigmoidal dose-response fit revealed finally the IC50 value.[129]  
3. The AChE inhibition assay was conducted according to the results from the preliminary 
testing. 12 methanolic solutions of the possible inhibitor were prepared with in-well-
concentrations around the preliminarily calculated IC50 value. The filling of the wells, the 
replicate number per inhibitor concentration and the blank and standard well quantity was 
kept the same as in the preliminary test. The pipetting scheme for all AChE inhibiton assays 
is shown here: 
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Figure 6.2: Pipetting scheme for AChE inhibiton assays. Preliminary tests had the same 
pipetting structure but less inhibitor concentrations.  
 
The inhibition assay was likewise performed as the preliminary test described above. After 
measurement of the absorbance increase per minute the IC50 value was calculated as detailed 
in 2. using Microsoft Excel and the GraphPad Prism software.  
  
blank standard
“Assay 50” 
“Assay 100” 
decreasing inhibitor concentration 
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6.5.3 Antileishmanial Activity  
All assays with the L. major parasite were performed by Dr. Anita Masic and Martina 
Schultheis in the laboratories of the former research group of Dr. Uta Schurigt (Institute for 
Molecular Infection Biology, Würzburg) and were already partly published in “Efficient 
synthesis of (R)-harmonine – the toxic principle of the multicolored Asian lady beetle 
(Harmonia axyridis)” (authors: Nagel, N. C. et al.).[55] The following methods are cited 
thereof.  
 
Antileishmanial activity. The virulent L. major isolate (MHOM/IL/81/FE/BNI) and 
Luciferase-transgenic (Luc-tg.) L. major were maintained by continuous passage in female 
BALB/c mice. L. major amastigotes were isolated from lesions as described previously[142, 
143] and promastigotes were grown in vitro in blood-agar cultures at 27 °C, 5% CO2, and 95% 
humidity. AlamarBlue assays for the determination of antileishmanial activities against 
L. major promastigotes and BMDM cytotoxicity and Britelite plus (PerkinElmer, Waltham, 
MA, USA) assays against intracellular Luc-tg. L. major amastigotes were performed as 
previously reported[143].[55]  
 
Diff-Quick staining for transmitted light microscopy. After incubation for 6 h, 10 h, and 
24 h in the presence of 30 μM harmonine or 1% DMSO as solvent control, L. major 
promastigotes were harvested and centrifuged in a Cytospin 3 centrifuge (Shandon, 
Frankfurt, Germany) on microscopic slides. Cytospin preparations were stained using the 
Differential Quick Stain (Diff-Quick) dye (Medion Diagnostics AG, Düdingen, Switzerland), 
according to the manufacturers’ protocol. Diff-Quick stains the leishmanial nuclei and the 
kinetoplasts dark purple and the cytoplasm light purple allowing the observation of 
phenotypic changes within the parasite. Stained cells were analyzed by transmitted light 
microscopy under a 50 × objective on a Nikon ECLIPSE 50i microscope equipped with a 
digital camera (Nikon, Tokyo, Japan). The images were proceeded using NIS Elements D 
software (Nikon).[55]  
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Determination of cell death phenotype by flow cytometric analysis. L. major promasti-
gotes were either treated for 6 h, 10 h, and 24 h with 30 μM harmonine or 1% DMSO as 
solvent control. Cell staining was performed using an Annexin V-FITC Apoptosis detection 
kit (Sigma-Aldrich, Saint Louis, MO, USA) according to the manufacturers´ protocol. 
Stained samples were immediately analyzed by flow cytometry using MACS Quant Analyzer 
(Miltenyi Biotech, Bergisch Gladbach, Germany).[55]  
 
6.5.4 Identification of “AChE-like Proteins” in L. major and Docking 
Studies 
The identification of putative “AChE-like proteins” in L. major was performed with the help 
of Ding Wang (MPI CE, Jena).  
First the protein sequence of the AChE from Caenorhabditis elegans (ace-1, sequence ID: 
NP_510660.1, length: 620) was blasted against the protein sequence of L. major strain 
Friedlin (taxid: 347515). The BLAST revealed 2 possible candidates:  
1. Conserved hypothetical protein (sequence ID: XP_001681951.1, length: 1022, identities: 
29%, query cover: 16%) 
2. Putative ecotin (sequence ID: XP_001681950.1, length: 761, identities: 27%, query cover: 
18%) 
 
Modeling and docking studies were performed by PD Dr. Wolfgang Brandt (Leibniz Institute 
of Plant Biochemistry, Halle).  
YASARA version 14.7.17[144] was used for homology modeling of the proteins. After search 
for templates in the protein database[140] 23 models were created based on alternative 
sequence alignments including secondary structure predictions and comparisons with found 
appropriate X-ray templates.  
Based on these most favored templates, a final hybrid model was created by replacing some 
small better folded fragments (loops) from other models. The model (after quality analysis, 
blow) based on 1qz3 appeared as best one (Fig. 6.3).  
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Figure 6.3: Template of the X-ray structure of 1qz3 (crystal structure of M211S/R215L 
mutant of carboxylesterase EST2; complexed with hexadecanesulfonate).[145] 
 
The quality of the resulting homology models was evaluated using PROCHECK[146] and 
ProSA.[147, 148] Only models of excellent quality (more than 87% of the residues being in the 
most favored region of the Ramachandran plot and two outliers; ProSA energy graphs all in 
negative range and calculated z-scores in the range of natively folded proteins) were used 
further on.  
 
The substrates were docked using the molecular modeling environment program MOE 
2014.09 (https://www.chemcomp.com/). All models with docked substrates were refined by 
energy minimization using the MMFF94[149] force field implemented in MOE. 
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A Appendix  
A.1 NMR Spectra of Compounds from Chapter 6.2.1 
(rac-Harmonine)  
 
 
 
Figure A.1.1: 1H NMR spectrum of 2-methylcyclooctan-1-one (rac-38). 
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Figure A.1.2: 13C NMR spectrum of 2-methylcyclooctan-1-one (rac-38). 
 
 
Figure A.1.3: 1H NMR spectrum of 9-methyloxonan-2-one (rac-36). 
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Figure A.1.4: APT spectrum of 9-methyloxonan-2-one (rac-36). 
 
 
Figure A.1.5: 1H NMR spectrum of isopropyl 9-bromononanoate (40). 
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Figure A.1.6: 13C NMR spectrum of isopropyl 9-bromononanoate (40). 
 
 
Figure A.1.7: 1H NMR spectrum of (9-isopropoxy-9-oxononyl)triphenylphosphonium 
bromide (35). 
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Figure A.1.8: APT NMR spectrum of (9-isopropoxy-9-oxononyl)triphenylphosphonium 
bromide (35).  
 
 
Figure A.1.9: 1H NMR spectrum of isopropyl (9Z)-17-hydroxyoctadec-9-enoate (rac-34).  
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Figure A.1.10: 13C NMR spectrum of isopropyl (9Z)-17-hydroxyoctadec-9-enoate (rac-34).  
 
 
Figure A.1.11: 1H NMR spectrum of (9Z)-octadec-9-ene-1,17-diol (rac-41).  
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Figure A.1.12: 13C NMR spectrum of (9Z)-octadec-9-ene-1,17-diol (rac-41).  
 
 
Figure A.1.13: 1H NMR spectrum of (9Z)-1,17-diazidooctadec-9-ene (rac-42).  
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Figure A.1.14: 13C NMR spectrum of (9Z)-1,17-diazidooctadec-9-ene (rac-42).  
 
 
Figure A.1.15: 1H NMR spectrum of (9Z)-octadec-9-ene-1,17-diamine (rac-5). 
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Figure A.1.16: 13C NMR spectrum of (9Z)-octadec-9-ene-1,17-diamine (rac-5). 
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A.2 1H and 13C NMR Spectra of Compounds from Chapter 6.2.2 
((R)-Harmonine)  
“*” indicates compounds that exclusively differ in stereochemistry from previously shown 
substances. Therefore, only the proton spectrum is shown.  
 
 
Figure A.2.1: 1H NMR spectrum of 9-methyloxonan-2-one ((S)-36)*. 
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Figure A.2.2: 1H NMR spectrum of (8R)-8-hydroxynonanoic acid ((R)-49). 
 
 
Figure A.2.3: 13C NMR spectrum of (8R)-8-hydroxynonanoic acid ((R)-49). 
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Figure A.2.4: 1H NMR spectrum of isopropyl (17S,9Z)-17-hydroxyoctadec-9-enoate 
((S)-34)*. 
 
 
Figure A.2.5: 1H NMR spectrum of (17S,9Z)-octadec-9-ene-1,17-diol ((S)-41)*. 
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Figure A.2.6: 1H NMR spectrum of (17R,9Z)-1,17-diazidooctadec-9-ene ((R)-42)*. 
 
 
Figure A.2.7: 1H NMR spectrum of (17R,9Z)-octadec-9-ene-1,17-diamine ((R)-5)*. 
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A.3 1H and 13C NMR Spectra of Compounds from Chapter 6.2.3 
((S)-Harmonine)  
“*” indicates compounds that exclusively differ in stereochemistry from previously shown 
substances. Therefore, only the proton spectrum is shown.  
 
 
Figure A.3.1: 1H NMR spectrum of methyl (8R)-8-((tert-butyldimethylsilyl)oxy)nonanoate 
((R)-50). 
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Figure A.3.2: 13C NMR spectrum of methyl (8R)-8-((tert-butyldimethylsilyl)oxy)nonanoate 
((R)-50). 
 
 
Figure A.3.3: 1H NMR spectrum of isopropyl (17R,9Z)-17-((tert-butyldimethylsilyl)oxy)-
octadec-9-enoate ((R)-51). 
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Figure A.3.4: 13C NMR spectrum of isopropyl (17R,9Z)-17-((tert-butyldimethylsilyl)oxy)-
octadec-9-enoate ((R)-51). 
 
 
Figure A.3.5: 1H NMR spectrum of (17R,9Z)-octadec-9-ene-1,17-diol ((R)-41)*. 
OH
HO
(R)-41
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Figure A.3.6: 1H NMR spectrum of (17S,9Z)-1,17-diazidooctadec-9-ene ((S)-42)*. 
 
 
Figure A.3.7: 1H NMR spectrum of (17S,9Z)-octadec-9-ene-1,17-diamine ((S)-5)*. 
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A.4 NMR Spectra of Compounds from Chapter 6.2.4 ((Z)-18-
Aminooctadec-9-en-2-ol)  
 
Figure A.4.1: 1H NMR spectrum of (9Z)-17-hydroxyoctadec-9-enamide (rac-47). 
 
 
Figure A.4.2: APT spectrum of (9Z)-17-hydroxyoctadec-9-enamide (rac-47). 
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Figure A.4.3: 1H NMR spectrum of (9Z)-18-aminooctadec-9-en-2-ol (rac-48).  
 
 
Figure A.4.4: 13C NMR spectrum of (9Z)-18-aminooctadec-9-en-2-ol (rac-48).  
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A.5 1H and 13C NMR Spectra of Compounds from Chapter 6.2.5 
(C17-Harmonine)  
 
Figure A.5.1: 1H NMR spectrum of isopropyl 8-bromooctanoate (53). 
 
 
Figure A.5.2: 13C NMR spectrum of isopropyl 8-bromooctanoate (53). 
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Figure A.5.3: 1H NMR spectrum of (8-isopropoxy-8-oxooctyl)triphenylphosphonium 
bromide (54). 
 
 
Figure A.5.4: 13C NMR spectrum of (8-isopropoxy-8-oxooctyl)triphenylphosphonium 
bromide (54). 
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Figure A.5.5: 1H NMR spectrum of isopropyl (8Z)-16-hydroxyheptadec-8-enoate (rac-55).  
 
 
Figure A.5.6: 13C NMR spectrum of isopropyl (8Z)-16-hydroxyheptadec-8-enoate (rac-55). 
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Figure A.5.7: 1H NMR spectrum of (8Z)-heptadec-8-ene-1,16-diol (rac-56).  
 
 
Figure A.5.8: 13C NMR spectrum of (8Z)-heptadec-8-ene-1,16-diol (rac-56).  
 
Appendix 
 
xxiv 
 
 
Figure A.5.9: 1H NMR spectrum of (8Z)-1,16-diazidoheptadec-8-ene (rac-57).  
 
 
Figure A.5.10: 13C NMR spectrum of (8Z)-1,16-diazidoheptadec-8-ene (rac-57).  
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Figure A.5.11: 1H NMR spectrum of (8Z)-heptadec-8-ene-1,16-diamine (rac-58). 
 
 
Figure A.5.12: 13C NMR spectrum of (8Z)-heptadec-8-ene-1,16-diamine (rac-58). 
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A.6 FTIR Spectra  
Only one of the spectra of compounds exclusively differing in stereochemistry at position 
C-17 is shown.  
 
Figure A.6.1: FTIR spectrum of 2-methylcyclooctan-1-one (rac-38). 
 
 
Figure A.6.2: FTIR spectrum of 9-methyloxonan-2-one (rac-36). 
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Figure A.6.3: FTIR spectrum of isopropyl 9-bromononanoate (40). 
 
 
Figure A.6.4: FTIR spectrum of (9-isopropoxy-9-oxononyl)triphenylphosphonium 
bromide (35).  
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Figure A.6.5: FTIR spectrum of isopropyl (17S,9Z)-17-hydroxyoctadec-9-enoate ((S)-34). 
 
 
Figure A.6.6: FTIR spectrum of (9Z)-octadec-9-ene-1,17-diol (rac-41). 
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Figure A.6.7: FTIR spectrum of (9Z)-1,17-diazidooctadec-9-ene (rac-42). 
 
 
Figure A.6.8: FTIR spectrum of (9Z)-octadec-9-ene-1,17-diamine (rac-5). 
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Figure A.6.9: FTIR spectrum of (8R)-8-hydroxynonanoic acid ((R)-49). 
 
 
Figure A.6.10: FTIR spectrum of methyl (8R)-8-((tert-butyldimethylsilyl)oxy)nonanoate 
((R)-50).  
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Figure A.6.11: FTIR spectrum of isopropyl (17R,9Z)-17-((tert-butyldimethylsilyl)oxy)-
octadec-9-enoate ((R)-51).  
 
 
Figure A.6.12: FTIR spectrum of (9Z)-17-hydroxyoctadec-9-enamide (rac-47). 
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Figure A.6.13: FTIR spectrum of (9Z)-18-aminooctadec-9-en-2-ol (rac-48). 
 
 
Figure A.6.14: FTIR spectrum of isopropyl 8-bromooctanoate (53). 
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Figure A.6.15: FTIR spectrum of (8-isopropoxy-8-oxooctyl)triphenylphosphonium bromide 
(54). 
 
 
Figure A.6.16: FTIR spectrum of isopropyl (8Z)-16-hydroxyheptadec-8-enoate (rac-55).  
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Figure A.6.17: FTIR spectrum of (8Z)-heptadec-8-ene-1,16-diol (rac-56).  
 
 
Figure A.6.18: FTIR spectrum of (8Z)-1,16-diazidoheptadec-8-ene (rac-57).  
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Figure A.6.19: FTIR spectrum of (8Z)-heptadec-8-ene-1,16-diamine (rac-58). 
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A.7 GC-MS Spectra  
Only one of the spectra of compounds exclusively differing in stereochemistry at position 
C-17 is shown.  
 
 
Figure A.7.1: MS (EI) spectrum of 2-methylcyclooctan-1-one (rac-38). 
 
  
Figure A.7.2: MS (EI) spectrum of 9-methyloxonan-2-one (rac-36). 
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Figure A.7.3: MS (EI) spectrum of isopropyl 9-bromononanoate (40). 
 
  
Figure A.7.4: MS (EI) spectrum of isopropyl (9Z)-17-hydroxyoctadec-9-enoate (rac-34).  
 
  
Figure A.7.5: MS (EI) spectrum of (9Z)-octadec-9-ene-1,17-diol (rac-41).  
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Figure A.7.6: MS (EI) spectrum of (9Z)-17-hydroxyoctadec-9-enamide (rac-47). 
 
  
Figure A.7.7: MS (EI) spectrum of (9Z)-18-aminooctadec-9-en-2-ol (rac-48).  
 
  
Figure A.7.8: MS (EI) spectrum of (8R)-8-hydroxynonanoic acid ((R)-49). 
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Figure A.7.9: MS (EI) spectrum of methyl (8R)-8-((tert-butyldimethylsilyl)oxy)nonanoate 
((R)-50).  
 
  
Figure A.7.10: MS (EI) spectrum of isopropyl (17R,9Z)-17-((tert-butyldimethylsilyl)oxy)-
octadec-9-enoate ((R)-51).  
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Figure A.7.11: MS (CI) spectrum of isopropyl 8-bromooctanoate (53). 
 
  
Figure A.7.12: MS (EI) spectrum of isopropyl (8Z)-16-hydroxyheptadec-8-enoate (rac-55).  
 
  
Figure A.7.13: MS (EI) spectrum of (8Z)-heptadec-8-ene-1,16-diol (rac-56).  
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A.8 AChE Inhibition Assays: Concentration-Dependency Curves 
for the Calculation of IC50 Values  
 
 
Figure A.8.1: Concentration-dependency curve of rac-harmonine rac-5 with sigmoidal dose-
response fitting (variable slope, n = 3, ± SEM). Concentration of rac-5: ȝM. 
 
 
 
Figure A.8.2: Concentration-dependency curve of (S)-harmonine (S)-5 with sigmoidal dose-
response fitting (variable slope, n = 3, ± SEM). Concentration of (S)-5: ȝM.  
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Figure A.8.3: Concentration-dependency curve of C17-harmonine (rac-58) with sigmoidal 
dose-response fitting (variable slope, n = 3, ± SEM). Concentration of rac-58: nM.  
 
 
 
Figure A.8.4: Concentration-dependency curve of (Z)-18-aminooctadec-9-en-2-ol (rac-48) 
with sigmoidal dose-response fitting (variable slope, n = 3, ± SEM) used for calculation 
(11 data points). Concentration of rac-48: nM.  
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A.9 Modeling and Docking Studies: Additional Figures  
 
Figure A.9.1: Alternative view of the model of the sequence XP_001681951.1 with bond 
harmonine. The amino groups interact with E406 (surface; no specificity of the chiral carbon) 
and with D739 (bottom, probably near the active site).  
 
 
Figure A.9.2: Second most favored docking arrangement of the C17-harmonine (rac-58) 
(interaction energy: -39.2 kcal mol-1). Alternatively to Fig. 3.19 (chapter 3.3.4.2) a salt bridge 
with E406 can be formed but not with D739. 
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